One    O
chemical    O
compound    O
found    O
in    O
"    O
T.    O
terrestris    O
"    O
is    O
protodioscin    B-Steroid115057744
(    O
PTN    O
)    O
.    O

Eckstine    O
also    O
scored    O
music    O
for    O
TV    O
and    O
Film    O
,    O
including    O
the    O
Fox    O
Television    O
series    O
T.R.A.X.    O
,    O
(    O
2001    O
)    O
,    O
directed    O
by    O
Renny    O
Harlin    O
,    O
and    O
the    O
television    O
commercials    O
for    O
CBS    O
,    O
"    O
Courting    O
Alex    O
,    O
"    O
starring    O
Jenna    O
Elfman    O
,    O
(    O
2006    O
)    O
,    O
and    O
TV    O
/    O
commercial    O
music    O
for    O
the    O
drug    O
Avodart    B-Steroid115057744
,    O
(    O
2006    O
)    O
.    O

Bicalutamide    O
has    O
also    O
been    O
studied    O
in    O
combination    O
with    O
the    O
5α-reductase    O
inhibitors    O
finasteride    B-Steroid115057744
and    O
dutasteride    B-Steroid115057744
in    O
prostate    O
cancer    O
.    O

Its    O
formation    O
can    O
be    O
blocked    O
by    O
the    O
coadministration    O
of    O
dutasteride    B-Steroid115057744
,    O
a    O
potent    O
and    O
selective    O
5α-reductase    O
inhibitor    O
.    O

5α-Reductase    O
inhibitors    O
(    O
5-ARIs    O
)    O
such    O
as    O
finasteride    B-Steroid115057744
,    O
dutasteride    B-Steroid115057744
,    O
epristeride    O
,    O
and    O
alfatradiol    B-Steroid115057744
prevent    O
the    O
conversion    O
of    O
testosterone    O
into    O
the    O
more    O
potent    O
androgen    O
dihydrotestosterone    O
(    O
DHT    O
)    O
and    O
are    O
used    O
in    O
the    O
treatment    O
of    O
benign    O
prostatic    O
hyperplasia    O
(    O
BPH    O
)    O
and    O
androgenic    O
alopecia    O
(    O
pattern    O
hair    O
loss    O
)    O
.    O

Finasteride    B-Steroid115057744
and    O
dutasteride    B-Steroid115057744
,    O
which    O
are    O
5α-reductase    O
inhibitors    O
and    O
inhibit    O
the    O
production    O
of    O
the    O
potent    O
androgen    O
dihydrotestosterone    O
(    O
DHT    O
)    O
.    O

Dutasteride    B-Steroid115057744
and    O
tamsulosin    O
are    O
on    O
the    O
market    O
as    O
combined    O
therapy    O
and    O
results    O
have    O
shown    O
that    O
they    O
improve    O
symptoms    O
significantly    O
versus    O
monotherapy    O
.    O

Algestone    B-Steroid115057744

This    O
family    O
is    O
subdivided    O
into    O
two    O
groups    O
:    O
the    O
estrane    B-Steroid115057744
and    O
the    O
gonane    B-Steroid115057744
.    O

Androstane    B-Steroid115057744
is    O
a    O
C19    O
steroid    O
with    O
a    O
gonane    B-Steroid115057744
core    O
.    O

Human    O
ingestion    O
of    O
solanidine    O
also    O
occurs    O
via    O
the    O
consumption    O
of    O
the    O
glycoalkaloids    B-Steroid115057744
,    O
α-solanine    B-Steroid115057744
and    O
α-chaconine    B-Steroid115057744
,    O
present    O
in    O
potatoes    O
.    O

Proligestone    B-Steroid115057744

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-Steroid115057744
derivatives    O
gestonorone    B-Steroid115057744
caproate    I-Steroid115057744
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
and    O
quingestanol    B-Steroid115057744
acetate    I-Steroid115057744
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Steroid115057744
)    O
,    O
desogestrel    B-Steroid115057744
,    O
ethylestrenol    O
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
ethinylestradiol    O
,    O
gestrinone    B-Steroid115057744
,    O
levonorgestrel    B-Steroid115057744
,    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    O
)    O
,    O
quinestrol    O
,    O
19-norprogesterone    B-Steroid115057744
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
.    O

Nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
abbreviated    O
as    O
NOMAC    B-Steroid115057744
,    O
is    O
a    O
progestin    O
,    O
or    O
a    O
synthetic    O
progestogen    O
,    O
which    O
was    O
first    O
introduced    O
in    O
the    O
mid-1980s    O
and    O
is    O
used    O
in    O
the    O
treatment    O
of    O
gynecological    O
disorders    O
,    O
in    O
hormone    O
replacement    O
therapy    O
(    O
HRT    O
)    O
for    O
menopausal    O
symptoms    O
,    O
and    O
in    O
hormonal    O
contraceptives    O
.    O

It    O
is    O
marketed    O
alone    O
under    O
the    O
brand    O
name    O
Lutenyl    B-Steroid115057744
and    O
in    O
combination    O
with    O
estradiol    O
under    O
the    O
brand    O
names    O
Naemis    B-Steroid115057744
and    O
Zoely    B-Steroid115057744
.    O

The    O
"    O
mono"-    O
and    O
"    O
bis    O
"-    O
quaternary    O
azasteroid    O
series    O
of    O
compounds    O
to    O
which    O
candocuronium    O
belongs    O
are    O
based    O
on    O
the    O
same    O
principle    O
that    O
led    O
to    O
aminosteroids    O
such    O
as    O
pancuronium    B-Steroid115057744
,    O
vecuronium    B-Steroid115057744
and    O
rocuronium    B-Steroid115057744
:    O
use    O
of    O
the    O
steroid    O
skeleton    O
to    O
provide    O
a    O
somewhat    O
rigid    O
distance    O
between    O
the    O
two    O
quaternary    O
ammonium    O
centers    O
,    O
with    O
appendages    O
incorporating    O
fragments    O
of    O
choline    O
or    O
acetylcholine    O
.    O

The    O
site    O
has    O
a    O
long    O
history    O
of    O
research    O
in    O
the    O
area    O
of    O
neuromuscular    O
blockers    O
,    O
which    O
are    O
commonly    O
used    O
during    O
surgery    O
,    O
and    O
was    O
responsible    O
for    O
the    O
identification    O
of    O
rocuronium    B-Steroid115057744
as    O
well    O
as    O
a    O
number    O
of    O
other    O
drugs    O
.    O

Rocuronium    B-Steroid115057744

Commonly    O
used    O
neuromuscular    O
blocking    O
agents    O
used    O
include    O
succinylcholine    O
and    O
rocuronium    B-Steroid115057744
.    O

Penicillium    O
aurantiogriseum    O
is    O
a    O
plant    O
pathogen    O
infecting    O
asparagus    O
and    O
strawberry."Penicillium    O
aurantiogriseum    O
"    O
produces    O
the    O
anticancer    O
compound    O
Anicequol    B-Steroid115057744
.    O

Oral    O
contraceptive    O
produced    O
by    O
Jenapharm    O
containing    O
ethinylestradiol    O
and    O
dienogest    B-Steroid115057744

It    O
is    O
said    O
to    O
be    O
a    O
weaker    O
antiandrogen    O
than    O
dienogest    B-Steroid115057744
(    O
another    O
commonly    O
used    O
progestin    O
with    O
antiandrogen    O
activity    O
)    O
,    O
but    O
still    O
may    O
be    O
useful    O
in    O
alleviating    O
acne    O
,    O
seborrhea    O
,    O
and    O
other    O
androgen    O
-    O
dependent    O
symptoms    O
in    O
women    O
.    O

Dienogest    B-Steroid115057744
,    O
which    O
is    O
antiandrogenic    O
,    O
features    O
extension    O
of    O
the    O
C17α    O
chain    O
in    O
the    O
form    O
of    O
a    O
cyanomethyl    O
group    O
at    O
the    O
C17α    O
position    O
.    O

In    O
contrast    O
,    O
dienogest    B-Steroid115057744
,    O
the    O
17α-cyanomethyl    O
derivative    O
of    O
dienolone    O
,    O
is    O
a    O
potent    O
progestogen    O
and    O
antiandrogen    O
.    O

Complex    O
formation    O
may    O
be    O
the    O
reason    O
why    O
tomatine    O
has    O
a    O
much    O
lower    O
oral    O
toxicity    O
than    O
other    O
glycoalkaloids    B-Steroid115057744
.    O

The    O
symptoms    O
of    O
acute    O
tomatine    O
poisoning    O
in    O
animals    O
are    O
similar    O
to    O
the    O
symptoms    O
of    O
poisoning    O
by    O
solanine    B-Steroid115057744
,    O
a    O
potato    O
glycoalkaloid    B-Steroid115057744
.    O

Human    O
ingestion    O
of    O
solanidine    O
also    O
occurs    O
via    O
the    O
consumption    O
of    O
the    O
glycoalkaloids    B-Steroid115057744
,    O
α-solanine    B-Steroid115057744
and    O
α-chaconine    B-Steroid115057744
,    O
present    O
in    O
potatoes    O
.    O

This    O
wild    O
species    O
contains    O
leptine    O
glycoalkaloid    B-Steroid115057744
which    O
make    O
it    O
resistant    O
to    O
the    O
Colorado    O
potato    O
beetle    O
(    O
"    O
Leptinotarsa    O
decemlineata    O
"    O
)    O
,    O
a    O
pest    O
of    O
potato    O
crops    O
.    O

Demegestone    B-Steroid115057744

demegestone    B-Steroid115057744
(    O
INN    O
)    O

File    O
:    O
Dydrogesterone    B-Steroid115057744
(    O
progestin    O
)    O

Progesterone    O
and    O
non    O
-    O
androgenic    O
progestins    O
,    O
such    O
as    O
dydrogesterone    B-Steroid115057744
,    O
do    O
not    O
affect    O
serum    O
IGF-1    O
levels    O
regardless    O
of    O
route    O
of    O
administration    O
.    O

Gynorest    B-Steroid115057744

Dermabet    B-Steroid115057744

Diprolene    B-Steroid115057744

Diprosone    B-Steroid115057744

Lotrisone    B-Steroid115057744

He    O
tested    O
positive    O
for    O
betamethasone    B-Steroid115057744
,    O
a    O
substance    O
that    O
was    O
banned    O
in    O
2016    O
.    O

Treatment    O
usually    O
involves    O
topical    O
corticosteroids    O
(    O
such    O
as    O
betamethasone    B-Steroid115057744
,    O
clobetasol    O
,    O
dexamethasone    O
,    O
and    O
triamcinolone    O
)    O
and    O
analgesics    O
,    O
or    O
if    O
these    O
are    O
ineffective    O
and    O
the    O
condition    O
is    O
severe    O
,    O
the    O
systemic    O
corticosteroids    O
may    O
be    O
used    O
.    O

Betamethasone    B-Steroid115057744

Beclometasone    O
,    O
betamethasone    B-Steroid115057744
,    O
dexamethasone    O
,    O
fluocortolone    O
,    O
halometasone    O
,    O
and    O
mometasone    O
.    O

Commonly    O
used    O
solutions    O
are    O
of    O
fluorometholone    B-Steroid115057744
,    O
medrysone    B-Steroid115057744
,    O
betamethasone    B-Steroid115057744
or    O
dexamethasone    O
.    O

Endogenous    O
estrogens    O
(    O
e.g.    O
,    O
estradiol    O
,    O
estrone    O
,    O
estriol    O
,    O
estetrol    B-Steroid115057744
)    O

During    O
pregnancy    O
,    O
DHEA    O
-    O
S    O
is    O
metabolized    O
into    O
the    O
sulfates    O
of    O
16α-hydroxy    O
-    O
DHEA    O
and    O
15α-hydroxy    O
-    O
DHEA    O
in    O
the    O
fetal    O
liver    O
as    O
intermediates    O
in    O
the    O
production    O
of    O
the    O
estrogens    O
estriol    O
and    O
estetrol    B-Steroid115057744
,    O
respectively    O
.    O

Estramustine    B-Steroid115057744

Estramustine    B-Steroid115057744

Some    O
isomers    O
of    O
DHEA    O
are    O
1-dehydroepiandrosterone    O
(    O
1-androsterone    O
)    O
and    O
4-dehydroepiandrosterone    B-Steroid115057744
.    O

NOMAC    O
is    O
the    O
C17α    O
acetate    O
ester    O
of    O
nomegestrol    B-Steroid115057744
and    O
the    O
19-demethylated    O
(    O
or    O
19-nor    O
)    O
analogue    O
of    O
megestrol    O
acetate    O
,    O
and    O
can    O
also    O
be    O
referred    O
to    O
as    O
19-normegestrol    O
acetate    O
.    O

Norsteroid    B-Steroid115057744
(    O
nor-    O
,    O
L.    O
"    O
norma    O
"    O
;    O
"    O
normal    O
"    O
in    O
chemistry    O
,    O
indicating    O
carbon    O
removal    O
)    O
and    O
homosteroids    O
(    O
homo-    O
,    O
Greek    O
"    O
homos    O
"    O
;    O
"    O
same    O
"    O
,    O
indicating    O
carbon    O
addition    O
)    O
are    O
structural    O
subclasses    O
of    O
steroids    O
formed    O
from    O
biosynthetic    O
steps    O
.    O

Avenasterol    B-Steroid115057744
is    O
a    O
natural    O
,    O
non    O
-    O
cholesterol    O
sterol    O
.    O

The    O
plant    O
contains    O
the    O
oleanane    O
-    O
type    O
triterpenoids    O
3beta    O
-    O
acetoxy-11alpha(2',3'-epoxyferulyloxy)-olean-13(18)-ene    O
and    O
α-spinasterol    B-Steroid115057744
.    O

Bolmantalate    B-Steroid115057744

Examples    O
of    O
important    O
progestogen    O
esters    O
include    O
the    O
17α-hydroxyprogesterone    O
derivatives    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
megestrol    O
acetate    O
,    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
hydroxyprogesterone    O
caproate    O
,    O
the    O
19-norprogesterone    B-Steroid115057744
derivative    O
nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
and    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
.    O

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-Steroid115057744
derivatives    O
gestonorone    B-Steroid115057744
caproate    I-Steroid115057744
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
and    O
quingestanol    B-Steroid115057744
acetate    I-Steroid115057744
.    O

Estradiol    O
undecylate    O
,    O
in    O
combination    O
with    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
(    O
at    O
doses    O
of    O
5    O
mg    O
and    O
50    O
mg    O
,    O
respectively    O
)    O
,    O
was    O
studied    O
as    O
a    O
combined    O
injectable    O
contraceptive    O
,    O
but    O
ultimately    O
was    O
not    O
marketed    O
for    O
this    O
purpose    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Steroid115057744
)    O
,    O
desogestrel    B-Steroid115057744
,    O
ethylestrenol    O
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
ethinylestradiol    O
,    O
gestrinone    B-Steroid115057744
,    O
levonorgestrel    B-Steroid115057744
,    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    O
)    O
,    O
quinestrol    O
,    O
19-norprogesterone    B-Steroid115057744
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
.    O

The    O
estranes    O
include    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
lynestrenol    B-Steroid115057744
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Steroid115057744
,    O
desogestrel    B-Steroid115057744
,    O
etonogestrel    B-Steroid115057744
,    O
gestodene    B-Steroid115057744
,    O
norgestimate    O
,    O
dienogest    B-Steroid115057744
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    O
.    O

Lumisterol    B-Steroid115057744
is    O
a    O
compound    O
that    O
is    O
part    O
of    O
the    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
family    O
of    O
steroid    O
compounds    O
.    O

Cardanolide    B-Steroid115057744

20α-Hydroxyprogesterone    B-Steroid115057744
↔    O
Progesterone    O

Also    O
converts    O
inactive    O
20α-hydroxyprogesterone    B-Steroid115057744
into    O
active    O
progesterone    O
.    O

Anabolic    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
use    O
can    O
also    O
increase    O
the    O
amount    O
of    O
RBCs    O
and    O
,    O
therefore    O
,    O
impact    O
the    O
hematocrit    O
,    O
in    O
particular    O
the    O
compounds    O
boldenone    B-Steroid115057744
and    O
oxymetholone    B-Steroid115057744
.    O

Oxymetholone    B-Steroid115057744

Oxymetholone    B-Steroid115057744

Jenapharm    O
developed    O
an    O
alternate    O
process    O
starting    O
from    O
hyodesoxycholic    B-Steroid115057744
acid    I-Steroid115057744
extracted    O
from    O
hog    O
bile    O
,    O
from    O
which    O
they    O
first    O
produced    O
pregnenolone    B-Steroid115057744
,    O
and    O
subsequently    O
progesterone    O
and    O
desoxycorticosterone    O
acetate    O
in    O
1954/1955    O
.    O

Epimestrol    B-Steroid115057744

Tetrahydrocortisone    B-Steroid115057744

Oxendolone    B-Steroid115057744

Oxendolone    B-Steroid115057744
(    O
INN    O
,    O
USAN    O
,    O
JAN    O
)    O
(    O
brand    O
names    O
Prostetin    B-Steroid115057744
,    O
Roxenone    B-Steroid115057744
;    O
former    O
developmental    O
code    O
name    O
TSAA-291    B-Steroid115057744
)    O
,    O
also    O
known    O
as    O
16β-ethyl-19-nortestosterone    B-Steroid115057744
or    O
16β-ethylestr-4-en-17β-ol-3-one    B-Steroid115057744
,    O
is    O
a    O
steroidal    O
antiandrogen    O
and    O
progestin    O
of    O
the    O
19-nortestosterone    O
group    O
that    O
has    O
been    O
marketed    O
in    O
Japan    O
by    O
Takeda    O
for    O
the    O
treatment    O
of    O
benign    O
prostatic    O
hyperplasia    O
(    O
BPH    O
)    O
since    O
1981    O
.    O

It    O
is    O
used    O
in    O
some    O
hair    O
colors    O
,    O
make    O
-    O
ups    O
,    O
and    O
some    O
other    O
cosmetic    O
preparations    O
;    O
e.g.    O
the    O
ISP    O
ColorFlow    O
line    O
is    O
based    O
on    O
mixtures    O
with    O
e.g.    O
cholesteryl    B-Steroid115057744
chloride    I-Steroid115057744
,    O
cholesteryl    B-Steroid115057744
oleyl    I-Steroid115057744
carbonate    I-Steroid115057744
and    O
BHT    O
.    O

Lanostane    B-Steroid115057744

The    O
δD    O
values    O
of    O
fatty    O
acids    O
in    O
methanotrophs    O
living    O
in    O
seawater    O
lie    O
between    O
-50    O
and    O
-170‰    O
,    O
and    O
that    O
of    O
sterols    O
and    O
hopanol    B-Steroid115057744
range    O
between    O
-150    O
and    O
-270‰.    O
[    O
See    O
Section    O
7.5.3    O
.    O

Phytosterols    B-Steroid115057744
,    O
such    O
as    O
sitosterol    O
and    O
stigmasterol    O
,    O
and    O
hopanoids    B-Steroid115057744
serve    O
a    O
similar    O
function    O
in    O
plants    O
and    O
prokaryotes    O
.    O

Metildigoxin    B-Steroid115057744
(    O
INN    O
)    O

Estradiol    B-Steroid115057744
dipropionate    I-Steroid115057744
(    O
BAN    O
,    O
JAN    O
)    O
(    O
brand    O
names    O
Agofollin    B-Steroid115057744
,    O
Di-Ovocyclin    B-Steroid115057744
,    O
Progynon    B-Steroid115057744
DP    I-Steroid115057744
,    O
others    O
)    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
that    O
is    O
or    O
has    O
been    O
marketed    O
in    O
the    O
United    O
States    O
and    O
Europe    O
.    O

Along    O
with    O
estradiol    B-Steroid115057744
benzoate    I-Steroid115057744
,    O
estradiol    O
dipropionate    O
was    O
one    O
of    O
the    O
first    O
estradiol    O
esters    O
to    O
be    O
developed    O
,    O
having    O
been    O
patented    O
in    O
1937    O
,    O
was    O
assessed    O
in    O
clinical    O
studies    O
by    O
1939    O
,    O
and    O
has    O
been    O
marketed    O
by    O
Schering    O
as    O
Progynon    B-Steroid115057744
DP    I-Steroid115057744
and    O
Ciba    O
Pharmaceutical    O
Products    O
as    O
Di-Ovocylin    B-Steroid115057744
since    O
at    O
least    O
1940    O
.    O

Steroid    O
sulfatase    O
(    O
STS    O
)    O
inhibitors    O
such    O
as    O
estradiol    O
sulfamate    O
,    O
estrone    O
sulfamate    O
,    O
irosustat    O
,    O
and    O
danazol    B-Steroid115057744
inhibit    O
the    O
conversion    O
of    O
steroid    O
sulfates    O
such    O
as    O
estrone    B-Steroid115057744
sulfate    I-Steroid115057744
and    O
DHEA    B-Steroid115057744
sulfate    I-Steroid115057744
into    O
their    O
hormonally    O
active    O
forms    O
.    O

Estrone    B-Steroid115057744
sulfate    I-Steroid115057744

E2S    O
can    O
also    O
be    O
metabolized    O
into    O
estrone    B-Steroid115057744
sulfate    I-Steroid115057744
(    O
E1S    O
)    O
,    O
which    O
in    O
turn    O
can    O
be    O
converted    O
into    O
estrone    O
and    O
estradiol    O
.    O

Like    O
many    O
other    O
progestogens    O
,    O
NOMAC    O
has    O
been    O
assessed    O
and    O
found    O
"    O
in    O
vitro    O
"    O
to    O
inhibit    O
the    O
conversion    O
of    O
estrone    B-Steroid115057744
sulfate    I-Steroid115057744
to    O
estrone    O
(    O
via    O
inhibition    O
of    O
steroid    O
sulfatase    O
)    O
and    O
estrone    O
to    O
estradiol    O
(    O
via    O
inhibition    O
of    O
)    O
at    O
high    O
concentrations    O
(    O
0.5–50    O
μM    O
)    O
and    O
to    O
stimulate    O
the    O
conversion    O
of    O
estrone    O
into    O
estrone    O
sulfate    O
(    O
via    O
activation    O
of    O
estrogen    O
sulfotransferase    O
activity    O
)    O
at    O
low    O
concentrations    O
(    O
0.05–0.5    O
μM    O
)    O
,    O
whilst    O
not    O
affecting    O
aromatase    O
activity    O
at    O
any    O
tested    O
concentration    O
(    O
up    O
to    O
10    O
μM    O
)    O
.    O

It    O
produces    O
8,9-dehydroestradiol    O
as    O
an    O
important    O
active    O
metabolite    O
,    O
analogously    O
to    O
conversion    O
of    O
estrone    O
or    O
estrone    B-Steroid115057744
sulfate    I-Steroid115057744
into    O
estradiol    O
.    O

Trenbolone    B-Steroid115057744
(    O
δ9,11    O
-    O
19-NT    O
)    O

Trenbolone    B-Steroid115057744

Other    O
steroids    O
stacked    O
with    O
metandienone    O
are    O
primarily    O
,    O
if    O
not    O
always    O
,    O
injectable    O
compounds    O
such    O
as    O
testosterone    O
,    O
trenbolone    B-Steroid115057744
and    O
nandrolone    O
.    O

Trenbolone    B-Steroid115057744
(    O
trienolone    O
)    O

The    O
infamous    O
"    O
duchess    O
"    O
cocktail    O
administered    O
to    O
Russian    O
athletes    O
at    O
the    O
Sochi    O
Winter    O
Olympics    O
consisted    O
of    O
oxandrolone    B-Steroid115057744
,    O
metenolone    O
,    O
and    O
trenbolone    B-Steroid115057744
.    O

Sterols    O
isolated    O
from    O
the    O
mushroom    O
include    O
,    O
ganoderol    B-Steroid115057744
,    O
ganoderenic    B-Steroid115057744
acid    I-Steroid115057744
,    O
ganoderiol    B-Steroid115057744
,    O
ganodermanontriol    B-Steroid115057744
,    O
lucidadiol    B-Steroid115057744
,    O
and    O
ganodermadiol    B-Steroid115057744
.    O

Pregnenolone    B-Steroid115057744
16α-carbonitrile    I-Steroid115057744
(    O
PCN    B-Steroid115057744
)    O
is    O
a    O
synthetic    O
,    O
steroidal    O
antiglucocorticoid    B-Steroid115057744
and    O
pregnane    O
X    O
receptor    O
agonist    O
.    O

Melengestrol    B-Steroid115057744

mesabolone    B-Steroid115057744
(    O
INN    O
)    O

Mesabolone    B-Steroid115057744

It    O
is    O
the    O
C17β    O
ester    O
metenolone    B-Steroid115057744
,    O
which    O
itself    O
is    O
1-methyl-δ1    O
-    O
4,5α-dihydrotestosterone    O
(    O
1-methyl-δ1-DHT    O
)    O
or    O
1-methyl-5α-androst-1-en-17β-ol-3-one    O
.    O

In    O
2005    O
,    O
she    O
received    O
a    O
two    O
-    O
year    O
ban    O
from    O
the    O
track    O
due    O
to    O
positive    O
testing    O
for    O
illegal    O
substance    O
Metenolone    B-Steroid115057744
.    O

On    O
13    O
August    O
2012    O
,    O
the    O
International    O
Olympic    O
Committee    O
stripped    O
shot    O
putter    O
Nadzeya    O
Astapchuk    O
of    O
her    O
gold    O
medal    O
after    O
testing    O
positive    O
for    O
the    O
anabolic    O
steroid    O
metenolone    B-Steroid115057744
,    O
and    O
the    O
gold    O
medal    O
was    O
subsequently    O
awarded    O
to    O
silver    O
medalist    O
Valerie    O
Adams    O
from    O
New    O
Zealand    O
.    O

On    O
August    O
13    O
,    O
International    O
Olympic    O
Committee    O
decided    O
the    O
shot    O
putter    O
Nadzeya    O
Astapchuk    O
,    O
the    O
nation    O
's    O
only    O
track    O
and    O
field    O
medalist    O
,    O
to    O
strip    O
off    O
her    O
gold    O
medal    O
at    O
the    O
London    O
games    O
after    O
she    O
was    O
tested    O
positive    O
for    O
the    O
anabolic    O
steroid    O
metenolone    B-Steroid115057744
.    O

Methenolone    B-Steroid115057744

Metenolone    B-Steroid115057744
,    O
or    O
methenolone    B-Steroid115057744
,    O
also    O
known    O
as    O
methylandrostenolone    B-Steroid115057744
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic    O
-    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
dihydrotestosterone    O
(    O
DHT    O
)    O
.    O

Osladine    B-Steroid115057744
is    O
a    O
naturally    O
occurring    O
,    O
high    O
-    O
intensity    O
sweetener    O
isolated    O
from    O
the    O
rhizome    O
of    O
"    O
Polypodium    O
vulgare    O
"    O
.    O

:    O
QG03XB90    O
Aglepristone    B-Steroid115057744

Examples    O
of    O
antiprogestogens    O
include    O
the    O
progesterone    O
receptor    O
weak    O
partial    O
agonist    O
mifepristone    O
,    O
the    O
selective    O
progesterone    O
receptor    O
modulator    O
(    O
SPRM    O
)    O
ulipristal    O
acetate    O
,    O
and    O
the    O
silent    O
antagonist    O
aglepristone    B-Steroid115057744
.    O

Chlormadinone    B-Steroid115057744
acetate    O
was    O
the    O
first    O
oral    O
contraceptive    O
produced    O
by    O
Jenapharm    O
.    O

It    O
produces    O
hippuristanol    B-Steroid115057744
,    O
a    O
molecule    O
with    O
apparent    O
anti    O
-    O
cancer    O
functions    O
.    O

Nonetheless    O
,    O
he    O
believed    O
it    O
was    O
poisonous    O
(    O
in    O
fact    O
,    O
the    O
plant    O
and    O
raw    O
fruit    O
do    O
have    O
low    O
levels    O
of    O
tomatine    B-Steroid115057744
,    O
but    O
are    O
not    O
generally    O
dangerous    O
;    O
see    O
below    O
)    O
.    O

Leaves    O
,    O
stems    O
,    O
and    O
green    O
unripe    O
fruit    O
of    O
the    O
tomato    O
plant    O
contain    O
small    O
amounts    O
of    O
the    O
toxic    O
alkaloid    O
tomatine    B-Steroid115057744
.    O

Analysis    O
of    O
the    O
methanolic    O
extract    O
of    O
the    O
aerial    O
parts    O
yields    O
sitosterol    B-Steroid115057744
,    O
stigmasterol    B-Steroid115057744
,    O
ursolic    O
acid    O
,    O
oleanolic    O
acid    O
and    O
brassicasterol    B-Steroid115057744
.    O

It    O
may    O
be    O
obtained    O
from    O
the    O
alcoholic    O
extract    O
of    O
the    O
residue    O
from    O
which    O
the    O
convallamarin    B-Steroid115057744
has    O
been    O
removed    O
with    O
water    O
.    O

:    O
V09DX01    O
Selenium    B-Steroid115057744
(75Se)    I-Steroid115057744
tauroselcholic    I-Steroid115057744
acid    I-Steroid115057744

SeHCAT    B-Steroid115057744
(    O
23-seleno-25-homotaurocholic    B-Steroid115057744
acid    I-Steroid115057744
,    O
selenium    B-Steroid115057744
homocholic    I-Steroid115057744
acid    I-Steroid115057744
taurine    I-Steroid115057744
,    O
or    O
tauroselcholic    B-Steroid115057744
acid    I-Steroid115057744
)    O
is    O
a    O
drug    O
used    O
in    O
a    O
clinical    O
test    O
to    O
diagnose    O
bile    O
acid    O
malabsorption    O
.    O

Blazein    B-Steroid115057744
is    O
a    O
bio    O
-    O
active    O
steroid    O
made    O
by    O
"    O
Agaricus    O
blazei    O
"    O
.    O

In    O
medical    O
use    O
,    O
it    O
is    O
administered    O
as    O
a    O
cholagogue    O
and    O
choleretic    B-Steroid115057744
.    O

Boldo    O
is    O
officially    O
listed    O
as    O
phytotherapic    O
plant    O
as    O
cholagogue    O
and    O
choleretic    B-Steroid115057744
,    O
for    O
treatment    O
of    O
mild    O
dyspepsia    O
in    O
Brazilian    O
pharmacopoeia    O
.    O

Muricholic    B-Steroid115057744
acids    I-Steroid115057744
are    O
a    O
group    O
of    O
bile    O
acids    O
found    O
as    O
one    O
of    O
the    O
main    O
forms    O
in    O
mice    O
,    O
which    O
gives    O
them    O
their    O
name    O
,    O
and    O
at    O
low    O
concentrations    O
in    O
other    O
species    O
.    O

Budesonide    B-Steroid115057744
,    O
by    O
its    O
trade    O
name    O
"    O
Giona    O
"    O

Amcinonide    O
,    O
budesonide    B-Steroid115057744
,    O
desonide    O
,    O
fluocinolone    O
acetonide    O
,    O
fluocinonide    O
,    O
halcinonide    O
,    O
and    O
triamcinolone    B-Steroid115057744
acetonide    I-Steroid115057744
.    O

Budesonide    B-Steroid115057744

Corticosteroids    O
:    O
Inhaled    O
corticosteroids    O
(    O
i.e.    O
fluticasone    O
,    O
budesonide    B-Steroid115057744
)    O
are    O
typically    O
used    O
when    O
bronchoconstrictive    O
disease    O
has    O
advanced    O
to    O
a    O
persistent    O
inflammatory    O
state    O
,    O
more    O
specifically    O
in    O
persistent    O
or    O
severe    O
asthma    O
and    O
chronic    O
obstructive    O
pulmonary    O
disease    O
(    O
COPD    O
)    O
.    O

Budesonide    B-Steroid115057744

In    O
this    O
case    O
,    O
the    O
main    O
compounds    O
used    O
are    O
beclometasone    O
,    O
budesonide    B-Steroid115057744
,    O
fluticasone    O
,    O
mometasone    O
and    O
ciclesonide    O
.    O

Taurochenodeoxycholate    B-Steroid115057744
(    O
TCDCA    O
)    O

Tauroursodeoxycholate    B-Steroid115057744
(    O
TUDCA    O
)    O

Taurochenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
is    O
a    O
bile    O
acid    O
formed    O
in    O
the    O
liver    O
of    O
most    O
species    O
,    O
including    O
humans    O
,    O
by    O
conjugation    O
of    O
chenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
with    O
taurine    O
.    O

The    O
fire    O
salamander    O
's    O
primary    O
alkaloid    O
toxin    O
,    O
Samandarin    B-Steroid115057744
,    O
causes    O
strong    O
muscle    O
convulsions    O
and    O
hypertension    O
combined    O
with    O
hyperventilation    O
in    O
all    O
vertebrates    O
.    O

Acebrochol    B-Steroid115057744
(    O
cholesteryl    O
acetate    O
dibromide    O
)    O
:    O
5α,6β-dibromocholestan-3β-ol    O
3β-acetate    O
–    O
GABAA    O
receptor    O
positive    O
allosteric    O
modulator    O

"    O
Penicillium    O
brasilianum    O
"    O
produces    O
the    O
compounds    O
isoroquefortine    O
C    O
,    O
griseofulvin    O
,    O
ergosterol    B-Steroid115057744
peroxide    I-Steroid115057744
,    O
3β-hydroxy-(22E,24R)-ergosta-5,8,22-trien-7-one    O
,    O
cerevisterol    B-Steroid115057744
,    O
(    O
22E,24R)-6β-methoxyergosta-7,22-diene-3β,5α-diol    O

Dinosterol    B-Steroid115057744

3β-HSD    O
is    O
potently    O
inhibited    O
by    O
azastene    B-Steroid115057744
,    O
cyanoketone    B-Steroid115057744
,    O
epostane    B-Steroid115057744
,    O
and    O
trilostane    B-Steroid115057744
.    O

Norclostebol    B-Steroid115057744
(    O
4-chloro-19-NT    O
)    O

Norclostebol    B-Steroid115057744

any    O
compound    O
(    O
not    O
being    O
Trilostane    B-Steroid115057744
or    O
a    O
compound    O
for    O
the    O
time    O
being    O
specified    O
in    O
sub    O
-    O
paragraph    O
(    O
b    O
)    O
above    O
)    O
structurally    O
derived    O
from    O
17-hydroxyandrostan-3-one    O
or    O
from    O
17-hydroxyestran-3-one    O
by    O
modification    O
in    O
any    O
of    O
the    O
following    O
ways    O
,    O
that    O
is    O
to    O
say    O
,    O

3β-HSD    O
is    O
potently    O
inhibited    O
by    O
azastene    B-Steroid115057744
,    O
cyanoketone    B-Steroid115057744
,    O
epostane    B-Steroid115057744
,    O
and    O
trilostane    B-Steroid115057744
.    O

Inotodiol    B-Steroid115057744

Blazeispirols    B-Steroid115057744
are    O
bioactive    O
ergostane    B-Steroid115057744
-    O
type    O
compounds    O
isolated    O
from    O
"    O
Agaricus    O
blazei    O
"    O
.    O

Formebolone    B-Steroid115057744

Quingestanol    B-Steroid115057744
acetate    I-Steroid115057744

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-Steroid115057744
derivatives    O
gestonorone    B-Steroid115057744
caproate    I-Steroid115057744
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
and    O
quingestanol    B-Steroid115057744
acetate    I-Steroid115057744
.    O

Mestanolone    B-Steroid115057744

Mestanolone    B-Steroid115057744
(methylandrostanolone)    I-Steroid115057744

Withaferin    B-Steroid115057744
A    I-Steroid115057744
,    O
a    O
potent    O
inhibitor    O
of    O
angiogenesis    O

Olesoxime    B-Steroid115057744
is    O
a    O
proprietary    O
neuroprotective    O
compound    O
developed    O
by    O
the    O
French    O
company    O
Trophos    O
which    O
showed    O
stabilising    O
effect    O
in    O
a    O
phase    O
-    O
II    O
clinical    O
trial    O
involving    O
people    O
with    O
SMA    O
types    O
2    O
and    O
3    O
.    O

It    O
is    O
also    O
used    O
in    O
some    O
pleochroic    O
dyes    O
and    O
together    O
with    O
e.g.    O
cholesteryl    B-Steroid115057744
oleyl    I-Steroid115057744
carbonate    I-Steroid115057744
and    O
cholesteryl    B-Steroid115057744
benzoate    I-Steroid115057744
in    O
some    O
thermochromic    O
applications    O
.    O

The    O
main    O
toxins    O
are    O
the    O
cardenolide    B-Steroid115057744
called    O
thevetin    B-Steroid115057744
A    I-Steroid115057744
and    O
thevetin    B-Steroid115057744
B    I-Steroid115057744
;    O
others    O
include    O
peruvoside    O
,    O
neriifolin    O
,    O
thevetoxin    O
and    O
ruvoside    O
.    O

Ouabain    B-Steroid115057744

Within    O
the    O
last    O
decade    O
[    O
when    O
?    O
]    O
,    O
many    O
independent    O
labs    O
have    O
demonstrated    O
that    O
,    O
in    O
addition    O
to    O
the    O
classical    O
ion    O
transporting    O
,    O
this    O
membrane    O
protein    O
can    O
also    O
relay    O
extracellular    O
ouabain    B-Steroid115057744
-    O
binding    O
signalling    O
into    O
the    O
cell    O
through    O
regulation    O
of    O
protein    O
tyrosine    O
phosphorylation    O
.    O

For    O
instance    O
,    O
--ATPase    O
found    O
in    O
the    O
membrane    O
of    O
heart    O
cells    O
is    O
an    O
important    O
target    O
of    O
cardiac    O
glycosides    O
(    O
for    O
example    O
digoxin    O
and    O
ouabain    B-Steroid115057744
)    O
,    O
inotropic    O
drugs    O
used    O
to    O
improve    O
heart    O
performance    O
by    O
increasing    O
its    O
force    O
of    O
contraction    O
.    O

Post    O
had    O
recently    O
discovered    O
that    O
three    O
sodium    O
ions    O
were    O
pumped    O
out    O
of    O
the    O
cell    O
for    O
every    O
two    O
potassium    O
ions    O
pumped    O
in    O
,    O
and    O
in    O
his    O
research    O
he    O
had    O
made    O
use    O
of    O
a    O
substance    O
called    O
ouabain    B-Steroid115057744
which    O
had    O
recently    O
been    O
shown    O
to    O
inhibit    O
the    O
pump    O
.    O

An    O
increase    O
in    O
extracellular    O
K+    O
has    O
been    O
shown    O
to    O
activate    O
an    O
ouabain    B-Steroid115057744
-    O
sensitive    O
electrogenic    O
Na+–K+-ATPase    O
followed    O
by    O
hyperpolarization    O
and    O
smooth    O
muscle    O
cell    O
relaxation    O
.    O

5-Dehydroepisterol    B-Steroid115057744
is    O
a    O
sterol    O
and    O
an    O
intermediate    O
in    O
steroid    O
biosynthesis    O
,    O
particularly    O
synthesis    O
of    O
brassinosteroid    B-Steroid115057744
.    O

An    O
inherited    O
disorder    O
associated    O
with    O
the    O
deposition    O
of    O
a    O
steroid    O
known    O
as    O
cholestanol    B-Steroid115057744
in    O
the    O
brain    O
and    O
other    O
tissues    O
and    O
with    O
elevated    O
levels    O
of    O
cholesterol    O
in    O
plasma    O
but    O
with    O
normal    O
total    O
cholesterol    O
level    O
;    O
it    O
is    O
characterized    O
by    O
progressive    O
cerebellar    O
ataxia    O
beginning    O
after    O
puberty    O
and    O
by    O
juvenile    O
cataracts    O
,    O
juvenile    O
or    O
infantile    O
onset    O
chronic    O
diarrhea    O
,    O
childhood    O
neurological    O
deficit    O
,    O
and    O
tendineous    O
or    O
tuberous    O
xanthomas    O
.    O

He    O
assisted    O
in    O
establishing    O
the    O
glycogenic    O
function    O
of    O
the    O
liver    O
;    O
showed    O
that    O
one    O
of    O
the    O
functions    O
of    O
the    O
liver    O
is    O
to    O
separate    O
from    O
the    O
blood    O
the    O
cholesterin    O
,    O
which    O
is    O
a    O
product    O
of    O
the    O
nervous    O
system    O
.    O
and    O
which    O
,    O
becoming    O
a    O
constituent    O
of    O
the    O
bile    O
,    O
is    O
afterward    O
converted    O
into    O
what    O
he    O
named    O
"    O
stercorin    O
"    O
(    O
better    O
known    O
as    O
coprosterol    B-Steroid115057744
)    O
,    O
the    O
odorous    O
principle    O
of    O
feces    O
.    O

For    O
instance    O
,    O
19-norsteroids    O
(    O
e.g.    O
,    O
19-norprogesterone    B-Steroid115057744
)    O
constitute    O
an    O
important    O
class    O
of    O
natural    O
and    O
synthetic    O
steroids    O
derived    O
by    O
removal    O
of    O
the    O
methyl    O
group    O
of    O
the    O
natural    O
product    O
progesterone    O
;    O
the    O
equivalent    O
change    O
between    O
testosterone    O
and    O
19-nortestosterone    O
(    O
nandrolone    O
)    O
is    O
illustrated    O
below    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Steroid115057744
)    O
,    O
desogestrel    B-Steroid115057744
,    O
ethylestrenol    O
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
ethinylestradiol    O
,    O
gestrinone    B-Steroid115057744
,    O
levonorgestrel    B-Steroid115057744
,    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    O
)    O
,    O
quinestrol    O
,    O
19-norprogesterone    B-Steroid115057744
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
.    O

The    O
elaboration    O
of    O
a    O
method    O
for    O
the    O
reduction    O
of    O
aromatic    O
rings    O
to    O
the    O
corresponding    O
dihydrobenzenes    O
under    O
controlled    O
conditions    O
by    O
A.    O
J.    O
Birch    O
opened    O
a    O
convenient    O
route    O
to    O
compounds    O
related    O
to    O
the    O
putative    O
19-norprogesterone    B-Steroid115057744
.    O

NOMAC    O
is    O
a    O
norpregnane    O
steroid    O
and    O
a    O
derivative    O
of    O
progesterone    O
belonging    O
to    O
the    O
19-norprogesterone    B-Steroid115057744
and    O
17α-hydroxyprogesterone    O
groups    O
.    O

include    O
,    O
megestrol    O
acetate    O
,    O
chlormadinone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
spironolactone    O
.    O

A    O
variety    O
of    O
analogues    O
of    O
medroxyprogesterone    O
acetate    O
,    O
such    O
as    O
chlormadinone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
megestrol    O
acetate    O
,    O
were    O
subsequently    O
developed    O
and    O
introduced    O
as    O
well    O
.    O

In    O
1969    O
,    O
along    O
with    O
a    O
variety    O
of    O
other    O
progestogens    O
including    O
progesterone    O
,    O
chlormadinone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
megestrol    O
acetate    O
,    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
ethynerone    O
,    O
and    O
chloroethynyl    O
norgestrel    O
,    O
anagestone    O
acetate    O
was    O
found    O
to    O
induce    O
the    O
development    O
of    O
mammary    O
gland    O
tumors    O
in    O
Beagle    O
dogs    O
after    O
extensive    O
treatment    O
(    O
2–7    O
years    O
)    O
with    O
very    O
high    O
doses    O
(    O
10–25    O
times    O
the    O
recommended    O
human    O
dose    O
)    O
,    O
though    O
notably    O
not    O
with    O
1–2    O
times    O
the    O
human    O
dosage    O
.    O

Subsequent    O
investigation    O
found    O
that    O
17α-hydroxyprogesterone    O
derivatves    O
included    O
anagestone    O
acetate    O
,    O
chlormadinone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
megestrol    O
acetate    O
produced    O
similar    O
mammary    O
gland    O
tumors    O
,    O
and    O
that    O
their    O
ability    O
to    O
do    O
so    O
correlated    O
directly    O
with    O
their    O
progestogenic    O
actions    O
.    O

It    O
is    O
a    O
17α-hydroxyprogesterone    O
derivative    O
and    O
a    O
derivative    O
of    O
the    O
less    O
potent    O
chlormadinone    B-Steroid115057744
acetate    I-Steroid115057744
.    O

Nidoflor    O
(    O
cream    O
,    O
combined    O
with    O
neomycin    O
sulfate    O
and    O
triamcinolone    B-Steroid115057744
acetonide    I-Steroid115057744
)    O

Animax    O
(    O
veterinary    O
topical    O
ointment    O
or    O
cream    O
;    O
combined    O
with    O
neomycin    O
sulfate    O
,    O
thiostrepton    O
and    O
triamcinolone    B-Steroid115057744
acetonide    I-Steroid115057744
)    O

Amcinonide    O
,    O
budesonide    B-Steroid115057744
,    O
desonide    O
,    O
fluocinolone    O
acetonide    O
,    O
fluocinonide    O
,    O
halcinonide    O
,    O
and    O
triamcinolone    B-Steroid115057744
acetonide    I-Steroid115057744
.    O

Triamcinolone    B-Steroid115057744
acetonide    I-Steroid115057744

It    O
is    O
injected    O
into    O
the    O
heel    O
when    O
treating    O
plantar    O
fasciitis    O
,    O
sometimes    O
in    O
conjunction    O
with    O
triamcinolone    B-Steroid115057744
acetonide    I-Steroid115057744
.    O

Additionally    O
,    O
intralesional    O
injection    O
with    O
a    O
corticosteroid    O
such    O
as    O
Kenalog    B-Steroid115057744
does    O
appear    O
to    O
aid    O
in    O
the    O
reduction    O
of    O
inflammation    O
and    O
pruritus    O
.    O

It    O
is    O
an    O
isomer    O
of    O
the    O
related    O
19-nortestosterone    O
derivative    O
progestins    O
lynestrenol    B-Steroid115057744
and    O
cingestol    O
.    O

The    O
estranes    O
include    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
lynestrenol    B-Steroid115057744
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Steroid115057744
,    O
desogestrel    B-Steroid115057744
,    O
etonogestrel    B-Steroid115057744
,    O
gestodene    B-Steroid115057744
,    O
norgestimate    O
,    O
dienogest    B-Steroid115057744
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    O
.    O

Examples    O
include    O
drugs    O
such    O
as    O
Norethisterone    B-Steroid115057744
,    O
Ethisterone    O
,    O
and    O
Lynestrenol    B-Steroid115057744
.    O

Delmadinone    B-Steroid115057744

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Steroid115057744
)    O
,    O
desogestrel    B-Steroid115057744
,    O
ethylestrenol    O
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
ethinylestradiol    O
,    O
gestrinone    B-Steroid115057744
,    O
levonorgestrel    B-Steroid115057744
,    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    O
)    O
,    O
quinestrol    O
,    O
19-norprogesterone    B-Steroid115057744
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
.    O

The    O
company    O
's    O
products    O
include    O
Botox    O
,    O
Namenda    O
,    O
Restasis    O
,    O
Linzess    O
,    O
Bystolic    O
,    O
Juvederm    O
,    O
Latisse    O
,    O
Lo    O
Loestrin    O
Fe    O
,    O
Estrace    O
,    O
Teflaro    O
,    O
Dalvance    O
,    O
Ozurdex    O
,    O
Optive    O
,    O
Natrelle    O
,    O
Viibryd    O
,    O
Liletta    B-Steroid115057744
,    O
Saphris    O
,    O
Enablex    O
,    O
Actonel    O
,    O
Androderm    O
,    O
Gelnique    O
and    O
others    O
.    O

The    O
estranes    O
include    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
lynestrenol    B-Steroid115057744
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Steroid115057744
,    O
desogestrel    B-Steroid115057744
,    O
etonogestrel    B-Steroid115057744
,    O
gestodene    B-Steroid115057744
,    O
norgestimate    O
,    O
dienogest    B-Steroid115057744
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    O
.    O

The    O
Yuzpe    O
Regimen    O
is    O
a    O
method    O
of    O
emergency    O
contraception    O
using    O
a    O
combination    O
of    O
estrogen    O
and    O
progestogen    O
hormones    O
(    O
100    O
μg    O
ethinylestradiol    O
and    O
0.5    O
mg    O
of    O
levonorgestrel    B-Steroid115057744
as    O
soon    O
as    O
possible    O
and    O
again    O
in    O
12    O
hrs    O
)    O
and    O
started    O
within    O
72    O
hours    O
of    O
sexual    O
intercourse    O
.    O

In    O
April    O
2005    O
,    O
Governor    O
Rod    O
Blagojevich    O
by    O
emergency    O
executive    O
order    O
required    O
all    O
pharmacists    O
to    O
provide    O
Plan    O
B    O
levonorgestrel    B-Steroid115057744
.    O

Other    O
-    O
hemodialysis    O
,    O
excessive    O
UV    O
-    O
A    O
,    O
cola    O
,    O
oral    O
contraceptive    O
pills    O
(    O
levonorgestrel    B-Steroid115057744
and    O
ethinylestradiol    O
)    O
,    O
narrowband    O
UV    O
-    O
B    O
phototherapy    O
(    O
rarely    O
)    O

Levonorgestrel    O
-    O
releasing    O
implant    O
,    O
sold    O
under    O
the    O
brand    O
name    O
Jadelle    O
among    O
others    O
,    O
is    O
a    O
device    O
made    O
up    O
of    O
a    O
two    O
rods    O
of    O
levonorgestrel    B-Steroid115057744
used    O
for    O
birth    O
control    O
.    O

The    O
original    O
Norplant    O
consisted    O
of    O
a    O
set    O
of    O
six    O
small    O
(    O
2.4    O
mm    O
×    O
34    O
mm    O
)    O
silicone    O
capsules    O
,    O
each    O
filled    O
with    O
36    O
mg    O
of    O
levonorgestrel    B-Steroid115057744
implanted    O
under    O
the    O
skin    O
in    O
the    O
upper    O
arm    O
and    O
effective    O
for    O
five    O
years    O
.    O

It    O
has    O
been    O
shown    O
to    O
prevent    O
about    O
62–85%    O
of    O
expected    O
pregnancies    O
,    O
and    O
prevents    O
more    O
pregnancies    O
than    O
emergency    O
contraception    O
with    O
levonorgestrel    B-Steroid115057744
.    O

It    O
might    O
also    O
interact    O
with    O
hormonal    O
contraceptives    O
and    O
progestogens    O
such    O
as    O
levonorgestrel    B-Steroid115057744
and    O
other    O
substrates    O
of    O
the    O
progesterone    O
receptor    O
,    O
as    O
well    O
as    O
with    O
glucocorticoids    O
.    O

Ethinylestradiol    O
/    O
levonorgestrel    O
(    O
also    O
ethinyl    O
estradiol    O
/    O
levonorgestrel    O
)    O
is    O
a    O
combined    O
birth    O
control    O
pill    O
made    O
up    O
of    O
ethinylestradiol    O
,    O
an    O
estrogen    O
and    O
levonorgestrel    B-Steroid115057744
a    O
progestin    O
.    O

A    O
2001    O
comparative    O
study    O
of    O
the    O
IMS    O
LifeLink    O
Health    O
Plan    O
Claims    O
Database    O
interpreted    O
that    O
in    O
a    O
large    O
cohort    O
of    O
women    O
using    O
oral    O
contraceptives    O
,    O
there    O
was    O
found    O
a    O
small    O
,    O
statistically    O
significant    O
increase    O
in    O
the    O
risk    O
of    O
gallbladder    O
disease    O
associated    O
with    O
desogestrel    B-Steroid115057744
,    O
drospirenone    O
and    O
norethisterone    B-Steroid115057744
compared    O
with    O
levonorgestrel    B-Steroid115057744
.    O

In    O
early    O
February    O
2006    O
,    O
Stephens    O
challenged    O
Blagojevich    O
in    O
an    O
appearance    O
on    O
"    O
The    O
Daily    O
Show    O
"    O
to    O
discuss    O
the    O
Governor    O
's    O
executive    O
order    O
that    O
pharmacists    O
must    O
dispense    O
any    O
drugs    O
for    O
which    O
a    O
customer    O
had    O
a    O
valid    O
prescription    O
,    O
including    O
birth    O
control    O
pills    O
and    O
Plan    B-Steroid115057744
B    I-Steroid115057744
Blagojevich    O
was    O
interviewed    O
by    O
Jason    O
Jones    O
,    O
who    O
repeatedly    O
pretended    O
to    O
be    O
unable    O
to    O
pronounce    O
Blagojevich    O
and    O
simply    O
called    O
him    O
"    O
Governor    O
Smith    O
"    O
.    O

Oleandrin    B-Steroid115057744
,    O
one    O
of    O
the    O
toxins    O
present    O
in    O
oleander    O
.    O

Scilliroside    O
and    O
other    O
cardiac    O
glycosides    O
like    O
oleandrin    B-Steroid115057744

Normethandrone    B-Steroid115057744
(    O
methylestrenolone    O
;    O
17α-methyl-19-NT    O
)    O

Normethandrone    B-Steroid115057744
(methylestrenolone,    I-Steroid115057744
normethisterone)    I-Steroid115057744

Phytoecdysteroids    B-Steroid115057744
are    O
plant    O
-    O
derived    O
ecdysteroid    B-Steroid115057744
.    O

Various    O
species    O
contain    O
apigenin    O
,    O
luteolin    O
,    O
quercetin    O
,    O
other    O
flavonoids    O
and    O
ecdysteroid    B-Steroid115057744
.    O

These    O
glands    O
secrete    O
an    O
ecdysteroid    B-Steroid115057744
called    O
ecdysone    B-Steroid115057744
,    O
or    O
the    O
moulting    O
hormone    O
,    O
which    O
initiates    O
the    O
epidermal    O
moulting    O
process    O
.    O

The    O
main    O
active    O
compounds    O
are    O
cardiac    O
glycosides    O
,    O
including    O
unique    O
bufadienolide    B-Steroid115057744
such    O
as    O
glucoscillaren    O
A    O
,    O
proscillaridine    O
A    O
,    O
scillaren    O
A    O
,    O
scilliglaucoside    O
and    O
scilliphaeoside    O
.    O

In    O
common    O
with    O
other    O
Crassulaceae    O
(    O
such    O
as    O
the    O
genera    O
"    O
Tylecodon    O
"    O
,    O
"    O
Cotyledon    O
"    O
and    O
"    O
Adromischus    O
"    O
)    O
,    O
some    O
"    O
Kalanchoe    O
"    O
species    O
contain    O
bufadienolide    B-Steroid115057744
cardiac    O
glycosides    O
which    O
can    O
cause    O
cardiac    O
poisoning    O
,    O
particularly    O
in    O
grazing    O
animals    O
.    O

The    O
parotoid    O
gland    O
on    O
either    O
side    O
of    O
the    O
head    O
of    O
a    O
cane    O
toad    O
produces    O
a    O
secretion    O
containing    O
bufadienolide    B-Steroid115057744
that    O
is    O
toxic    O
to    O
most    O
animals    O
.    O

However    O
,    O
the    O
leaves    O
contain    O
a    O
bufanolide    B-Steroid115057744
called    O
cotyledontoxin    O
,    O
which    O
is    O
toxic    O
to    O
sheep    O
,    O
goats    O
,    O
horses    O
,    O
cattle    O
,    O
poultry    O
,    O
and    O
dogs    O
,    O
causing    O
a    O
condition    O
known    O
as    O
cotyledonosis    O
.    O

According    O
to    O
the    O
report    O
,    O
Bigbie    O
admitted    O
to    O
purchasing    O
and    O
using    O
a    O
variety    O
of    O
performance    O
-    O
enhancing    O
substances    O
from    O
Kirk    O
Radomski    O
from    O
2001    O
to    O
2005    O
,    O
including    O
human    O
growth    O
hormone    O
,    O
Deca    O
-    O
Durabolin    O
,    O
Sustanon    B-Steroid115057744
,    O
testosterone    O
,    O
and    O
anti    O
-    O
estrogen    O
drugs    O
.    O

Products    O
include    O
:    O
Bridion    O
,    O
Esmirtazapine    O
,    O
Remeron    O
,    O
Remeron    O
SolTab    O
,    O
Sustanon    B-Steroid115057744
,    O
Deca    O
-    O
Durabolin    O
,    O
Pregnyl    O
,    O
Implanon    O
,    O
NuvaRing    O
,    O
Marvelon    O
,    O
Desolett    O
and    O
a    O
variety    O
of    O
other    O
contraceptive    O
products    O
.    O

Sterols    O
isolated    O
from    O
the    O
mushroom    O
include    O
,    O
ganoderol    B-Steroid115057744
,    O
ganoderenic    B-Steroid115057744
acid    I-Steroid115057744
,    O
ganoderiol    B-Steroid115057744
,    O
ganodermanontriol    B-Steroid115057744
,    O
lucidadiol    B-Steroid115057744
,    O
and    O
ganodermadiol    B-Steroid115057744
.    O

Phytosterols    B-Steroid115057744
,    O
which    O
encompass    O
plant    O
sterols    O
and    O
stanols    B-Steroid115057744
,    O
are    O
phytosteroids    O
similar    O
to    O
cholesterol    O
which    O
occur    O
in    O
plants    O
and    O
vary    O
only    O
in    O
carbon    O
side    O
chains    O
and/or    O
presence    O
or    O
absence    O
of    O
a    O
double    O
bond    O
.    O

The    O
equivalent    O
ability    O
and    O
safety    O
of    O
plant    O
sterols    O
and    O
plant    O
stanol    B-Steroid115057744
to    O
lower    O
cholesterol    O
continues    O
to    O
be    O
a    O
hotly    O
debated    O
topic    O
.    O

Faslodex    B-Steroid115057744
(    O
IPR    O
)    O

If    O
abiraterone    O
acetate    O
is    O
used    O
in    O
the    O
treatment    O
of    O
breast    O
cancer    O
,    O
it    O
should    O
be    O
combined    O
with    O
an    O
estrogen    O
receptor    O
antagonist    O
like    O
fulvestrant    B-Steroid115057744
.    O

The    O
MONARCH    O
2    O
study    O
is    O
investigating    O
the    O
effectiveness    O
of    O
Abemaciclib    O
in    O
combination    O
with    O
Fulvestrant    B-Steroid115057744
for    O
women    O
with    O
breast    O
cancer    O
.    O

Examples    O
of    O
progonadotropic    O
drugs    O
include    O
gonadotropin    O
-    O
releasing    O
hormone    O
(    O
GnRH    O
)    O
agonists    O
when    O
administered    O
in    O
a    O
pulsatile    O
(    O
as    O
opposed    O
to    O
continuous    O
)    O
manner    O
,    O
antiestrogens    O
such    O
as    O
tamoxifen    O
,    O
clomifene    O
,    O
fulvestrant    B-Steroid115057744
,    O
and    O
aromatase    O
inhibitors    O
like    O
anastrozole    O
,    O
and    O
,    O
only    O
in    O
men    O
,    O
pure    O
antiandrogens    O
such    O
as    O
flutamide    O
,    O
bicalutamide    O
,    O
and    O
enzalutamide    O
.    O

A    O
1,6-addition    O
is    O
also    O
possible    O
,    O
for    O
example    O
in    O
one    O
step    O
of    O
the    O
commercial    O
-    O
scale    O
production    O
of    O
fulvestrant    B-Steroid115057744
:    O

In    O
addition    O
,    O
though    O
17α-MP    O
itself    O
was    O
never    O
introduced    O
for    O
medical    O
use    O
,    O
progestogen    O
derivatives    O
of    O
the    O
compound    O
,    O
including    O
medrogestone    B-Steroid115057744
(    O
1966    O
)    O
and    O
the    O
19-norprogesterone    O
derivatives    O
demegestone    B-Steroid115057744
(    O
1974    O
)    O
,    O
promegestone    B-Steroid115057744
(    O
1983    O
)    O
,    O
and    O
trimegestone    B-Steroid115057744
(    O
2001    O
)    O
,    O
have    O
been    O
marketed    O
.    O

Trimegestone    B-Steroid115057744

Physalins    B-Steroid115057744
are    O
steroidal    O
constituents    O
of    O
"    O
Physalis    O
"    O
plants    O
which    O
possess    O
an    O
unusual    O
13,14-seco-16,24-cyclo    O
-    O
steroidal    O
ring    O
skeleton    O
(    O
where    O
the    O
bond    O
that    O
is    O
normally    O
present    O
between    O
the    O
13    O
and    O
14    O
positions    O
in    O
other    O
steroids    O
is    O
broken    O
while    O
a    O
new    O
bond    O
between    O
positions    O
16    O
and    O
24    O
is    O
formed    O
;    O
see    O
figure    O
below    O
)    O
.    O

Sarsasapogenin    B-Steroid115057744
is    O
a    O
steroidal    O
sapogenin    O
,    O
that    O
is    O
the    O
aglycosidic    O
portion    O
of    O
a    O
plant    O
saponin    O
.    O

Ursodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
therapy    O
is    O
beneficial    O
,    O
but    O
the    O
disease    O
often    O
progresses    O
and    O
may    O
require    O
liver    O
transplantation    O
.    O

Urso    B-Steroid115057744

Some    O
medication    O
,    O
such    O
as    O
ursodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
,    O
may    O
be    O
used    O
;    O
and    O
lithotripsy    O
,    O
a    O
procedure    O
used    O
to    O
break    O
down    O
the    O
stones    O
,    O
may    O
also    O
be    O
used    O
.    O

Disease    O
might    O
be    O
investigated    O
using    O
ultrasound    O
or    O
ERCP    O
,    O
and    O
might    O
be    O
treated    O
with    O
drugs    O
such    O
as    O
antibiotics    O
or    O
UDCA    B-Steroid115057744
,    O
or    O
by    O
the    O
surgical    O
removal    O
of    O
the    O
gallbladder    O
.    O

Upon    O
diagnosis    O
,    O
many    O
providers    O
will    O
prescribe    O
Ursodeoxycholic    B-Steroid115057744
Acid    I-Steroid115057744
.    O

Her    O
internet    O
work    O
has    O
also    O
garnered    O
Web    O
Marketing    O
Association    O
's    O
best    O
education    O
website    O
,    O
numerous    O
CASE    O
awards    O
,    O
and    O
a    O
UCDA    B-Steroid115057744
Gold    O
award    O
.    O

Sterols    O
isolated    O
from    O
the    O
mushroom    O
include    O
,    O
ganoderol    B-Steroid115057744
,    O
ganoderenic    B-Steroid115057744
acid    I-Steroid115057744
,    O
ganoderiol    B-Steroid115057744
,    O
ganodermanontriol    B-Steroid115057744
,    O
lucidadiol    B-Steroid115057744
,    O
and    O
ganodermadiol    B-Steroid115057744
.    O

Calorie    O
restriction    O
has    O
been    O
shown    O
to    O
increase    O
DHEA    B-Steroid115057744
in    O
primates    O
,    O
but    O
it    O
has    O
not    O
been    O
shown    O
to    O
increase    O
DHEA    B-Steroid115057744
in    O
post    O
-    O
pubescent    O
primates    O
.    O

By    O
inhibiting    O
3β-HSD    O
,    O
epostane    O
blocks    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-Steroid115057744
(    O
and    O
also    O
the    O
conversion    O
of    O
dehydroepiandrosterone    B-Steroid115057744
to    O
androstenedione    O
)    O
,    O
thereby    O
functioning    O
as    O
an    O
antiprogestogen    O
and    O
terminating    O
pregnancy    O
.    O

A    O
Δ5    O
-    O
3-ketosteroid    O
isomerase    O
-    O
disrupted    O
mutant    O
of    O
strain    O
TA441    O
can    O
grow    O
on    O
dehydroepiandrosterone    B-Steroid115057744
,    O
which    O
has    O
a    O
double    O
bond    O
at    O
Δ5    O
,    O
but    O
can    O
not    O
grow    O
on    O
epiandrosterone    O
,    O
which    O
lacks    O
a    O
double    O
bond    O
at    O
Δ5    O
,    O
indicating    O
that    O
"    O
C.    O
testosteroni    O
"    O
KSI    O
is    O
responsible    O
for    O
transfer    O
of    O
the    O
double    O
bond    O
from    O
Δ5    O
to    O
Δ4    O
and    O
transfer    O
of    O
the    O
double    O
bond    O
by    O
hydrogenation    O
at    O
Δ5    O
and    O
following    O
dehydrogenation    O
at    O
Δ4    O
is    O
not    O
possible    O
.    O

In    O
vitro    O
"    O
cell    O
proliferation    O
assay    O
indicates    O
that    O
G6PD    O
inhibitors    O
,    O
DHEA    B-Steroid115057744
(    O
dehydroepiandrosterone    O
)    O
and    O
ANAD    O
(    O
6-aminonicotinamide    O
)    O
,    O
effectively    O
decrease    O
the    O
growth    O
of    O
AML    O
cell    O
lines    O
.    O

In    O
December    O
2009    O
,    O
a    O
urine    O
test    O
taken    O
at    O
the    O
2009    O
USPRO    O
Time    O
Trial    O
Championships    O
the    O
previous    O
August    O
,    O
in    O
which    O
Zirbel    O
came    O
second    O
,    O
tested    O
positive    O
for    O
DHEA    B-Steroid115057744
.    O

Levels    O
of    O
progesterone    O
,    O
17α-hydroxyprogesterone    O
,    O
androstenedione    O
,    O
testosterone    O
,    O
and    O
dihydrotestosterone    O
(    O
DHT    O
)    O
were    O
elevated    O
in    O
the    O
sisters    O
,    O
while    O
concentrations    O
of    O
adrenal    O
steroids    O
including    O
cortisol    O
,    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
,    O
11β-hydroxyandrostenedione    O
,    O
11-deoxycortisol    O
,    O
and    O
21-deoxycortisol    O
were    O
within    O
normal    O
ranges    O
.    O

It    O
has    O
been    O
demonstrated    O
that    O
,    O
after    O
controlling    O
for    O
age    O
,    O
sex    O
,    O
and    O
BMI    O
,    O
larger    O
quantities    O
of    O
DHEA    B-Steroid115057744
and    O
DHEA-S    B-Steroid115057744
tended    O
to    O
be    O
linked    O
to    O
larger    O
pituitary    O
volume    O
.    O

Again    O
controlling    O
for    O
age    O
,    O
sex    O
,    O
and    O
BMI    O
,    O
DHEA    B-Steroid115057744
and    O
DHEA-S    B-Steroid115057744
have    O
been    O
found    O
to    O
be    O
predictive    O
of    O
larger    O
pituitary    O
gland    O
volume    O
,    O
which    O
was    O
also    O
associated    O
with    O
increased    O
ratings    O
of    O
social    O
anxiety    O
.    O

Dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
is    O
the    O
most    O
abundant    O
circulating    O
androgen    O
hormone    O
and    O
can    O
be    O
rapidly    O
metabolized    O
within    O
target    O
tissues    O
into    O
potent    O
androgens    O
and    O
estrogens    O
.    O

A    O
small    O
human    O
study    O
in    O
2011    O
found    O
that    O
monitoring    O
blood    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
variations    O
in    O
response    O
to    O
an    O
oxidative    O
stress    O
could    O
be    O
a    O
useful    O
proxy    O
test    O
:    O
the    O
subjects    O
with    O
MCI    O
did    O
not    O
have    O
a    O
DHEA    O
variation    O
,    O
while    O
the    O
healthy    O
controls    O
did    O
.    O

The    O
17α-hydroxylase    O
activity    O
of    O
CYP17A1    O
is    O
required    O
for    O
the    O
generation    O
of    O
glucocorticoids    O
such    O
as    O
cortisol    O
,    O
but    O
both    O
the    O
hydroxylase    O
and    O
17,20-lyase    O
activities    O
of    O
CYP17A1    O
are    O
required    O
for    O
the    O
production    O
of    O
androgenic    O
and    O
oestrogenic    O
sex    O
steroids    O
by    O
converting    O
17α-hydroxypregnenolone    O
to    O
dehydroepiandrosterone    B-Steroid115057744
(DHEA)    I-Steroid115057744
.    O

Other    O
androgens    O
,    O
however    O
,    O
such    O
as    O
DHEA    B-Steroid115057744
,    O
increase    O
immune    O
response    O
.    O

It    O
produces    O
androgens    O
,    O
mainly    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
,    O
DHEA    B-Steroid115057744
sulfate    I-Steroid115057744
(    O
DHEA    O
-    O
S    O
)    O
,    O
and    O
androstenedione    O
(    O
the    O
precursor    O
to    O
testosterone    O
)    O
in    O
humans    O
.    O

Cells    O
in    O
zona    O
reticularis    O
of    O
the    O
adrenal    O
glands    O
produce    O
male    O
sex    O
hormones    O
,    O
or    O
androgens    O
,    O
the    O
most    O
important    O
of    O
which    O
is    O
DHEA    B-Steroid115057744
.    O

During    O
early    O
childhood    O
androgen    O
synthesis    O
and    O
secretion    O
remain    O
low    O
,    O
but    O
several    O
years    O
before    O
puberty    O
(    O
from    O
6–8    O
years    O
of    O
age    O
)    O
changes    O
occur    O
in    O
both    O
anatomical    O
and    O
functional    O
aspects    O
of    O
cortical    O
androgen    O
production    O
that    O
lead    O
to    O
increased    O
secretion    O
of    O
the    O
steroids    O
DHEA    B-Steroid115057744
and    O
DHEA-S    B-Steroid115057744
These    O
changes    O
are    O
part    O
of    O
a    O
process    O
called    O
adrenarche    O
,    O
which    O
has    O
only    O
been    O
described    O
in    O
humans    O
and    O
some    O
other    O
primates    O
.    O

This    O
includes    O
interconversion    O
of    O
DHEA    B-Steroid115057744
and    O
androstenediol    O
,    O
androstenedione    O
and    O
testosterone    O
,    O
and    O
estrone    O
and    O
estradiol    O
.    O

The    O
endogenous    O
steroids    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
and    O
its    O
sulfate    O
ester    O
,    O
DHEA    B-Steroid115057744
sulfate    I-Steroid115057744
(    O
DHEA    O
-    O
S    O
)    O
,    O
have    O
been    O
identified    O
as    O
small    O
-    O
molecule    O
agonists    O
of    O
the    O
TrkA    O
and    O
p75NTR    O
with    O
high    O
affinity    O
(    O
around    O
5    O
nM    O
)    O
,    O
and    O
hence    O
as    O
so    O
-    O
called    O
"    O
microneurotrophins    O
"    O
.    O

3β-Hydroxysteroid    O
dehydrogenase/Δ5    O
-    O
4    O
isomerase    O
(    O
3β-HSD    O
)    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-Steroid115057744
,    O
17α-hydroxyprogesterone    O
from    O
17α-hydroxypregnenolone    O
,    O
and    O
androstenedione    O
from    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
in    O
the    O
adrenal    O
gland    O
.    O

DHEA    B-Steroid115057744
to    O
androstenedione    O

5α-Dihydroprogesterone    B-Steroid115057744

5α-Dihydroprogesterone    B-Steroid115057744

5α-Dihydroprogesterone    B-Steroid115057744

It    O
has    O
also    O
been    O
found    O
to    O
act    O
as    O
an    O
agonist    O
of    O
the    O
human    O
pregnane    O
X    O
receptor    O
,    O
albeit    O
with    O
an    O
EC50    O
that    O
is    O
more    O
than    O
an    O
order    O
of    O
magnitude    O
lower    O
than    O
that    O
of    O
other    O
endogenous    O
pregnane    B-Steroid115057744
like    O
pregnenolone    B-Steroid115057744
,    O
pregnanediol    O
,    O
allopregnanedione    B-Steroid115057744
,    O
and    O
allopregnanolone    O
.    O

Metenolone    O
enanthate    O
,    O
also    O
known    O
as    O
metenolone    O
17β-enanthate    O
,    O
is    O
a    O
synthetic    O
androstane    B-Steroid115057744
steroid    O
and    O
a    O
derivative    O
of    O
DHT    O
.    O

Boldenone    O
,    O
also    O
known    O
as    O
Δ1-testosterone    O
,    O
1-dehydrotestosterone    O
,    O
or    O
androsta-1,4-dien-17β-ol-3-one    O
,    O
is    O
a    O
synthetic    O
androstane    B-Steroid115057744
steroid    O
and    O
a    O
derivative    O
of    O
testosterone    O
.    O

Androstane    B-Steroid115057744
is    O
a    O
C19    O
steroid    O
with    O
a    O
gonane    B-Steroid115057744
core    O
.    O

Androstane    O
can    O
exist    O
as    O
either    O
of    O
two    O
isomers    O
,    O
known    O
as    O
5α-androstane    B-Steroid115057744
and    O
5β-androstane    B-Steroid115057744
.    O

Metandienone    O
,    O
also    O
known    O
structurally    O
as    O
17α-methyl-δ1-testosterone    O
or    O
as    O
17α-methylandrost-1,4-dien-17β-ol-3-one    O
,    O
is    O
a    O
17α-alkylated    O
androstane    B-Steroid115057744
steroid    O
and    O
a    O
derivative    O
of    O
testosterone    O
.    O

Steranes    O
have    O
an    O
androstane    B-Steroid115057744
skeleton    O
with    O
a    O
side    O
chain    O
at    O
carbon    O
C-17    O
.    O

Metenolone    O
,    O
also    O
known    O
as    O
1-methyl-4,5α-dihydro-δ1-testosterone    O
(    O
1-methyl-δ1-DHT    O
)    O
or    O
as    O
1-methyl-5α-androst-1-en-17β-ol-3-one    O
,    O
is    O
a    O
synthetic    O
androstane    B-Steroid115057744
steroid    O
and    O
derivative    O
of    O
dihydrotestosterone    O
(    O
DHT    O
)    O
.    O

A    O
brand    O
name    O
of    O
co-cyprindiol    B-Steroid115057744
(    O
cyproterone    O
acetate    O
/    O
ethinylestradiol    O
)    O
,    O
an    O
oral    O
contraceptive    O

Cyproterone    B-Steroid115057744
acetate    I-Steroid115057744

A    O
phase    O
III    O
clinical    O
trial    O
comparing    O
high    O
-    O
dose    O
intramuscular    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
(    O
300    O
mg    O
/    O
week    O
)    O
and    O
high    O
-    O
dose    O
intramuscular    O
estradiol    O
undecylate    O
(    O
100    O
mg    O
/    O
month    O
)    O
in    O
the    O
treatment    O
of    O
prostate    O
cancer    O
found    O
that    O
estradiol    O
undecylate    O
suppressed    O
testosterone    O
levels    O
into    O
the    O
castrate    O
range    O
(    O
<    O
50    O
ng    O
/    O
dL    O
)    O
within    O
at    O
least    O
3    O
months    O
whereas    O
testosterone    O
levels    O
with    O
cyproterone    O
acetate    O
were    O
significantly    O
higher    O
and    O
above    O
the    O
castrate    O
range    O
even    O
after    O
6    O
months    O
of    O
treatment    O
.    O

Spironolactone    O
is    O
frequently    O
used    O
as    O
a    O
component    O
of    O
hormone    O
replacement    O
therapy    O
in    O
transgender    O
women    O
,    O
especially    O
in    O
the    O
United    O
States    O
(    O
where    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
is    O
not    O
available    O
)    O
,    O
usually    O
in    O
addition    O
to    O
an    O
estrogen    O
.    O

Spironolactone    O
,    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
flutamide    O
are    O
some    O
of    O
the    O
most    O
well    O
-    O
known    O
and    O
widely    O
used    O
drugs    O
.    O

Spironolactone    O
,    O
similarly    O
to    O
other    O
steroidal    O
antiandrogens    O
such    O
as    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
is    O
actually    O
not    O
a    O
pure    O
,    O
or    O
"    O
silent    O
"    O
,    O
antagonist    O
of    O
the    O
AR    O
,    O
but    O
rather    O
is    O
a    O
weak    O
partial    O
agonist    O
with    O
the    O
capacity    O
for    O
both    O
antagonistic    O
and    O
agonistic    O
effects    O
.    O

Unlike    O
other    O
steroidal    O
antiandrogens    O
such    O
as    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
(    O
CPA    O
)    O
,    O
it    O
is    O
not    O
also    O
a    O
progestogen    O
,    O
instead    O
acting    O
as    O
a    O
selective    O
androgen    O
receptor    O
antagonist    O
similarly    O
to    O
nonsteroidal    O
antiandrogens    O
such    O
as    O
bicalutamide    O
.    O

The    O
binding    O
affinity    O
of    O
oxendolone    O
for    O
the    O
AR    O
is    O
far    O
lower    O
than    O
that    O
of    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
.    O

A    O
brand    O
name    O
of    O
the    O
oral    O
contraceptive    O
co-cyprindiol    B-Steroid115057744
(    O
cyproterone    O
acetate    O
/    O
ethinylestradiol    O
)    O

NOMAC    O
has    O
weak    O
or    O
moderate    O
antiandrogenic    O
activity    O
(    O
5    O
to    O
20    O
times    O
less    O
than    O
that    O
of    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
(    O
a    O
strong    O
antiandrogen    O
)    O
,    O
with    O
approximately    O
12–31%    O
of    O
the    O
of    O
testosterone    O
for    O
the    O
androgen    O
receptor    O
)    O
.    O

Cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
:    O
A    O
dual    O
antiandrogen    O
and    O
progestogen    O
.    O

A    O
brand    O
name    O
of    O
co-cyprindiol    B-Steroid115057744
(    O
cyproterone    O
acetate    O
/    O
ethinylestradiol    O
)    O
,    O
an    O
oral    O
contraceptive    O

The    O
seed    O
contain    O
insect    O
moulting    O
hormones    O
including    O
rubrosterone    B-Steroid115057744
,    O
ecdysterone    O
,    O
and    O
inokosterone    O
.    O

Phytoecdysteroids    B-Steroid115057744
are    O
plant    O
-    O
derived    O
ecdysteroid    B-Steroid115057744
.    O

In    O
2001    O
he    O
tested    O
positive    O
for    O
norandrosterone    B-Steroid115057744
,    O
and    O
became    O
the    O
first    O
Czech    O
athlete    O
to    O
receive    O
a    O
life    O
ban    O
.    O

Metabolites    O
of    O
nandrolone    O
include    O
5α-dihydronandrolone    O
,    O
19-norandrosterone    B-Steroid115057744
,    O
and    O
19-noretiocholanolone    O
,    O
and    O
these    O
metabolites    O
may    O
be    O
detected    O
in    O
urine    O
.    O

Nandrolone    O
use    O
is    O
directly    O
detectable    O
in    O
hair    O
or    O
indirectly    O
detectable    O
in    O
urine    O
by    O
testing    O
for    O
the    O
presence    O
of    O
19-norandrosterone    B-Steroid115057744
,    O
a    O
metabolite    O
.    O

Bakhit    O
tested    O
positive    O
for    O
norandrosterone    B-Steroid115057744
at    O
a    O
competition    O
in    O
Sollentuna    O
,    O
Sweden    O
in    O
June    O
2009    O
and    O
was    O
subsequently    O
handed    O
a    O
two    O
-    O
year    O
ban    O
from    O
sports    O
.    O

However    O
,    O
he    O
was    O
disqualified    O
after    O
his    O
2006    O
win    O
because    O
his    O
doping    O
test    O
at    O
the    O
race    O
was    O
positive    O
for    O
the    O
banned    O
steroid    O
norandrosterone    B-Steroid115057744
.    O

In    O
2013    O
Urzu    O
tested    O
positive    O
for    O
Norandrosterone    B-Steroid115057744
in    O
an    O
out    O
of    O
competition    O
test    O
,    O
and    O
was    O
given    O
another    O
two    O
-    O
year    O
sanction    O
.    O

Starting    O
in    O
2011    O
,    O
POGO    O
conducted    O
an    O
investigation    O
into    O
conflicts    O
of    O
interest    O
of    O
an    O
advisory    O
committee    O
at    O
the    O
Food    O
and    O
Drug    O
Administration    O
that    O
was    O
reviewing    O
the    O
Yaz    O
and    O
Yasmin    B-Steroid115057744
birth    O
control    O
pills    O
.    O

Drospirenone    B-Steroid115057744

This    O
was    O
determined    O
to    O
be    O
due    O
to    O
metabolic    O
conversion    O
of    O
spirorenone    O
into    O
drospirenone    B-Steroid115057744
(    O
1,2-dihydrospirorenone    O
)    O
by    O
the    O
enzyme    O
Δ1-hydrase    O
,    O
a    O
transformation    O
that    O
occurs    O
only    O
in    O
monkeys    O
and    O
humans    O
.    O

Spironolactone    O
is    O
closely    O
structurally    O
related    O
to    O
other    O
clinically    O
used    O
spirolactones    O
such    O
as    O
canrenone    O
,    O
potassium    B-Steroid115057744
canrenoate    I-Steroid115057744
,    O
drospirenone    B-Steroid115057744
,    O
and    O
eplerenone    B-Steroid115057744
,    O
as    O
well    O
as    O
to    O
the    O
never    O
-    O
marketed    O
spirolactones    O
SC-5233    O
(    O
6,7-dihydrocanrenone    O
;    O
7α-desthioacetylspironolactone    O
)    O
,    O
SC-8109    O
(    O
19-nor-6,7-dihydrocanrenone    O
)    O
,    O
spiroxasone    O
,    O
prorenone    O
(    O
SC-23133    O
)    O
,    O
mexrenone    B-Steroid115057744
(    O
SC-25152    O
,    O
ZK-32055    O
)    O
,    O
dicirenone    O
(    O
SC-26304    O
)    O
,    O
spirorenone    O
(    O
ZK-35973    O
)    O
,    O
and    O
mespirenone    O
(    O
ZK-94679    O
)    O
.    O

Some    O
,    O
such    O
as    O
those    O
containing    O
cyproterone    O
acetate    O
or    O
drospirenone    B-Steroid115057744
,    O
also    O
have    O
additional    O
direct    O
antiandrogen    O
activity    O
.    O

A    O
new    O
4th    O
generation    O
progestin    O
,    O
drospirenone    B-Steroid115057744
,    O
used    O
in    O
some    O
oral    O
contraceptives    O
may    O
further    O
heighten    O
the    O
risk    O
of    O
gallstone    O
disease    O
and    O
cholecystectomy    O
;    O
however    O
,    O
the    O
increased    O
risk    O
is    O
quite    O
modest    O
and    O
not    O
likely    O
to    O
be    O
clinically    O
meaningful    O
.    O

20α,22"R"-Dihydroxycholesterol    B-Steroid115057744
,    O
or    O
(3β)-cholest-5-ene-3,20,22-triol    B-Steroid115057744
is    O
an    O
endogenous    O
,    O
metabolic    O
intermediate    O
in    O
the    O
biosynthesis    O
of    O
the    O
steroid    O
hormones    O
from    O
cholesterol    O
.    O

Examples    O
of    O
important    O
progestogen    O
esters    O
include    O
the    O
17α-hydroxyprogesterone    O
derivatives    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
megestrol    O
acetate    O
,    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
hydroxyprogesterone    O
caproate    O
,    O
the    O
19-norprogesterone    B-Steroid115057744
derivative    O
nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
and    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
.    O

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-Steroid115057744
derivatives    O
gestonorone    B-Steroid115057744
caproate    I-Steroid115057744
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
and    O
quingestanol    B-Steroid115057744
acetate    I-Steroid115057744
.    O

The    O
estranes    O
include    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
lynestrenol    B-Steroid115057744
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Steroid115057744
,    O
desogestrel    B-Steroid115057744
,    O
etonogestrel    B-Steroid115057744
,    O
gestodene    B-Steroid115057744
,    O
norgestimate    O
,    O
dienogest    B-Steroid115057744
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    O
.    O

1,4,6-Androstatriene-3,17-dione    B-Steroid115057744
(    O
ATD    B-Steroid115057744
)    O
is    O
a    O
potent    O
irreversible    O
aromatase    O
inhibitor    O
that    O
inhibits    O
estrogen    O
biosynthesis    O
by    O
permanently    O
binding    O
and    O
inactivating    O
aromatase    O
in    O
adipose    O
and    O
peripheral    O
tissue    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
1,2-diacyl    O
-    O
sn    O
-    O
glycerol    O
and    O
sterol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
monoacylglycerol    O
and    O
sterol    B-Steroid115057744
ester    I-Steroid115057744
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
phosphatidylcholine    O
and    O
sterol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
1-acylglycerophosphocholine    O
and    O
sterol    B-Steroid115057744
ester    I-Steroid115057744
.    O

Convallarin    B-Steroid115057744
is    O
a    O
crystalline    O
glucoside    O
extracted    O
from    O
the    O
Lily    O
of    O
the    O
Valley    O
plant    O
(    O
"    O
Convallaria    O
majalis    O
"    O
)    O

Zhankuic    B-Steroid115057744
acids    I-Steroid115057744
are    O
bio    O
-    O
active    O
sterol    O
isolates    O
of    O
"    O
Taiwanofungus    O
camphoratus    O
"    O
.    O

Levonorgestrel    O
,    O
also    O
known    O
as    O
17α-ethynyl-18-methyl-19-nortestosterone    O
or    O
as    O
17α-ethynyl-18-methylestr-4-en-17β-ol-3-one    O
,    O
is    O
a    O
synthetic    O
estrane    B-Steroid115057744
steroid    O
and    O
a    O
derivative    O
of    O
testosterone    O
.    O

The    O
horse    O
's    O
urine    O
sample    O
had    O
been    O
found    O
to    O
contain    O
Estrane-3.17    B-Steroid115057744
Diol    I-Steroid115057744
a    O
substance    O
produced    O
by    O
the    O
breakdown    O
of    O
anabolic    O
steroids    O
.    O

Estradiol    O
undecylate    O
is    O
a    O
synthetic    O
estrane    B-Steroid115057744
(    O
C18    O
)    O
steroid    O
and    O
the    O
C17β    O
undecylate    O
(    O
or    O
undecanoate    O
)    O
fatty    O
acid    O
ester    O
of    O
estradiol    O
.    O

Nandrolone    O
,    O
also    O
known    O
as    O
19-nortestosterone    O
(    O
19-NT    O
)    O
or    O
as    O
estrenolone    O
,    O
as    O
well    O
as    O
estra-4-en-17β-ol-3-one    O
or    O
19-norandrost-4-en-17β-ol-3-one    O
,    O
is    O
a    O
naturally    O
occurring    O
estrane    B-Steroid115057744
(    O
19-norandrostane    O
)    O
steroid    O
and    O
a    O
derivative    O
of    O
testosterone    O
(    O
androst-4-en-17β-ol-3-one    O
)    O
.    O

This    O
family    O
is    O
subdivided    O
into    O
two    O
groups    O
:    O
the    O
estrane    B-Steroid115057744
and    O
the    O
gonane    B-Steroid115057744
.    O

Estrane    B-Steroid115057744
and    O
pregnane    B-Steroid115057744

DMT    O
became    O
a    O
controlled    O
substance    O
in    O
the    O
US    O
on    O
January    O
4    O
,    O
2010    O
,    O
and    O
is    O
classified    O
as    O
a    O
Schedule    O
III    O
anabolic    O
steroid    O
under    O
the    O
United    O
States    O
Controlled    O
Substances    O
Act    O
along    O
with    O
boldione    B-Steroid115057744
and    O
dienedione    O
.    O

Boldione    B-Steroid115057744
(    O
androsta-1,4-diene-3,17-dione    O
)    O

Solanine    B-Steroid115057744

They    O
also    O
contain    O
small    O
amounts    O
of    O
solanine    B-Steroid115057744
,    O
a    O
toxic    O
alkaloid    O
found    O
in    O
potato    O
leaves    O
and    O
other    O
plants    O
in    O
the    O
nightshade    O
family    O
.    O

Like    O
all    O
parts    O
of    O
the    O
plant    O
except    O
the    O
tubers    O
,    O
the    O
fruit    O
contain    O
the    O
toxic    O
alkaloid    O
solanine    B-Steroid115057744
and    O
are    O
therefore    O
unsuitable    O
for    O
consumption    O
.    O

The    O
fruits    O
have    O
no    O
value    O
to    O
gardeners    O
as    O
the    O
fruits    O
are    O
inedible    O
as    O
they    O
are    O
filled    O
with    O
solanine    B-Steroid115057744
,    O
which    O
causes    O
severe    O
illnesses    O
.    O

The    O
Westphalen    O
–    O
Lettré    O
rearrangement    O
is    O
a    O
classic    O
organic    O
reaction    O
in    O
organic    O
chemistry    O
describing    O
a    O
rearrangement    O
reaction    O
of    O
cholestane-3β,5α,6β-triol    B-Steroid115057744
diacetate    I-Steroid115057744
with    O
acetic    O
anhydride    O
and    O
sulfuric    O
acid    O
.    O

cholestane    B-Steroid115057744

Calcifediol    O
is    O
then    O
converted    O
in    O
the    O
kidneys    O
(    O
by    O
the    O
enzyme    O
25(OH)D-1α-hydroxylase    O
)    O
into    O
calcitriol    O
(    O
1,25-(OH)2D3    O
)    O
,    O
a    O
secosteroid    B-Steroid115057744
hormone    O
that    O
is    O
the    O
active    O
form    O
of    O
vitamin    O
D.    O
It    O
can    O
also    O
be    O
converted    O
into    O
24-hydroxycalcidiol    O
in    O
the    O
kidneys    O
via    O
24-hydroxylation    O
.    O

It    O
is    O
classified    O
as    O
a    O
secosteroid    B-Steroid115057744
,    O
since    O
one    O
of    O
the    O
four    O
rings    O
of    O
cholesterol    O
from    O
which    O
it    O
is    O
derived    O
is    O
broken    O
.    O

Fecosterol    B-Steroid115057744
is    O
a    O
sterol    O
made    O
by    O
certain    O
fungi    O
and    O
lichens    O
.    O

The    O
same    O
,    O
or    O
a    O
closely    O
similar    O
substance    O
,    O
is    O
found    O
in    O
soapwort    O
(    O
"    O
Saponaria    O
officinalis    O
"    O
)    O
,    O
in    O
senega    O
root    O
(    O
"    O
Polygala    O
senega    O
"    O
)    O
and    O
in    O
sarsaparilla    O
;    O
it    O
appears    O
to    O
be    O
chemically    O
related    O
to    O
digitonin    B-Steroid115057744
,    O
which    O
occurs    O
in    O
"    O
digitalis    O
"    O
.    O

In    O
addition    O
,    O
its    O
metabolite    O
2-methoxyestradiol    B-Steroid115057744
is    O
a    O
very    O
potent    O
inhibitor    O
of    O
tumor    O
growth    O
and    O
angiogenesis    O
,    O
and    O
this    O
may    O
contribute    O
as    O
well    O
.    O

2-Hydroxyestradiol    O
has    O
been    O
identified    O
as    O
a    O
prodrug    O
of    O
2-methoxyestradiol    B-Steroid115057744
,    O
a    O
transformation    O
which    O
is    O
very    O
efficiently    O
catalyzed    O
by    O
catechol    O
O    O
-    O
methyltransferase    O
in    O
the    O
liver    O
.    O

Apocholic    B-Steroid115057744
acid    I-Steroid115057744
is    O
an    O
unsaturated    O
bile    O
acid    O
first    O
characterized    O
in    O
the    O
1920s    O
.    O

Barrios    O
originally    O
finished    O
4th    O
in    O
the    O
2012    O
Summer    O
Olympics    O
,    O
but    O
she    O
moved    O
up    O
a    O
position    O
after    O
Darya    O
Pishchalnikova    O
was    O
disqualified    O
for    O
testing    O
positive    O
for    O
the    O
anabolic    O
steroid    O
oxandrolone    B-Steroid115057744
.    O

On    O
1    O
May    O
2013    O
,    O
the    O
IOC    O
stripped    O
Russian    O
discus    O
thrower    O
Darya    O
Pishchalnikova    O
of    O
her    O
silver    O
medal    O
in    O
the    O
women    O
's    O
discus    O
throw    O
after    O
testing    O
positive    O
for    O
Oxandrolone    B-Steroid115057744
(    O
an    O
anabolic    O
steroid    O
)    O
.    O

However    O
,    O
the    O
validity    O
of    O
her    O
record    O
and    O
title    O
was    O
called    O
into    O
question    O
by    O
a    O
positive    O
blood    O
test    O
result    O
for    O
the    O
banned    O
steroids    O
oxandrolone    B-Steroid115057744
and    O
stanozolol    B-Steroid115057744
,    O
and    O
she    O
was    O
"    O
provisionally    O
suspended    O
"    O
by    O
the    O
International    O
Weightlifting    O
Federation    O
.    O

In    O
June    O
2016    O
,    O
IWF    O
announced    O
that    O
retests    O
of    O
the    O
samples    O
taken    O
from    O
the    O
2012    O
Olympics    O
indicated    O
that    O
Zulfiya    O
Chinshanlo    O
had    O
tested    O
positive    O
for    O
prohibited    O
substances    O
,    O
namely    O
Oxandrolone    B-Steroid115057744
and    O
Stanazolol    B-Steroid115057744
.    O

Anabolic    O
-    O
androgenic    O
steroids    O
like    O
oxandrolone    B-Steroid115057744
may    O
be    O
beneficial    O
in    O
cancer    O
cachexia    O
but    O
their    O
use    O
is    O
recommended    O
for    O
maximal    O
2    O
weeks    O
since    O
a    O
longer    O
duration    O
of    O
treatment    O
increases    O
the    O
burden    O
from    O
side    O
effects    O
.    O

Oxandrolone    B-Steroid115057744

Oxandrolone    B-Steroid115057744

The    O
infamous    O
"    O
duchess    O
"    O
cocktail    O
administered    O
to    O
Russian    O
athletes    O
at    O
the    O
Sochi    O
Winter    O
Olympics    O
consisted    O
of    O
oxandrolone    B-Steroid115057744
,    O
metenolone    O
,    O
and    O
trenbolone    B-Steroid115057744
.    O

"    O
P.    O
notoginseng    O
"    O
contains    O
dammarane    B-Steroid115057744
-    O
type    O
ginsenosides    B-Steroid115057744
as    O
major    O
constituents    O
.    O

Hodulcine    O
(    O
or    O
hoduloside    O
)    O
are    O
glycosides    O
(    O
dammarane    B-Steroid115057744
-    O
type    O
triterpenes    O
)    O
which    O
are    O
isolated    O
from    O
the    O
leaves    O
of    O
"    O
Hovenia    O
dulcis    O
Thunb    O
.    O
"    O

Desoxymethyltestosterone    B-Steroid115057744

Desoxymethyltestosterone    B-Steroid115057744
(DMT)    I-Steroid115057744

These    O
drugs    O
also    O
inhibit    O
the    O
formation    O
of    O
neurosteroids    O
such    O
as    O
allopregnanolone    B-Steroid115057744
,    O
tetrahydrodeoxycorticosterone    O
(    O
THDOC    O
)    O
,    O
and    O
3α-androstanediol    B-Steroid115057744
from    O
progesterone    O
,    O
11-deoxycorticosterone    O
,    O
and    O
DHT    O
,    O
respectively    O
,    O
which    O
may    O
contribute    O
to    O
side    O
effects    O
such    O
as    O
depression    O
and    O
sexual    O
dysfunction    O
.    O

Androstadienol    O
is    O
then    O
sequentially    O
converted    O
into    O
androstenol    O
by    O
3β-hydroxysteroid    O
dehydrogenase    O
(    O
androstadienol    O
to    O
androstadienone    B-Steroid115057744
)    O
,    O
5α-reductase    O
(    O
androstadienone    O
to    O
androstenone    B-Steroid115057744
)    O
,    O
and    O
3α-hydroxysteroid    O
dehydrogenase    O
(    O
androstenone    O
to    O
androstenol    O
)    O
,    O
in    O
a    O
manner    O
analogous    O
to    O
the    O
biosynthesis    O
of    O
3α-androstanediol    B-Steroid115057744
from    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
.    O

Androstenol    O
,    O
similarly    O
to    O
the    O
related    O
endogenous    O
steroids    O
3α-androstanediol    B-Steroid115057744
and    O
androsterone    O
,    O
has    O
been    O
found    O
to    O
act    O
as    O
a    O
potent    O
positive    O
allosteric    O
modulator    O
of    O
the    O
GABAA    O
.    O

Dihydrotestosterone    O
↔    O
5α-Androstanedione    B-Steroid115057744
/    O
3α-Androstanediol    B-Steroid115057744
/    O
3β-Androstanediol    O

The    O
behaviour    O
and    O
aposematic    O
coloration    O
of    O
the    O
larvae    O
suggests    O
chemical    O
protection    O
in    O
this    O
stage    O
,    O
although    O
they    O
have    O
not    O
been    O
analyzed    O
for    O
alkaloid    O
or    O
cardenolide    B-Steroid115057744
content    O
,    O
nor    O
have    O
the    O
adults    O
.    O

k-Strophanthidin    B-Steroid115057744
is    O
a    O
cardenolide    B-Steroid115057744
found    O
in    O
species    O
of    O
the    O
genus    O
"    O
Strophanthus    O
"    O
.    O

The    O
cardenolide    B-Steroid115057744
syriogenin    O
has    O
also    O
been    O
isolated    O
in    O
the    O
root    O
of    O
'    O
D.    O
contrajerva    O
'    O
.    O

Common    O
defenses    O
include    O
:    O
cardiac    O
glycosides    O
(    O
or    O
cardenolide    B-Steroid115057744
)    O
,    O
pyrrolizidine    O
alkaloids    O
,    O
pyrazines    O
and    O
histamines    O
.    O

Terpenoids    O
,    O
flavonoids    O
,    O
sterols    O
and    O
cardenolide    B-Steroid115057744
are    O
among    O
the    O
chemicals    O
that    O
have    O
been    O
isolated    O
from    O
either    O
the    O
leaves    O
,    O
stems    O
,    O
shoots    O
,    O
roots    O
,    O
seeds    O
or    O
fruit    O
.    O

Many    O
insects    O
acquire    O
toxins    O
from    O
their    O
food    O
plants    O
;    O
"    O
Danaus    O
"    O
caterpillars    O
accumulate    O
toxic    O
cardenolides    B-Steroid115057744
from    O
milkweeds    O
(    O
Asclepiadaceae    O
)    O
.    O

Mexrenone    B-Steroid115057744
(    O
code    O
names    O
ZK-32055    B-Steroid115057744
,    O
SC-25152    B-Steroid115057744
)    O
is    O
a    O
steroidal    O
antimineralocorticoid    O
of    O
the    O
spirolactone    O
group    O
related    O
to    O
spironolactone    O
that    O
was    O
never    O
marketed    O
.    O

Along    O
with    O
estradiol    B-Steroid115057744
valerate    I-Steroid115057744
,    O
estradiol    B-Steroid115057744
cypionate    I-Steroid115057744
,    O
and    O
estradiol    B-Steroid115057744
benzoate    I-Steroid115057744
,    O
estradiol    O
undecylate    O
is    O
or    O
has    O
been    O
used    O
as    O
an    O
intramuscular    O
estrogen    O
in    O
hormone    O
replacement    O
therapy    O
for    O
transgender    O
women    O
.    O

Along    O
with    O
estradiol    B-Steroid115057744
benzoate    I-Steroid115057744
,    O
estradiol    O
dipropionate    O
was    O
one    O
of    O
the    O
first    O
estradiol    O
esters    O
to    O
be    O
developed    O
,    O
having    O
been    O
patented    O
in    O
1937    O
,    O
was    O
assessed    O
in    O
clinical    O
studies    O
by    O
1939    O
,    O
and    O
has    O
been    O
marketed    O
by    O
Schering    O
as    O
Progynon    B-Steroid115057744
DP    I-Steroid115057744
and    O
Ciba    O
Pharmaceutical    O
Products    O
as    O
Di-Ovocylin    B-Steroid115057744
since    O
at    O
least    O
1940    O
.    O

Estradiol    B-Steroid115057744
benzoate    I-Steroid115057744

A    O
paper    O
published    O
in    O
1973    O
discussed    O
the    O
structure    O
-    O
activity    O
relationships    O
of    O
a    O
series    O
of    O
aminosteroid    B-Steroid115057744
muscle    O
relaxants    O
,    O
including    O
the    O
mono    O
-    O
quaternary    O
analogue    O
of    O
pancuronium    O
,    O
later    O
called    O
vecuronium    O
.    O

Candocuronium    O
iodide    O
(    O
INN    O
,    O
formerly    O
chandonium    O
,    O
HS-310    O
)    O
is    O
an    O
aminosteroid    B-Steroid115057744
neuromuscular    O
-    O
blocking    O
drug    O
or    O
skeletal    O
muscle    O
relaxant    O
in    O
the    O
category    O
of    O
non    O
-    O
depolarizing    O
neuromuscular    O
-    O
blocking    O
drugs    O
.    O

Sterols    O
isolated    O
from    O
the    O
mushroom    O
include    O
,    O
ganoderol    B-Steroid115057744
,    O
ganoderenic    B-Steroid115057744
acid    I-Steroid115057744
,    O
ganoderiol    B-Steroid115057744
,    O
ganodermanontriol    B-Steroid115057744
,    O
lucidadiol    B-Steroid115057744
,    O
and    O
ganodermadiol    B-Steroid115057744
.    O

Although    O
hormonally    O
inactive    O
,    O
some    O
steroid    O
sulfates    O
,    O
such    O
as    O
pregnenolone    B-Steroid115057744
sulfate    I-Steroid115057744
and    O
DHEA    B-Steroid115057744
sulfate    I-Steroid115057744
,    O
are    O
important    O
neurosteroids    O
.    O

Pregnenolone    B-Steroid115057744
sulfate    I-Steroid115057744

Pregnenolone    B-Steroid115057744
sulfate    I-Steroid115057744

Low    O
-    O
dosage    O
steroidal    O
eye    O
-    O
drops    O
,    O
such    O
as    O
prednisone    O
,    O
fluorometholone    B-Steroid115057744
,    O
loteprednol    O
(    O
Lotemax    O
0.5%    O
)    O
or    O
rimexolone    O
.    O

FML    B-Steroid115057744

Commonly    O
used    O
solutions    O
are    O
of    O
fluorometholone    B-Steroid115057744
,    O
medrysone    B-Steroid115057744
,    O
betamethasone    B-Steroid115057744
or    O
dexamethasone    O
.    O

The    O
primary    O
method    O
of    O
execution    O
in    O
the    O
US    O
is    O
via    O
lethal    O
injection    O
which    O
generally    O
involves    O
the    O
administration    O
of    O
three    O
drugs    O
:    O
sodium    O
thiopental    O
,    O
a    O
sedative    O
to    O
induce    O
unconsciousness    O
,    O
pancuronium    B-Steroid115057744
bromide    I-Steroid115057744
(    O
Pavulon    O
)    O
,    O
a    O
muscle    O
relaxant    O
to    O
cause    O
respiratory    O
arrest    O
,    O
and    O
potassium    O
chloride    O
to    O
trigger    O
cardiac    O
arrest    O
.    O

Pancuronium    B-Steroid115057744

They    O
paralyze    O
him    O
for    O
the    O
procedure    O
with    O
pancuronium    B-Steroid115057744
.    O

One    O
contained    O
saline    O
,    O
another    O
contained    O
a    O
sleep    O
-    O
inducing    O
barbiturate    O
called    O
sodium    O
thiopental    O
and    O
the    O
third    O
a    O
lethal    O
mixture    O
of    O
potassium    O
chloride    O
,    O
which    O
immediately    O
stopped    O
the    O
heart    O
,    O
and    O
pancuronium    B-Steroid115057744
bromide    I-Steroid115057744
,    O
a    O
paralytic    O
medication    O
to    O
prevent    O
spasms    O
during    O
the    O
dying    O
process    O
.    O

Its    O
potential    O
adjunctive    O
use    O
in    O
anesthesia    O
to    O
facilitate    O
endotracheal    O
intubation    O
and    O
to    O
provide    O
skeletal    O
muscle    O
relaxation    O
during    O
surgery    O
or    O
mechanical    O
ventilation    O
was    O
briefly    O
evaluated    O
in    O
clinical    O
studies    O
in    O
India    O
,    O
but    O
further    O
development    O
discontinued    O
because    O
of    O
attendant    O
cardiovasular    O
effects    O
,    O
primarily    O
tachycardia    O
that    O
was    O
no    O
worse    O
than    O
but    O
also    O
not    O
an    O
improvement    O
over    O
the    O
clinically    O
established    O
pancuronium    B-Steroid115057744
bromide    I-Steroid115057744
.    O

The    O
"    O
mono"-    O
and    O
"    O
bis    O
"-    O
quaternary    O
azasteroid    O
series    O
of    O
compounds    O
to    O
which    O
candocuronium    O
belongs    O
are    O
based    O
on    O
the    O
same    O
principle    O
that    O
led    O
to    O
aminosteroids    O
such    O
as    O
pancuronium    B-Steroid115057744
,    O
vecuronium    B-Steroid115057744
and    O
rocuronium    B-Steroid115057744
:    O
use    O
of    O
the    O
steroid    O
skeleton    O
to    O
provide    O
a    O
somewhat    O
rigid    O
distance    O
between    O
the    O
two    O
quaternary    O
ammonium    O
centers    O
,    O
with    O
appendages    O
incorporating    O
fragments    O
of    O
choline    O
or    O
acetylcholine    O
.    O

The    O
hairpin    O
is    O
attached    O
to    O
the    O
glass    O
surface    O
via    O
a    O
digoxigenin    B-Steroid115057744
-    O
antidigoxigenin    O
bond    O
.    O

Digoxigenin    B-Steroid115057744
(    O
DIG    O
)    O
is    O
a    O
steroid    O
found    O
exclusively    O
in    O
the    O
flowers    O
and    O
leaves    O
of    O
the    O
plants    O
"    O
Digitalis    O
purpurea    O
"    O
and    O
"    O
Digitalis    O
lanata    O
"    O
.    O

Norboletone    B-Steroid115057744
(norbolethone)    I-Steroid115057744

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    O
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-Steroid115057744
,    O
ethyldienolone    B-Steroid115057744
,    O
tetrahydrogestrinone    B-Steroid115057744
,    O
bolenol    O
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    O
.    O

In    O
addition    O
,    O
according    O
to    O
the    O
respected    O
French    O
paper    O
"    O
L'Equipe    O
,    O
"    O
Tzekos    O
was    O
directly    O
dealing    O
with    O
the    O
creator    O
of    O
norbolethone    B-Steroid115057744
and    O
THG    O
(    O
tetrahydrogestrinone    B-Steroid115057744
)    O
Patrick    O
Arnold    O
,    O
the    O
father    O
of    O
pro    O
-    O
hormone    O
craze    O
and    O
some    O
undetectable    O
designer    O
steroids    O
.    O

finasteride    B-Steroid115057744
(    O
INN    O
)    O

It    O
is    O
a    O
selective    O
,    O
transition    O
-    O
state    O
,    O
non    O
-    O
competitive    O
or    O
uncompetitive    O
,    O
irreversible    O
inhibitor    O
of    O
5α-reductase    O
,    O
and    O
is    O
specific    O
to    O
the    O
type    O
II    O
isoform    O
of    O
the    O
enzyme    O
similarly    O
to    O
finasteride    B-Steroid115057744
and    O
turosteride    O
.    O

Finasteride    B-Steroid115057744
is    O
likely    O
an    O
effective    O
treatment    O
for    O
acne    O
.    O

Bicalutamide    O
has    O
also    O
been    O
studied    O
in    O
combination    O
with    O
the    O
5α-reductase    O
inhibitors    O
finasteride    B-Steroid115057744
and    O
dutasteride    B-Steroid115057744
in    O
prostate    O
cancer    O
.    O

5α-Reductase    O
inhibitors    O
(    O
5-ARIs    O
)    O
such    O
as    O
finasteride    B-Steroid115057744
,    O
dutasteride    B-Steroid115057744
,    O
epristeride    O
,    O
and    O
alfatradiol    B-Steroid115057744
prevent    O
the    O
conversion    O
of    O
testosterone    O
into    O
the    O
more    O
potent    O
androgen    O
dihydrotestosterone    O
(    O
DHT    O
)    O
and    O
are    O
used    O
in    O
the    O
treatment    O
of    O
benign    O
prostatic    O
hyperplasia    O
(    O
BPH    O
)    O
and    O
androgenic    O
alopecia    O
(    O
pattern    O
hair    O
loss    O
)    O
.    O

Unlike    O
the    O
case    O
of    O
most    O
other    O
inhibitory    O
neurosteroids    O
,    O
3α-DHP    O
production    O
is    O
not    O
blocked    O
by    O
5α-reductase    O
inhibitors    O
like    O
finasteride    B-Steroid115057744
.    O

Finasteride    B-Steroid115057744

However    O
,    O
the    O
combination    O
of    O
spironolactone    O
and    O
the    O
potent    O
5α-reductase    O
inhibitor    O
finasteride    B-Steroid115057744
has    O
been    O
found    O
to    O
have    O
significant    O
improved    O
effectiveness    O
in    O
the    O
treatment    O
of    O
hirsutism    O
relative    O
to    O
spironolactone    O
therapy    O
alone    O
,    O
suggesting    O
that    O
any    O
inhibition    O
of    O
5α-reductase    O
by    O
spironolactone    O
is    O
only    O
weak    O
or    O
at    O
best    O
incomplete    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    O
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    B-Steroid115057744
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    O
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

Finasteride    B-Steroid115057744
and    O
dutasteride    B-Steroid115057744
,    O
which    O
are    O
5α-reductase    O
inhibitors    O
and    O
inhibit    O
the    O
production    O
of    O
the    O
potent    O
androgen    O
dihydrotestosterone    O
(    O
DHT    O
)    O
.    O

The    O
benefit    O
verses    O
harm    O
for    O
5-alpha    O
-    O
reductase    O
inhibitor    O
such    O
as    O
finasteride    B-Steroid115057744
is    O
not    O
clear    O
.    O

Hydrocortisone    B-Steroid115057744
21-butyrate    I-Steroid115057744
is    O
a    O
form    O
of    O
hydrocortisone    O
butyrate    O
.    O

Lichesterol    B-Steroid115057744
is    O
a    O
sterol    O
made    O
by    O
certain    O
fungi    O
and    O
lichens    O
.    O

Brassinosteroids    B-Steroid115057744
(    O
BRs    O
)    O
are    O
a    O
class    O
of    O
polyhydroxysteroids    O
that    O
have    O
been    O
recognized    O
as    O
a    O
sixth    O
class    O
of    O

They    O
are    O
also    O
linked    O
to    O
cell    O
enlargement    O
and    O
cell    O
wall    O
changes    O
induced    O
by    O
other    O
plant    O
hormones    O
such    O
as    O
gibberellin    O
,    O
cytokinin    O
,    O
ethylene    O
and    O
brassinosteroids    B-Steroid115057744
.    O

Rosterolone    B-Steroid115057744
(    O
INN    O
)    O
(    O
developmental    O
code    O
name    O
SH-434    B-Steroid115057744
)    O
,    O
also    O
known    O
as    O
17α-propylmesterolone    B-Steroid115057744
or    O
1α-methyl-17α-propyl-5α-androstan-17β-ol-3-one    B-Steroid115057744
,    O
is    O
a    O
steroidal    O
antiandrogen    O
that    O
was    O
first    O
reported    O
in    O
1984    O
and    O
was    O
developed    O
for    O
topical    O
administration    O
but    O
was    O
never    O
marketed    O
.    O

Relatively    O
small    O
portions    O
of    O
progesterone    O
are    O
hydroxylated    O
via    O
17α-hydroxylase    O
(    O
CYP17A1    O
)    O
and    O
21-hydroxylase    O
(    O
CYP21A2    O
)    O
into    O
17α-hydroxyprogesterone    O
and    O
11-deoxycorticosterone    O
(    O
21-hydroxyprogesterone    O
)    O
,    O
respectively    O
,    O
and    O
pregnanetriol    B-Steroid115057744
are    O
formed    O
secondarily    O
to    O
17α-hydroxylation    O
.    O

Pregnanetriol    B-Steroid115057744

Trimethylamine    O
then    O
builds    O
up    O
and    O
is    O
released    O
in    O
the    O
person    O
's    O
sweat    O
,    O
urine    O
,    O
and    O
breath    O
,    O
giving    O
off    O
a    O
strong    O
fishy    B-Steroid115057744
odor    I-Steroid115057744
or    O
strong    O
body    O
odor    O
.    O

Normally    O
,    O
the    O
"    O
FMO3    O
"    O
enzyme    O
converts    O
fishy    O
-    O
smelling    O
trimethylamine    O
into    O
trimethylamine    B-Steroid115057744
"N"-oxide    I-Steroid115057744
which    O
has    O
no    O
odor    O
.    O

A    O
growing    O
body    O
of    O
evidence    O
indicates    O
lecithin    O
is    O
converted    O
by    O
gut    O
bacteria    O
into    O
trimethylamine-N-oxide    B-Steroid115057744
(    O
TMAO    O
)    O
,    O
which    O
is    O
released    O
into    O
circulation    O
,    O
and    O
may    O
with    O
time    O
contribute    O
to    O
atherosclerosis    O
and    O
heart    O
attacks    O
.    O

For    O
example    O
,    O
trimethylamine    B-Steroid115057744
oxide    I-Steroid115057744
and    O
bistrimethylsilylamide    O
convert    O
CO    O
ligands    O
to    O
CO2    O
and    O
CN−    O
,    O
respectively    O
.    O

Trimethylamine    B-Steroid115057744
oxides    I-Steroid115057744
present    O
in    O
ingested    O
elasmobranch    O
blood    O
aid    O
in    O
counteracting    O
the    O
detrimental    O
effects    O
of    O
high    O
urea    O
concentration    O
in    O
the    O
lamprey    O
's    O
bloodstream    O
as    O
it    O
feeds    O
.    O

New    O
York    O
New    O
York    O
Yankees    O
outfielder    O
Matt    O
Lawton    O
tested    O
positive    O
for    O
boldenone    B-Steroid115057744
,    O
in    O
violation    O
of    O
Major    O
League    O
Baseball    O
drug    O
policy    O
,    O
and    O
will    O
be    O
suspended    O
for    O
the    O
first    O
ten    O
games    O
of    O
the    O
2006    O
season    O
.    O

Anabolic    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
use    O
can    O
also    O
increase    O
the    O
amount    O
of    O
RBCs    O
and    O
,    O
therefore    O
,    O
impact    O
the    O
hematocrit    O
,    O
in    O
particular    O
the    O
compounds    O
boldenone    B-Steroid115057744
and    O
oxymetholone    B-Steroid115057744
.    O

Boldenone    B-Steroid115057744
,    O
also    O
known    O
as    O
Δ1-testosterone    B-Steroid115057744
,    O
is    O
a    O
synthetic    O
anabolic    O
-    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
and    O
the    O
1(2)-dehydrogenated    O
analogue    O
of    O
testosterone    O
.    O

Boldenone    B-Steroid115057744

The    O
drug    O
is    O
also    O
the    O
17α-methylated    O
derivative    O
of    O
boldenone    B-Steroid115057744
(    O
δ1-testosterone    O
)    O
and    O
the    O
δ1    O
analogue    O
of    O
methyltestosterone    O
(    O
17α-methyltestosterone    O
)    O
.    O

In    O
February    O
2012    O
,    O
Thompson    O
,    O
alongside    O
Comunicaciones    O
teammates    O
Adolfo    O
Machado    O
and    O
Marvin    O
Ceballos    O
,    O
was    O
temporarily    O
suspended    O
from    O
playing    O
by    O
FIFA    O
after    O
a    O
positive    O
test    O
on    O
the    O
banned    O
substance    O
boldenone    B-Steroid115057744
.    O

Enestebol    B-Steroid115057744

medrogestone    B-Steroid115057744
(    O
INN    O
)    O

6-Methyl-16-dehydropregnenolone    O
acetate    O
(    O
5    O
)    O
is    O
the    O
key    O
intermediate    O
to    O
the    O
preparation    O
of    O
both    O
melengesterol    O
acetate    O
and    O
medrogestone    B-Steroid115057744
.    O

Medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
and    O
medrogestone    B-Steroid115057744
are    O
weak    O
inhibitors    O
of    O
3β-HSD    O
which    O
may    O
substantially    O
inhibit    O
it    O
at    O
high    O
dosages    O
.    O

Methylprednisolone    B-Steroid115057744
aceponate    I-Steroid115057744
(    O
INN    O
)    O

Antiglucocorticoid    B-Steroid115057744
–    O
e.g.    O
,    O
mifepristone    O
,    O
ketoconazole    O
,    O
aminoglutethimide    O

Because    O
of    O
this    O
,    O
glucocorticoid    O
levels    O
might    O
be    O
expected    O
to    O
be    O
lowered    O
,    O
and    O
hence    O
,    O
spironolactone    O
might    O
have    O
some    O
antiglucocorticoid    B-Steroid115057744
effects    O
.    O

It    O
also    O
binds    O
to    O
the    O
glucocorticoid    O
receptor    O
,    O
but    O
is    O
only    O
a    O
weak    O
antiglucocorticoid    B-Steroid115057744
relative    O
to    O
mifepristone    O
,    O
and    O
has    O
no    O
relevant    O
affinity    O
to    O
the    O
estrogen    O
,    O
androgen    O
and    O
mineralocorticoid    O
receptors    O
.    O

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    O
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-Steroid115057744
,    O
ethyldienolone    B-Steroid115057744
,    O
tetrahydrogestrinone    B-Steroid115057744
,    O
bolenol    O
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    O
.    O

Androstadienol    O
is    O
then    O
sequentially    O
converted    O
into    O
androstenol    O
by    O
3β-hydroxysteroid    O
dehydrogenase    O
(    O
androstadienol    O
to    O
androstadienone    B-Steroid115057744
)    O
,    O
5α-reductase    O
(    O
androstadienone    O
to    O
androstenone    B-Steroid115057744
)    O
,    O
and    O
3α-hydroxysteroid    O
dehydrogenase    O
(    O
androstenone    O
to    O
androstenol    O
)    O
,    O
in    O
a    O
manner    O
analogous    O
to    O
the    O
biosynthesis    O
of    O
3α-androstanediol    B-Steroid115057744
from    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
.    O

Androstadienol    O
to    O
androstadienone    B-Steroid115057744

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Steroid115057744
)    O
,    O
desogestrel    B-Steroid115057744
,    O
ethylestrenol    O
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
ethinylestradiol    O
,    O
gestrinone    B-Steroid115057744
,    O
levonorgestrel    B-Steroid115057744
,    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    O
)    O
,    O
quinestrol    O
,    O
19-norprogesterone    B-Steroid115057744
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
.    O

The    O
estranes    O
include    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
lynestrenol    B-Steroid115057744
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Steroid115057744
,    O
desogestrel    B-Steroid115057744
,    O
etonogestrel    B-Steroid115057744
,    O
gestodene    B-Steroid115057744
,    O
norgestimate    O
,    O
dienogest    B-Steroid115057744
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    O
.    O

A    O
2001    O
comparative    O
study    O
of    O
the    O
IMS    O
LifeLink    O
Health    O
Plan    O
Claims    O
Database    O
interpreted    O
that    O
in    O
a    O
large    O
cohort    O
of    O
women    O
using    O
oral    O
contraceptives    O
,    O
there    O
was    O
found    O
a    O
small    O
,    O
statistically    O
significant    O
increase    O
in    O
the    O
risk    O
of    O
gallbladder    O
disease    O
associated    O
with    O
desogestrel    B-Steroid115057744
,    O
drospirenone    O
and    O
norethisterone    B-Steroid115057744
compared    O
with    O
levonorgestrel    B-Steroid115057744
.    O

Exemestane    B-Steroid115057744
,    O
a    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
breast    O
cancer    O
,    O
is    O
an    O
inhibitor    O
of    O
the    O
aromatase    O
enzyme    O
.    O

Certain    O
medications    O
that    O
block    O
the    O
effect    O
of    O
estrogen    O
(    O
i.e.    O
tamoxifen    O
,    O
raloxifen    O
,    O
exemestane    B-Steroid115057744
)    O
can    O
reduce    O
the    O
risk    O
by    O
about    O
50%    O
but    O
also    O
have    O
side    O
effects    O
.    O

Breast    O
cancer    O
in    O
post    O
-    O
menopausal    O
women    O
with    O
advanced    O
hormone    O
-    O
receptor    O
positive    O
,    O
HER2-negative    O
type    O
cancer    O
,    O
in    O
conjunction    O
with    O
exemestane    B-Steroid115057744
(    O
US    O
FDA    O
July    O
2012    O
)    O

Interim    O
phase    O
III    O
trial    O
results    O
in    O
2011    O
showed    O
that    O
adding    O
Afinitor    O
(    O
everolimus    O
)    O
to    O
exemestane    B-Steroid115057744
therapy    O
against    O
advanced    O
breast    O
cancer    O
can    O
significantly    O
improve    O
progression    O
-    O
free    O
survival    O
compared    O
with    O
exemestane    O
therapy    O
alone    O
.    O

:    O
H    O
=    O
fucosterol    B-Steroid115057744

7-Dehydrodesmosterol    B-Steroid115057744
(    O
or    O
cholesta-5,7,24-trien-3-beta-ol    B-Steroid115057744
)    O
is    O
a    O
cholesterol    O
intermediate    O
.    O

List    O
of    O
estrogen    O
esters    O
–    O
estrogen    B-Steroid115057744
ester    I-Steroid115057744

Estradiol    O
diundecylenate    O
(    O
brand    O
name    O
Etrosteron    O
)    O
,    O
or    O
estradiol    O
diundecenoate    O
,    O
also    O
known    O
as    O
17β-estradiol    O
3,17β-diundec-10-enoate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-Steroid115057744
ester    I-Steroid115057744
–    O
specifically    O
,    O
the    O
3,17β-diundecylenate    O
ester    O
of    O
estradiol    O
–    O
which    O
is    O
marketed    O
in    O
Argentina    O
.    O

Estrone    O
cyanate    O
,    O
or    O
estrone    O
3-O    O
-    O
cyanate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-Steroid115057744
ester    I-Steroid115057744
–    O
specifically    O
,    O
the    O
3-O    O
-    O
cyanate    O
ester    O
of    O
estrone    O
–    O
that    O
was    O
investigated    O
for    O
use    O
in    O
oral    O
contraceptives    O
but    O
was    O
found    O
to    O
be    O
of    O
relatively    O
low    O
potency    O
and    O
ultimately    O
was    O
never    O
marketed    O
.    O

Estriol    O
triacetate    O
,    O
also    O
known    O
as    O
estra-1,3,5(10)-triene-3,16α,17β-triol    O
3,16α,17β-triacetate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-Steroid115057744
ester    I-Steroid115057744
–    O
specifically    O
,    O
the    O
triacetate    O
ester    O
of    O
estriol    O
–    O
which    O
was    O
never    O
marketed    O
.    O

Estradiol    O
mustard    O
(    O
developmental    O
code    O
name    O
NSC-112259    O
)    O
,    O
also    O
known    O
as    O
chlorphenacyl    O
estradiol    O
diester    O
,    O
as    O
well    O
as    O
estradiol    O
3,17β-bis(4-(bis(2-chloroethyl)amino)phenyl)acetate    O
,    O
is    O
a    O
synthetic    O
,    O
steroidal    O
estrogen    O
and    O
alkylating    O
antineoplastic    O
agent    O
and    O
a    O
chlorphenacyl    O
nitrogen    O
mustard    O
-    O
coupled    O
estrogen    B-Steroid115057744
ester    I-Steroid115057744
that    O
was    O
never    O
marketed    O
.    O

Estradiol    O
butyrate    O
benzoate    O
,    O
or    O
estradiol    O
3-benzoate    O
17β-n    O
-    O
butyrate    O
,    O
also    O
known    O
as    O
estra-1,3,5(10)-triene-3,17β-diol    O
3-benzoate    O
17β-n    O
-    O
butyrate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-Steroid115057744
ester    I-Steroid115057744
–    O
specifically    O
,    O
the    O
3-benzoate    O
17β-n    O
-    O
butyrate    O
diester    O
of    O
estradiol    O
–    O
which    O
was    O
never    O
marketed    O
.    O

etonogestrel    B-Steroid115057744
(    O
INN    O
)    O

The    O
estranes    O
include    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
lynestrenol    B-Steroid115057744
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Steroid115057744
,    O
desogestrel    B-Steroid115057744
,    O
etonogestrel    B-Steroid115057744
,    O
gestodene    B-Steroid115057744
,    O
norgestimate    O
,    O
dienogest    B-Steroid115057744
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    O
.    O

Zanoterone    B-Steroid115057744
(    O
INN    O
,    O
USAN    O
)    O
(    O
former    O
developmental    O
codename    O
WIN-49596    B-Steroid115057744
)    O
,    O
also    O
known    O
as    O
(    O
5α,17α)-1'-(methylsulfonyl)-1'-H    O
-    O
pregn-20-yno[3,2-c]pyrazol-17-ol    O
,    O
is    O
a    O
steroidal    O
antiandrogen    O
that    O
was    O
never    O
marketed    O
.    O

Delmadinone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
a    O
progestin    O
and    O
antigonadotropin    O
used    O
as    O
an    O
antiandrogen    O

Delmadinone    B-Steroid115057744
acetate    I-Steroid115057744

The    O
standard    O
treatment    O
is    O
chenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
(    O
CDCA    O
)    O
replacement    O
therapy    O
.    O

The    O
balance    O
between    O
these    O
two    O
steroids    O
determines    O
the    O
relative    O
amounts    O
of    O
the    O
two    O
primary    O
bile    O
acids    O
,    O
cholic    O
acid    O
and    O
chenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
,    O
both    O
of    O
which    O
are    O
secreted    O
in    O
the    O
bile    O
.    O

The    O
natural    O
bile    O
acid    O
,    O
chenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
,    O
was    O
identified    O
in    O
1999    O
as    O
the    O
most    O
active    O
physiological    O
ligand    O
for    O
the    O
farnesoid    O
X    O
receptor    O
(    O
FXR    O
)    O
,    O
which    O
is    O
involved    O
in    O
many    O
physiological    O
and    O
pathological    O
processes    O
.    O

Muricholic    O
acids    O
differ    O
from    O
the    O
more    O
common    O
bile    O
acids    O
,    O
such    O
as    O
cholic    O
acid    O
or    O
chenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
,    O
by    O
having    O
a    O
hydroxyl    O
group    O
at    O
the    O
6-position    O
.    O

Fusidic    B-Steroid115057744
acid    I-Steroid115057744
is    O
a    O
steroid    O
antibiotic    O
that    O
is    O
often    O
used    O
topically    O
in    O
creams    O
and    O
eyedrops    O
but    O
may    O
also    O
be    O
given    O
systemically    O
as    O
tablets    O
or    O
injections    O
.    O

The    O
company    O
launched    O
Fucidin    B-Steroid115057744
to    O
be    O
used    O
to    O
treat    O
staphylococcus    O
infections    O

After    O
her    O
successful    O
publications    O
,    O
Barber    O
was    O
hired    O
by    O
the    O
Medical    O
Research    O
Council    O
to    O
study    O
semisynthetic    O
penicillin    O
,    O
cephalosporin    O
,    O
fucidin    B-Steroid115057744
,    O
lincomycin    O
,    O
and    O
pristinamycin    O
.    O

Methicillin    O
-    O
resistant    O
Staphylococcus    O
aureus    O
infections    O
may    O
be    O
treated    O
with    O
a    O
combination    O
therapy    O
of    O
fusidic    B-Steroid115057744
acid    I-Steroid115057744
and    O
rifampicin    O
.    O

22"R"-Hydroxycholesterol    B-Steroid115057744

k-Strophanthidin    B-Steroid115057744
is    O
a    O
cardenolide    B-Steroid115057744
found    O
in    O
species    O
of    O
the    O
genus    O
"    O
Strophanthus    O
"    O
.    O

Estradiol    B-Steroid115057744
acetate    I-Steroid115057744

For    O
comparison    O
,    O
the    O
ester    O
chains    O
of    O
estradiol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
estradiol    B-Steroid115057744
valerate    I-Steroid115057744
,    O
and    O
estradiol    B-Steroid115057744
enanthate    I-Steroid115057744
have    O
2    O
,    O
5    O
,    O
and    O
7    O
carbon    O
atoms    O
,    O
respectively    O
.    O

Estradiol    B-Steroid115057744
acetate    I-Steroid115057744

Ginsenoside    B-Steroid115057744
,    O
unique    O
phytochemicals    O
of    O
the    O
"    O
Panax    O
"    O
species    O
,    O
are    O
being    O
studied    O
for    O
their    O
potential    O
biological    O
properties    O
.    O

"    O
P.    O
notoginseng    O
"    O
contains    O
dammarane    B-Steroid115057744
-    O
type    O
ginsenosides    B-Steroid115057744
as    O
major    O
constituents    O
.    O

"    O
Panax    O
"    O
species    O
are    O
characterized    O
by    O
the    O
presence    O
of    O
ginsenoside    B-Steroid115057744
and    O
gintonin    O
.    O

Glycodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
is    O
a    O
bile    O
acid    O
derived    O
from    O
deoxycholic    B-Steroid115057744
acid    I-Steroid115057744
and    O
glycine    O
.    O

Hydrocholeretic    B-Steroid115057744

estradiol    B-Steroid115057744
undecylate    I-Steroid115057744
(    O
INN    O
)    O

Estradiol    B-Steroid115057744
undecylate    I-Steroid115057744
,    O
or    O
estradiol    B-Steroid115057744
undecanoate    I-Steroid115057744
,    O
sold    O
under    O
the    O
brand    O
name    O
Progynon    B-Steroid115057744
Depot    I-Steroid115057744
100    I-Steroid115057744
among    O
others    O
,    O
is    O
an    O
estrogen    O
which    O
is    O
or    O
has    O
been    O
used    O
in    O
Europe    O
,    O
including    O
in    O
Germany    O
,    O
the    O
Netherlands    O
,    O
Switzerland    O
,    O
and    O
Monaco    O
.    O

Estradiol    B-Steroid115057744
undecylate    I-Steroid115057744

Tauroursodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
,    O
an    O
epimer    O

Trametenolic    B-Steroid115057744
acid    I-Steroid115057744
is    O
an    O
anti    O
-    O
inflammatory    O
sterol    O
isolated    O
from    O
"    O
Inonotus    O
obliquus    O
"    O
.    O

27-Hydroxycholesterol    B-Steroid115057744

Penmesterol    B-Steroid115057744
(penmestrol)    I-Steroid115057744

Taurodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
is    O
a    O
bile    O
acid    O
.    O

This    O
method    O
has    O
been    O
used    O
in    O
natural    O
product    O
synthesis    O
of    O
Taxol    O
by    O
Danishefsky    O
and    O
Cortistatin    B-Steroid115057744
A    I-Steroid115057744
by    O
Shair    O
.    O

Their    O
presence    O
has    O
been    O
indirectly    O
detected    O
by    O
fossilized    O
steroids    O
,    O
called    O
sterane    B-Steroid115057744
,    O
hydrocarbon    O
markers    O
characteristic    O
of    O
the    O
cell    O
membranes    O
of    O
the    O
sponges    O
,    O
rather    O
than    O
from    O
direct    O
fossils    O
of    O
the    O
sponges    O
themselves    O
.    O

A    O
theoretical    O
prediction    O
estimated    O
this    O
to    O
be    O
-80‰    O
to    O
-95‰    O
for    O
sterane    B-Steroid115057744
,    O
-90‰    O
to    O
-95‰    O
for    O
hopanes    O
,    O
and    O
-70‰    O
to    O
-95‰    O
for    O
typical    O
cycloparaffins    O
between    O
0    O
°C    O
to    O
100    O
°C    O
.    O

Sterane    B-Steroid115057744
(    O
cyclopentanoperhydrophenanthrenes    B-Steroid115057744
or    O
cyclopentane    B-Steroid115057744
perhydro    I-Steroid115057744
phenanthrene    I-Steroid115057744
)    O
compounds    O
are    O
a    O
class    O
of    O
4-cyclic    O
compounds    O
derived    O
from    O
steroids    O
or    O
sterols    O
via    O
diagenetic    O
and    O
catagenetic    O
degradation    O
and    O
saturation    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
cycloartenol    B-Steroid115057744
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
(    O
24R)-24-methylcycloart-25-en-3beta    O
-    O
ol    O
.    O

Squalene    O
is    O
then    O
processed    O
biosynthetically    O
to    O
generate    O
either    O
lanosterol    B-Steroid115057744
or    O
cycloartenol    B-Steroid115057744
,    O
the    O
structural    O
precursors    O
to    O
all    O
the    O
steroids    O
.    O

It    O
is    O
a    O
prodrug    O
of    O
norethisterone    B-Steroid115057744
,    O
with    O
both    O
quingestanol    B-Steroid115057744
and    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
serving    O
as    O
intermediates    O
in    O
the    O
transformation    O
.    O

medrysone    B-Steroid115057744
(    O
INN    O
)    O

Commonly    O
used    O
solutions    O
are    O
of    O
fluorometholone    B-Steroid115057744
,    O
medrysone    B-Steroid115057744
,    O
betamethasone    B-Steroid115057744
or    O
dexamethasone    O
.    O

Lathosterol    B-Steroid115057744
is    O
a    O
cholesterol    O
-    O
like    O
molecule    O
.    O

The    O
antigonadotropic    O
antiandrogens    O
,    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
(    O
MPA    O
)    O
,    O
and    O
analogues    O
have    O
all    O
been    O
widely    O
used    O
to    O
treat    O
paraphilias    O
(    O
e.g.    O
,    O
pedophilia    O
)    O
and    O
hypersexuality    O
in    O
men    O
.    O

The    O
Food    O
and    O
Drug    O
Administration    O
approves    O
Depo-Provera    B-Steroid115057744
for    O
use    O
as    O
a    O
contraceptive    O
in    O
the    O
United    O
States    O
.    O

Medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744

Most    O
inhibitors    O
of    O
CYP2C9    O
are    O
competitive    O
inhibitors    O
.    O
Noncompetitive    O
inhibitors    O
of    O
CYP2C9    O
include    O
nifedipine    O
,    O
phenethyl    O
isothiocyanate    O
,    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
and    O
6-hydroxyflavone    O
.    O

Examples    O
of    O
important    O
progestogen    O
esters    O
include    O
the    O
17α-hydroxyprogesterone    O
derivatives    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
megestrol    O
acetate    O
,    O
cyproterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
hydroxyprogesterone    O
caproate    O
,    O
the    O
19-norprogesterone    B-Steroid115057744
derivative    O
nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
and    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
.    O

Medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
(    O
Provera    O
)    O
entered    O
clinical    O
use    O
and    O
became    O
widely    O
marketed    O
,    O
largely    O
superseding    O
the    O
17α-hydroxyprogesterone    O
esters    O
.    O

Medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
(    O
Provera    O
)    O
,    O
the    O
most    O
popular    O
and    O
widely    O
used    O
progestogen    O
ester    O
.    O

In    O
1969    O
,    O
along    O
with    O
a    O
variety    O
of    O
other    O
progestogens    O
including    O
progesterone    O
,    O
chlormadinone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
megestrol    O
acetate    O
,    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
ethynerone    O
,    O
and    O
chloroethynyl    O
norgestrel    O
,    O
anagestone    O
acetate    O
was    O
found    O
to    O
induce    O
the    O
development    O
of    O
mammary    O
gland    O
tumors    O
in    O
Beagle    O
dogs    O
after    O
extensive    O
treatment    O
(    O
2–7    O
years    O
)    O
with    O
very    O
high    O
doses    O
(    O
10–25    O
times    O
the    O
recommended    O
human    O
dose    O
)    O
,    O
though    O
notably    O
not    O
with    O
1–2    O
times    O
the    O
human    O
dosage    O
.    O

Subsequent    O
investigation    O
found    O
that    O
17α-hydroxyprogesterone    O
derivatves    O
included    O
anagestone    O
acetate    O
,    O
chlormadinone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
megestrol    O
acetate    O
produced    O
similar    O
mammary    O
gland    O
tumors    O
,    O
and    O
that    O
their    O
ability    O
to    O
do    O
so    O
correlated    O
directly    O
with    O
their    O
progestogenic    O
actions    O
.    O

Use    O
of    O
progestin    O
-    O
only    O
contraceptives    O
,    O
such    O
as    O
Depo    B-Steroid115057744
Provera    I-Steroid115057744

A    O
phase-2    O
study    O
involving    O
the    O
administration    O
of    O
antioxidants    O
,    O
pharmaconutritional    O
support    O
,    O
progestin    O
(    O
megestrol    O
acetate    O
and    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
)    O
,    O
and    O
anticyclooxygenase-2    O
drugs    O
,    O
showed    O
efficacy    O
and    O
safety    O
in    O
the    O
treatment    O
of    O
patients    O
with    O
advanced    O
cancer    O
of    O
different    O
sites    O
suffering    O
cachexia    O
.    O

NOMAC    O
is    O
a    O
potent    O
and    O
pure    O
progestogen    O
,    O
acting    O
as    O
a    O
selective    O
,    O
high    O
-    O
affinity    O
full    O
agonist    O
of    O
the    O
progesterone    O
receptor    O
(    O
PR    O
)    O
(    O
Ki    O
=    O
3    O
nM    O
,    O
67–303%    O
of    O
the    O
of    O
progesterone    O
)    O
,    O
and    O
is    O
said    O
to    O
have    O
higher    O
potency    O
and    O
substantially    O
improved    O
selectivity    O
for    O
the    O
PR    O
relative    O
to    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
(    O
the    O
6-hydrogenated    O
or    O
non-6    O
-    O
7-double    O
bonded    O
analogue    O
of    O
megestrol    O
acetate    O
and    O
the    O
most    O
widely    O
used    O
progestin    O
)    O
.    O

Along    O
with    O
that    O
two    O
contraceptive    O
pills    O
,    O
MPA    O
(    O
Medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
)    O
under    O
Antara    O
program    O
and    O
Chaya    O
(    O
earlier    O
marketed    O
as    O
Saheli    O
)    O
will    O
be    O
made    O
freely    O
available    O
to    O
all    O
government    O
hospitals    O
.    O

,    O
Keith    O
Ablow    O
responded    O
to    O
Kaplan    O
's    O
column    O
,    O
arguing    O
that    O
although    O
he    O
agreed    O
with    O
it    O
on    O
many    O
points    O
,    O
he    O
thought    O
that    O
Kaplan    O
"    O
is    O
wrong    O
to    O
suggest    O
that    O
,    O
merely    O
because    O
something    O
is    O
a    O
known    O
disorder    O
,    O
it    O
should    O
result    O
in    O
protections    O
under    O
the    O
law    O
"    O
and    O
arguing    O
that    O
"    O
If    O
a    O
pedophile    O
wants    O
to    O
not    O
attack    O
children    O
,    O
he    O
can    O
receive    O
confidential    O
psychiatric    O
treatment    O
–    O
including    O
Depo-Provera    B-Steroid115057744
to    O
lower    O
testosterone    O
levels    O
–    O
to    O
make    O
it    O
much    O
less    O
likely    O
.    O
"    O

The    O
people    O
in    O
the    O
program    O
experienced    O
injections    O
of    O
Depro-Provera    B-Steroid115057744
and    O
individual    O
and    O
group    O
therapy    O
aimed    O
at    O
helping    O
priests    O
regain    O
their    O
celibacy    O
;    O
the    O
latter    O
differed    O
from    O
secular    O
treatment    O
,    O
in    O
which    O
the    O
effort    O
was    O
to    O
get    O
the    O
men    O
to    O
transfer    O
their    O
sexual    O
attraction    O
to    O
adults    O
.    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
)    O
,    O
danazol    B-Steroid115057744
,    O
gestrinone    B-Steroid115057744
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    O
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

Non    O
-    O
permanent    O
forms    O
of    O
sterilization    O
were    O
also    O
used    O
including    O
Depo-Provera    B-Steroid115057744
and    O
Norplant    O
.    O

Medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
and    O
medrogestone    B-Steroid115057744
are    O
weak    O
inhibitors    O
of    O
3β-HSD    O
which    O
may    O
substantially    O
inhibit    O
it    O
at    O
high    O
dosages    O
.    O

A    O
neurotoxin    O
called    O
homobatrachotoxin    B-Steroid115057744
found    O
in    O
the    O
birds    O
'    O
skin    O
and    O
feathers    O
causes    O
numbness    O
and    O
tingling    O
in    O
those    O
touching    O
the    O
bird    O
.    O

This    O
genus    O
of    O
beetle    O
is    O
known    O
to    O
have    O
high    O
levels    O
of    O
batrachotoxin    B-Steroid115057744
and    O
is    O
believed    O
to    O
be    O
a    O
possible    O
toxin    O
source    O
for    O
Pitohui    O
and    O
Blue    O
-    O
capped    O
ifrit    O
birds    O
in    O
New    O
Guinea    O
.    O

The    O
combined    O
brachial    O
secretion    O
and    O
saliva    O
of    O
recently    O
captured    O
wild    O
lorises    O
was    O
shown    O
to    O
contain    O
batrachotoxin    B-Steroid115057744
,    O
which    O
were    O
not    O
found    O
in    O
slow    O
lorises    O
held    O
in    O
captivity    O
for    O
more    O
than    O
a    O
year    O
.    O

Batrachotoxin    B-Steroid115057744

batrachotoxin    B-Steroid115057744

Potassium    B-Steroid115057744
canrenoate    I-Steroid115057744

Potassium    B-Steroid115057744
canrenoate    I-Steroid115057744

CHAPS    B-Steroid115057744
detergent    I-Steroid115057744
,    O
zwitterionic    O
detergent    O
used    O
in    O
the    O
laboratory    O
to    O
solubilize    O
biological    O
macromolecules    O
such    O
as    O
proteins    O

Cucurbitacin    B-Steroid115057744
E    I-Steroid115057744
(    O
aelaterin    O
)    O
,    O
from    O
roots    O
of    O
"    O
Wilbrandia    O
ebracteata    O
"    O
.    O

CYP8B1    O
is    O
an    O
endoplasmic    O
reticulum    O
membrane    O
protein    O
and    O
catalyzes    O
the    O
conversion    O
of    O
7    B-Steroid115057744
alpha-hydroxy-4-cholesten-3-one    I-Steroid115057744
into    O
7-alpha,12-alpha    O
-    O
dihydroxy-4-cholesten-3-one    O
.    O

This    O
demethylation    O
step    O
is    O
regarded    O
as    O
the    O
initial    O
checkpoint    O
in    O
the    O
transformation    O
of    O
lanosterol    B-Steroid115057744
to    O
other    O
sterols    O
that    O
are    O
widely    O
used    O
within    O
the    O
cell    O
(    O
Lepesheva    O
et    O
al    O
.    O
)    O
.    O

In    O
fungi    O
,    O
CYP51    O
catalyzes    O
the    O
demethylation    O
of    O
lanosterol    B-Steroid115057744
to    O
create    O
an    O
important    O
precursor    O
that    O
is    O
eventually    O
converted    O
into    O
ergosterol    O
(    O
Lepesheva    O
et    O
al    O
.    O
)    O
.    O

The    O
enzyme    O
-    O
catalyzed    O
demethylation    O
of    O
lanosterol    B-Steroid115057744
is    O
believed    O
to    O
occur    O
in    O
three    O
steps    O
,    O
each    O
of    O
which    O
requires    O
one    O
molecule    O
of    O
diatomic    O
oxygen    O
and    O
one    O
molecule    O
of    O
NADPH    O
(    O
or    O
some    O
other    O
reducing    O
equivalent    O
)    O
.    O

Lanosterol    O
14α-demethylase    O
(    O
CYP51A1    O
)    O
inhibitors    O
such    O
as    O
clotrimazole    O
,    O
fluconazole    O
,    O
itraconazole    O
,    O
ketoconazole    O
,    O
miconazole    O
,    O
and    O
voriconazole    O
prevent    O
the    O
production    O
of    O
ergosterol    O
from    O
lanosterol    B-Steroid115057744
.    O

Through    O
several    O
more    O
biosynthetic    O
steps    O
,    O
squalene    O
is    O
transformed    O
into    O
lanosterol    B-Steroid115057744
,    O
a    O
direct    O
precursor    O
for    O
cholesterol    O
.    O

Squalene    O
is    O
then    O
processed    O
biosynthetically    O
to    O
generate    O
either    O
lanosterol    B-Steroid115057744
or    O
cycloartenol    B-Steroid115057744
,    O
the    O
structural    O
precursors    O
to    O
all    O
the    O
steroids    O
.    O

Recent    O
studies    O
have    O
found    O
that    O
great    O
mullein    O
contains    O
glycyrrhizin    B-Steroid115057744
compounds    O
with    O
bactericide    O
and    O
potential    O
anti    O
-    O
tumoral    O
action    O
.    O

This    O
deficiency    O
—    O
known    O
as    O
apparent    O
mineralocorticoid    O
excess    O
syndrome    O
—    O
can    O
either    O
be    O
congenital    O
or    O
caused    O
by    O
consumption    O
of    O
glycyrrhizin    B-Steroid115057744
,    O
which    O
is    O
contained    O
in    O
extract    O
of    O
licorice    O
,    O
sometimes    O
found    O
in    O
herbal    O
supplements    O
,    O
candies    O
,    O
and    O
chewing    O
tobacco    O
.    O

Glycyrrhizin    B-Steroid115057744

Together    O
these    O
plants    O
are    O
used    O
to    O
create    O
a    O
drink    O
containing    O
puerarin    O
,    O
daidzein    O
,    O
paenoflorin    O
,    O
cinnamic    O
acid    O
,    O
glycyrrhizin    B-Steroid115057744
,    O
ephedrine    O
and    O
gingerol    O
.    O

It    O
contains    O
the    O
chemical    O
glycyrrhizin    B-Steroid115057744
,    O
which    O
has    O
medicinal    O
uses    O
,    O
but    O
at    O
higher    O
levels    O
it    O
can    O
be    O
toxic    O
.    O

Tixocortol    B-Steroid115057744
=    O
11β,17α-dihydroxy-21-sulfanylpregn-4-ene-3,20-dione    O

A    O
kuguacin    B-Steroid115057744
is    O
one    O
of    O
several    O
chemical    O
compounds    O
isolated    O
from    O
the    O
bitter    O
melon    O
vine    O
(    O
"    O
Momordica    O
charantia    O
"    O
,    O
"    O
kǔguā    O
"    O
in    O
Chinese    O
)    O
by    O
J    O
.-    O
C.    O
Chen    O
and    O
others    O
.    O

Brassinolide    B-Steroid115057744

19-Norandrostenedione    B-Steroid115057744

This    O
entry    O
mechanism    O
is    O
inhibited    O
by    O
myrcludex    O
B    O
,    O
cyclosporin    O
A    O
,    O
progesterone    O
,    O
propranolol    O
,    O
bosentan    O
,    O
ezetimibe    O
,    O
as    O
well    O
as    O
NTCP    O
substrates    O
like    O
taurocholate    B-Steroid115057744
,    O
tauroursodeoxycholate    B-Steroid115057744
and    O
bromosulfophthalein    O
.    O

It    O
is    O
also    O
used    O
along    O
with    O
sodium    B-Steroid115057744
taurocholate    I-Steroid115057744
for    O
simulating    O
fed-    O
and    O
fasted    O
-    O
state    O
biorelevant    O
media    O
in    O
dissolution    O
studies    O
of    O
highly    O
lipophilic    O
drugs    O
.    O

Taurocholic    B-Steroid115057744
acid    I-Steroid115057744
,    O
known    O
also    O
as    O
cholaic    B-Steroid115057744
acid    I-Steroid115057744
,    O
cholyltaurine    B-Steroid115057744
,    O
or    O
acidum    B-Steroid115057744
cholatauricum    I-Steroid115057744
,    O
is    O
a    O
deliquescent    O
yellowish    O
crystalline    O
bile    O
acid    O
involved    O
in    O
the    O
emulsification    O
of    O
fats    O
.    O

In    O
addition    O
,    O
though    O
17α-MP    O
itself    O
was    O
never    O
introduced    O
for    O
medical    O
use    O
,    O
progestogen    O
derivatives    O
of    O
the    O
compound    O
,    O
including    O
medrogestone    B-Steroid115057744
(    O
1966    O
)    O
and    O
the    O
19-norprogesterone    O
derivatives    O
demegestone    B-Steroid115057744
(    O
1974    O
)    O
,    O
promegestone    B-Steroid115057744
(    O
1983    O
)    O
,    O
and    O
trimegestone    B-Steroid115057744
(    O
2001    O
)    O
,    O
have    O
been    O
marketed    O
.    O

Promegestone    B-Steroid115057744
(    O
INN    O
)    O
(    O
brand    O
name    O
Surgestone    B-Steroid115057744
)    O
,    O
also    O
known    O
as    O
17α,21-dimethyl-Δ9-19-norprogesterone    B-Steroid115057744
or    O
17α,21-dimethyl-19-norpregna-4,9-diene-3,20-dione    B-Steroid115057744
,    O
is    O
a    O
steroidal    O
progestin    O
of    O
the    O
19-norprogesterone    B-Steroid115057744
group    O
which    O
was    O
introduced    O
in    O
1983    O
and    O
is    O
marketed    O
in    O
France    O
,    O
Portugal    O
,    O
and    O
Argentina    O
.    O

"    O
Convallaria    O
majalis    O
"    O
(    O
Lily    O
of    O
the    O
Valley    O
)    O
:    O
convallotoxin    B-Steroid115057744

In    O
March    O
2016    O
,    O
it    O
was    O
revealed    O
that    O
Slice    O
had    O
tested    O
positive    O
for    O
nandrolone    O
and    O
an    O
elevated    O
testosterone    O
to    O
epitestosterone    B-Steroid115057744
ratio    O
(    O
T    O
/    O
E    O
ratio    O
)    O
in    O
a    O
pre    O
-    O
fight    O
drug    O
test    O
.    O

In    O
the    O
ensuing    O
years    O
nasal    O
spray    O
preparations    O
containing    O
testosterone    O
or    O
androstenedione    O
were    O
developed    O
in    O
collaboration    O
with    O
Jenapharm    O
,    O
tested    O
,    O
and    O
used    O
in    O
top    O
athletes    O
—    O
some    O
of    O
whom    O
did    O
not    O
like    O
this    O
mode    O
of    O
application    O
.    O
Doping    O
tests    O
at    O
the    O
time    O
used    O
the    O
T    O
:    O
E    O
(    O
testosterone    O
:    O
epitestosterone    B-Steroid115057744
)    O
ratio    O
.    O

Since    O
1983    O
,    O
Jenapharm    O
had    O
produced    O
preparations    O
of    O
epitestosterone    B-Steroid115057744
propionate    O
,    O
a    O
biologically    O
inactive    O
compound    O
that    O
had    O
no    O
commercial    O
value    O
but    O
was    O
prepared    O
exclusively    O
for    O
the    O
governmental    O
doping    O
system    O
.    O

In    O
June    O
that    O
year    O
she    O
tested    O
positive    O
for    O
excess    O
testosterone    O
against    O
her    O
epitestosterone    B-Steroid115057744
levels    O
and    O
the    O
IAAF    O
gave    O
her    O
a    O
two    O
-    O
year    O
ban    O
from    O
the    O
sport    O
,    O
stretching    O
from    O
June    O
2005    O
to    O
June    O
2007    O
.    O

He    O
was    O
also    O
found    O
to    O
have    O
an    O
elevated    O
testosterone    O
/    O
epitestosterone    B-Steroid115057744
(    O
T    O
/    O
E    O
)    O
ratio    O
of    O
6.4:1    O
,    O
which    O
is    O
above    O
the    O
maximum    O
allowed    O
limit    O
of    O
4:1    O
.    O

On    O
5    O
August    O
2006    O
Phonak    O
dismissed    O
Floyd    O
Landis    O
after    O
confirmation    O
that    O
a    O
urine    O
sample    O
taken    O
after    O
his    O
Stage    O
17    O
win    O
twice    O
tested    O
positive    O
for    O
synthetic    O
testosterone    O
as    O
well    O
as    O
a    O
ratio    O
of    O
testosterone    O
to    O
epitestosterone    B-Steroid115057744
nearly    O
three    O
times    O
the    O
limit    O
allowed    O
by    O
World    O
Anti    O
-    O
Doping    O
Agency    O
rules    O
.    O

Spironolactone    O
is    O
closely    O
structurally    O
related    O
to    O
other    O
clinically    O
used    O
spirolactones    O
such    O
as    O
canrenone    O
,    O
potassium    B-Steroid115057744
canrenoate    I-Steroid115057744
,    O
drospirenone    B-Steroid115057744
,    O
and    O
eplerenone    B-Steroid115057744
,    O
as    O
well    O
as    O
to    O
the    O
never    O
-    O
marketed    O
spirolactones    O
SC-5233    O
(    O
6,7-dihydrocanrenone    O
;    O
7α-desthioacetylspironolactone    O
)    O
,    O
SC-8109    O
(    O
19-nor-6,7-dihydrocanrenone    O
)    O
,    O
spiroxasone    O
,    O
prorenone    O
(    O
SC-23133    O
)    O
,    O
mexrenone    B-Steroid115057744
(    O
SC-25152    O
,    O
ZK-32055    O
)    O
,    O
dicirenone    O
(    O
SC-26304    O
)    O
,    O
spirorenone    O
(    O
ZK-35973    O
)    O
,    O
and    O
mespirenone    O
(    O
ZK-94679    O
)    O
.    O

Difficult    O
or    O
resistant    O
cases    O
of    O
hypokalemia    O
may    O
be    O
amenable    O
to    O
a    O
potassium    O
-    O
sparing    O
diuretic    O
,    O
such    O
as    O
amiloride    O
,    O
triamterene    O
,    O
spironolactone    O
,    O
or    O
eplerenone    B-Steroid115057744
.    O

Eplerenone    B-Steroid115057744
is    O
the    O
9    O
-    O
11α-epoxy    O
analogue    O
of    O
mexrenone    O
.    O

Important    O
antimineralocorticoids    O
are    O
spironolactone    O
and    O
eplerenone    B-Steroid115057744
.    O

This    O
suggests    O
an    O
important    O
pathway    O
for    O
the    O
elimination    O
of    O
toxic    O
and    O
cholestatic    O
bile    O
acids    O
,    O
e.g.    O
lithocholic    B-Steroid115057744
and    O
chenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
which    O
can    O
form    O
hyodeoxycholic    O
and    O
hyocholic    O
acids    O
,    O
respectively    O
,    O
after    O
6α-hydroxilation    O
.    O

This    O
receptor    O
also    O
functions    O
as    O
a    O
receptor    O
for    O
the    O
secondary    O
bile    O
acid    O
lithocholic    B-Steroid115057744
acid    I-Steroid115057744
.    O

gestonorone    B-Steroid115057744
caproate    I-Steroid115057744
(    O
INN    O
)    O

The    O
C17α    O
caproate    O
ester    O
of    O
gestronol    O
,    O
gestonorone    B-Steroid115057744
caproate    I-Steroid115057744
(    O
gestronol    O
hexanoate    O
)    O
,    O
in    O
contrast    O
,    O
has    O
been    O
marketed    O
.    O

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-Steroid115057744
derivatives    O
gestonorone    B-Steroid115057744
caproate    I-Steroid115057744
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
and    O
quingestanol    B-Steroid115057744
acetate    I-Steroid115057744
.    O

They    O
have    O
unusual    O
green    O
bones    O
(    O
due    O
to    O
the    O
presence    O
of    O
biliverdin    B-Steroid115057744
)    O
which    O
discourages    O
many    O
people    O
from    O
eating    O
them    O
,    O
but    O
the    O
green    O
colour    O
is    O
harmless    O
.    O

Skinks    O
in    O
the    O
genus    O
"    O
Prasinohaema    O
"    O
have    O
green    O
blood    O
because    O
of    O
a    O
buildup    O
of    O
the    O
waste    O
product    O
biliverdin    B-Steroid115057744
.    O

Common    O
naturally    O
produced    O
molecules    O
containing    O
pyrroles    O
include    O
vitamin    O
B12    O
,    O
bile    O
pigments    O
like    O
bilirubin    O
and    O
biliverdin    B-Steroid115057744
,    O
and    O
the    O
porphyrins    O
of    O
heme    O
,    O
chlorophyll    O
,    O
chlorins    O
,    O
bacteriochlorins    O
,    O
and    O
porphyrinogens    O
.    O

This    O
fish    O
has    O
green    O
blood    O
plasma    O
,    O
the    O
color    O
caused    O
by    O
biliverdin    B-Steroid115057744
tightly    O
bound    O
in    O
protein    O
complexes    O
.    O

The    O
colour    O
may    O
be    O
due    O
to    O
biliverdin    B-Steroid115057744
,    O
but    O
this    O
has    O
not    O
been    O
established    O
beyond    O
doubt    O
.    O

The    O
skin    O
is    O
a    O
striking    O
silver    O
in    O
adult    O
lampreys    O
caught    O
fresh    O
from    O
the    O
sea    O
but    O
soon    O
changes    O
to    O
brown    O
after    O
they    O
have    O
been    O
in    O
fresh    O
water    O
for    O
some    O
time    O
,    O
due    O
to    O
deposition    O
of    O
biliverdin    B-Steroid115057744
.    O

This    O
condition    O
is    O
caused    O
by    O
an    O
excess    O
buildup    O
of    O
the    O
bile    O
pigment    O
biliverdin    B-Steroid115057744
.    O

It    O
has    O
green    O
-    O
colored    O
blood    O
and    O
turquoise    O
-    O
hued    O
bones    O
,    O
a    O
result    O
of    O
a    O
pigment    O
in    O
waste    O
products    O
,    O
biliverdin    B-Steroid115057744
.    O

Depo-Estradiol    B-Steroid115057744

Along    O
with    O
estradiol    B-Steroid115057744
valerate    I-Steroid115057744
,    O
estradiol    B-Steroid115057744
cypionate    I-Steroid115057744
,    O
and    O
estradiol    B-Steroid115057744
benzoate    I-Steroid115057744
,    O
estradiol    O
undecylate    O
is    O
or    O
has    O
been    O
used    O
as    O
an    O
intramuscular    O
estrogen    O
in    O
hormone    O
replacement    O
therapy    O
for    O
transgender    O
women    O
.    O

Prior    O
to    O
the    O
development    O
and    O
introduction    O
of    O
estradiol    B-Steroid115057744
valerate    I-Steroid115057744
and    O
estradiol    B-Steroid115057744
cypionate    I-Steroid115057744
in    O
the    O
1950s    O
,    O
estradiol    O
dipropionate    O
and    O
estradiol    O
benzoate    O
were    O
the    O
most    O
widely    O
used    O
estradiol    O
esters    O
.    O

Examples    O
include    O
testosterone    O
cypionate    O
,    O
estradiol    B-Steroid115057744
cypionate    I-Steroid115057744
,    O
hydrocortisone    O
cypionate    O
,    O
and    O
oxabolone    O
cypionate    O
.    O

A    O
licence    O
was    O
granted    O
to    O
Phytopharm    O
,    O
for    O
development    O
of    O
the    O
active    O
ingredient    O
in    O
the    O
"    O
Hoodia    O
"    O
plant    O
,    O
p57    B-Steroid115057744
(glycoside)    I-Steroid115057744
,    O
to    O
be    O
used    O
as    O
a    O
pharmaceutical    O
drug    O
for    O
dieting    O
.    O

Delanterone    B-Steroid115057744

Cyproterone    B-Steroid115057744

However    O
,    O
although    O
it    O
is    O
described    O
as    O
not    O
being    O
a    O
progestogen    O
,    O
benorterone    O
was    O
found    O
to    O
produce    O
"    O
a    O
highly    O
variable    O
decrease    O
in    O
plasma    O
testosterone    O
levels    O
"    O
(    O
the    O
reasons    O
for    O
this    O
are    O
unclear    O
,    O
as    O
other    O
pure    O
antiandrogens    O
such    O
as    O
cyproterone    B-Steroid115057744
(    O
"    O
not    O
"    O
CPA    O
)    O
and    O
bicalutamide    O
do    O
not    O
do    O
this    O
and    O
instead    O
produce    O
consistent    O
increases    O
in    O
testosterone    O
levels    O
)    O
.    O

It    O
follows    O
that    O
an    O
increase    O
in    O
vitamin    O
D3    O
intake    O
should    O
lead    O
to    O
a    O
decrease    O
in    O
bone    O
resorption    O
—    O
it    O
has    O
been    O
shown    O
that    O
oral    O
administration    O
of    O
vitamin    O
D    O
does    O
not    O
linearly    O
correlate    O
to    O
increased    O
serum    O
levels    O
of    O
calcifediol    B-Steroid115057744
,    O
the    O
precursor    O
to    O
calcitriol    O
.    O

T    O
-    O
cells    O
have    O
a    O
symbiotic    O
relationship    O
with    O
vitamin    O
D.    O
Not    O
only    O
does    O
the    O
T    O
-    O
cell    O
extend    O
a    O
vitamin    O
D    O
receptor    O
,    O
in    O
essence    O
asking    O
to    O
bind    O
to    O
the    O
steroid    O
hormone    O
version    O
of    O
vitamin    O
D    O
,    O
calcitriol    O
,    O
but    O
the    O
T    O
-    O
cell    O
expresses    O
the    O
gene    O
CYP27B1    O
,    O
which    O
is    O
the    O
gene    O
responsible    O
for    O
converting    O
the    O
pre    O
-    O
hormone    O
version    O
of    O
vitamin    O
D    O
,    O
calcidiol    B-Steroid115057744
into    O
the    O
steroid    O
hormone    O
version    O
,    O
calcitriol    O
.    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Steroid115057744
(    O
a    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
)    O
-Standard    O
reference    O
range    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Steroid115057744
-Therapeutic    O
target    O
range    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Steroid115057744
(    O
a    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
)    O

Steroid    B-Steroid115057744
use    I-Steroid115057744
in    I-Steroid115057744
Bollywood    I-Steroid115057744

Ganoderic    O
acid    O
,    O
or    O
Ganoderol    B-Steroid115057744
B    O
are    O
thought    O
to    O
be    O
the    O
compounds    O
in    O
the    O
mushroom    O
that    O
are    O
specifically    O
active    O
.    O

The    O
closely    O
related    O
compound    O
androstenone    B-Steroid115057744
is    O
involved    O
in    O
communicating    O
dominance    O
,    O
aggression    O
or    O
competition    O
;    O
sex    O
hormone    O
influences    O
on    O
androstenone    O
perception    O
in    O
humans    O
showed    O
high    O
testosterone    O
level    O
related    O
to    O
heightened    O
androstenone    O
sensitivity    O
in    O
men    O
,    O
a    O
high    O
testosterone    O
level    O
related    O
to    O
unhappiness    O
in    O
response    O
to    O
androstenone    O
in    O
men    O
,    O
and    O
a    O
high    O
estradiol    O
level    O
related    O
to    O
disliking    O
of    O
androstenone    O
in    O
women    O
.    O

Androstadienol    O
and    O
androstadienone    B-Steroid115057744
are    O
odorless    O
compounds    O
secreted    O
by    O
the    O
apocrine    O
glands    O
,    O
and    O
via    O
conversion    O
into    O
the    O
more    O
powerfully    O
-    O
odorous    O
androstenone    B-Steroid115057744
and    O
androstenol    B-Steroid115057744
(    O
catalyzed    O
by    O
aerobic    O
corynebacteria    O
,    O
particularly    O
"    O
Corynebacterium    O
xerosis    O
"    O
,    O
in    O
men    O
,    O
and    O
"    O
Micrococcaceae    O
spp    O
.    O
"    O
in    O
women    O
)    O
,    O
are    O
considered    O
to    O
be    O
mainly    O
responsible    O
for    O
the    O
"    O
musky    O
"    O
component    O
of    O
axillary    O
(    O
underarm    O
)    O
odor    O
.    O

Androstadienol    O
is    O
then    O
sequentially    O
converted    O
into    O
androstenol    O
by    O
3β-hydroxysteroid    O
dehydrogenase    O
(    O
androstadienol    O
to    O
androstadienone    B-Steroid115057744
)    O
,    O
5α-reductase    O
(    O
androstadienone    O
to    O
androstenone    B-Steroid115057744
)    O
,    O
and    O
3α-hydroxysteroid    O
dehydrogenase    O
(    O
androstenone    O
to    O
androstenol    O
)    O
,    O
in    O
a    O
manner    O
analogous    O
to    O
the    O
biosynthesis    O
of    O
3α-androstanediol    B-Steroid115057744
from    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
.    O

Cholestenes    B-Steroid115057744
are    O
derivatives    O
of    O
cholestanes    B-Steroid115057744
that    O
have    O
a    O
double    O
bond    O
.    O

Tetrahydrocortisol    B-Steroid115057744

Prednimustine    B-Steroid115057744

Prednimustine    B-Steroid115057744
(    O
prednisolone    O
chlorambucil    O
ester    O
)    O

7α-Hydroxycholesterol    B-Steroid115057744
is    O
a    O
precursor    O
of    O
bile    O
acids    O
,    O
created    O
by    O
cholesterol    O
7α-hydroxylase    O
.    O

He    O
took    O
up    O
a    O
two    O
-    O
year    O
post    O
-    O
doctoral    O
research    O
position    O
assisting    O
Erik    O
J.    O
Sorensen    O
at    O
The    O
Scripps    O
Research    O
Institute    O
and    O
helped    O
to    O
synthesise    O
furanosteriod    O
viridin    B-Steroid115057744
.    O

6-Ketoprogesterone    B-Steroid115057744
is    O
an    O
orally    O
active    O
oxidized    O
form    O
of    O
progesterone    O
that    O
contains    O
a    O
keto    O
group    O
at    O
position-6    O
.    O

Androstenol    B-Steroid115057744

It    O
is    O
described    O
as    O
having    O
a    O
musky    O
odor    O
similar    O
to    O
that    O
of    O
androstenol    B-Steroid115057744
.    O

Androstadienol    O
and    O
androstadienone    B-Steroid115057744
are    O
odorless    O
compounds    O
secreted    O
by    O
the    O
apocrine    O
glands    O
,    O
and    O
via    O
conversion    O
into    O
the    O
more    O
powerfully    O
-    O
odorous    O
androstenone    B-Steroid115057744
and    O
androstenol    B-Steroid115057744
(    O
catalyzed    O
by    O
aerobic    O
corynebacteria    O
,    O
particularly    O
"    O
Corynebacterium    O
xerosis    O
"    O
,    O
in    O
men    O
,    O
and    O
"    O
Micrococcaceae    O
spp    O
.    O
"    O
in    O
women    O
)    O
,    O
are    O
considered    O
to    O
be    O
mainly    O
responsible    O
for    O
the    O
"    O
musky    O
"    O
component    O
of    O
axillary    O
(    O
underarm    O
)    O
odor    O
.    O

Androstenol    B-Steroid115057744
,    O
also    O
known    O
as    O
5α-androst-16-en-3α-ol    B-Steroid115057744
(    O
shortened    O
to    O
3α,5α-androstenol    B-Steroid115057744
or    O
3α-androstenol    B-Steroid115057744
)    O
,    O
is    O
a    O
steroidal    O
pheromone    O
and    O
neurosteroid    O
in    O
humans    O
and    O
other    O
mammals    O
,    O
notably    O
pigs    O
.    O

For    O
mild    O
-    O
moderate    O
eczema    O
a    O
weak    O
steroid    O
may    O
be    O
used    O
(    O
e.g.    O
,    O
hydrocortisone    O
)    O
,    O
while    O
in    O
more    O
severe    O
cases    O
a    O
higher    O
-    O
potency    O
steroid    O
(    O
e.g.    O
,    O
clobetasol    B-Steroid115057744
propionate    I-Steroid115057744
)    O
may    O
be    O
used    O
.    O

Alclometasone    O
dipropionate    O
,    O
betamethasone    O
dipropionate    O
,    O
betamethasone    O
valerate    O
,    O
clobetasol    B-Steroid115057744
propionate    I-Steroid115057744
,    O
clobetasone    O
butyrate    O
,    O
fluprednidene    O
acetate    O
,    O
and    O
mometasone    O
furoate    O
.    O

A    O
propionate    O
ester    O
of    O
clobetasol    O
,    O
clobetasol    B-Steroid115057744
propionate    I-Steroid115057744
,    O
has    O
also    O
been    O
marketed    O
,    O
and    O
is    O
far    O
more    O
widely    O
used    O
in    O
comparison    O
.    O

Additionally    O
,    O
other    O
wild    O
species    O
have    O
bitter    O
fruit    O
containing    O
cucurbitacin    B-Steroid115057744
.    O

Important    O
sub    O
-    O
classes    O
include    O
sterols    O
and    O
cucurbitacin    B-Steroid115057744
.    O

The    O
fruit    O
and    O
foliage    O
are    O
toxic    O
due    O
to    O
the    O
presence    O
of    O
cucurbitacin    B-Steroid115057744
.    O

This    O
plant    O
,    O
and    O
especially    O
its    O
fruit    O
,    O
is    O
poisonous    O
,    O
containing    O
cucurbitacin    B-Steroid115057744
.    O

Cucurbitacin    B-Steroid115057744

Hydrocortisone-17-butyrate    B-Steroid115057744
,    O
hydrocortisone-17-valerate    O
,    O
alclometasone    O
dipropionate    O
,    O
betamethasone    O
valerate    O
,    O
betamethasone    O
dipropionate    O
,    O
prednicarbate    O
,    O
clobetasone-17-butyrate    O
,    O
Clobetasol-17    B-Steroid115057744
propionate    I-Steroid115057744
,    O
fluocortolone    O
caproate    O
,    O
fluocortolone    O
pivalate    O
,    O
fluprednidene    O
acetate    O
,    O
and    O
mometasone    O
furoate    O

3β-HSD    O
is    O
also    O
known    O
as    O
delta    O
Δ5    O
-    O
4-isomerase    O
,    O
which    O
catalyzes    O
the    O
oxidative    O
conversion    O
of    O
Δ5    O
-    O
hydroxysteroid    B-Steroid115057744
to    O
the    O
Δ4    O
-    O
3-keto    O
configuration    O
and    O
is    O
,    O
therefore    O
,    O
essential    O
for    O
the    O
biosynthesis    O
of    O
all    O
classes    O
of    O
hormonal    O
steroids    O
,    O
namely    O
progesterone    O
,    O
glucocorticoids    O
,    O
mineralocorticoids    O
,    O
androgens    O
,    O
and    O
estrogens    O
.    O

Members    O
of    O
this    O
enzyme    O
family    O
metabolize    O
a    O
wide    O
variety    O
of    O
substrates    O
,    O
including    O
ethanol    O
,    O
retinol    O
,    O
other    O
aliphatic    O
alcohols    O
,    O
hydroxysteroid    B-Steroid115057744
,    O
and    O
lipid    O
peroxidation    O
products    O
.    O

Tirilazad    B-Steroid115057744
-    O
neuroprotective    O
agent    O

Melengestrol    B-Steroid115057744
acetate    I-Steroid115057744

There    O
are    O
three    O
natural    O
hormones    O
(    O
estradiol    O
,    O
progesterone    O
,    O
and    O
testosterone    O
)    O
and    O
their    O
synthetic    O
alternatives    O
(    O
zeranol    O
,    O
melengestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
and    O
trenbolone    O
acetate    O
)    O
have    O
been    O
approved    O
by    O
the    O
for    O
use    O
in    O
Canadian    O
beef    O
production    O
.    O

The    O
1990s    O
saw    O
the    O
introduction    O
of    O
artificial    O
pulmonary    O
surfactants    O
and    O
antenatal    B-Steroid115057744
steroids    I-Steroid115057744
which    O
reduced    O
infant    O
mortality    O
and    O
meant    O
more    O
premature    O
babies    O
began    O
to    O
survive    O
.    O

7-Dehydrocholesterol    O
reductase    O
(    O
7-DHCR    O
)    O
inhibitors    O
such    O
as    O
AY-9944    O
and    O
BM-15766    O
inhibit    O
the    O
production    O
of    O
cholesterol    O
from    O
7-dehydrocholesterol    B-Steroid115057744
,    O
one    O
of    O
the    O
last    O
steps    O
in    O
cholesterol    O
biosynthesis    O
.    O

Opitz    O
syndrome    O
(    O
SLOS    O
)    O
and    O
dramatic    O
accumulation    O
of    O
7-dehydrocholesterol    B-Steroid115057744
.    O

The    O
key    O
phytochemical    O
constituents    O
of    O
the    O
herb    O
are    O
pregnane    B-Steroid115057744
glycosides    O
,    O
flavone    O
glycosides    O
,    O
megastigmane    O
glycosides    O
,    O
and    O
saponins    O
.    O

Estrane    B-Steroid115057744
and    O
pregnane    B-Steroid115057744

Dexamethasone    O
is    O
a    O
synthetic    O
pregnane    B-Steroid115057744
corticosteroid    O
and    O
derivative    O
of    O
cortisol    O
(    O
hydrocortisone    O
)    O
and    O
is    O
also    O
known    O
as    O
1-dehydro-9α-fluoro-16α-methylhydrocortisone    O
or    O
as    O
9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione    O
.    O

Prednisone    O
is    O
a    O
synthetic    O
pregnane    B-Steroid115057744
corticosteroid    O
and    O
derivative    O
of    O
cortisone    O
and    O
is    O
also    O
known    O
as    O
δ1-cortisone    O
or    O
1,2-dehydrocortisone    O
or    O
as    O
17α,21-dihydroxypregna-1,4-diene-3,11,20-trione    O
.    O

Hydrocortisone    O
,    O
also    O
known    O
as    O
11β,17α,21-trihydroxypregn-4-ene-3,20-dione    O
,    O
is    O
a    O
naturally    O
occurring    O
pregnane    B-Steroid115057744
steroid    O
.    O

Cortisone    O
(    O
or    O
)    O
,    O
also    O
known    O
as    O
17α,21-dihydroxypregn-4-ene-3,11,20-trione    O
,    O
is    O
a    O
pregnane    B-Steroid115057744
(    O
21-carbon    O
)    O
steroid    O
hormone    O
.    O

It    O
has    O
also    O
been    O
found    O
to    O
act    O
as    O
an    O
agonist    O
of    O
the    O
human    O
pregnane    O
X    O
receptor    O
,    O
albeit    O
with    O
an    O
EC50    O
that    O
is    O
more    O
than    O
an    O
order    O
of    O
magnitude    O
lower    O
than    O
that    O
of    O
other    O
endogenous    O
pregnane    B-Steroid115057744
like    O
pregnenolone    B-Steroid115057744
,    O
pregnanediol    O
,    O
allopregnanedione    B-Steroid115057744
,    O
and    O
allopregnanolone    O
.    O

The    O
company    O
discovers    O
,    O
develops    O
and    O
commercializes    O
anti    O
-    O
infective    O
drugs    O
based    O
on    O
its    O
proprietary    O
class    O
of    O
compounds    O
,    O
Ceragenins    B-Steroid115057744
.    O

7-Dehydrositosterol    B-Steroid115057744
is    O
a    O
sterol    O
which    O
serves    O
as    O
a    O
precursor    O
for    O
sitocalciferol    O
(    O
vitamin    O
D5    O
)    O
.    O

Norvinisterone    B-Steroid115057744

Aside    O
from    O
vinyltestosterone    O
itself    O
,    O
two    O
19-nortestosterone    O
derivatives    O
of    O
vinyltestosterone    O
,    O
norvinisterone    B-Steroid115057744
(    O
17α-vinyl-19-nortestosterone    O
)    O
and    O
norgesterone    O
(    O
17α-vinyl-δ5(10)-19-nortestosterone    O
)    O
,    O
have    O
,    O
in    O
contrast    O
,    O
been    O
marketed    O
.    O

24-Dehydrocholesterol    O
reductase    O
(    O
24-DHCR    O
)    O
inhibitors    O
such    O
as    O
azacosterol    B-Steroid115057744
and    O
triparanol    O
inhibit    O
the    O
production    O
of    O
cholesterol    O
from    O
desmosterol    B-Steroid115057744
,    O
one    O
of    O
the    O
last    O
steps    O
in    O
cholesterol    O
biosynthesis    O
,    O
and    O
were    O
formerly    O
used    O
to    O
treat    O
hypercholesterolemia    O
,    O
but    O
were    O
withdrawn    O
from    O
the    O
market    O
due    O
to    O
toxicity    O
caused    O
by    O
accumulation    O
of    O
desmosterol    O
in    O
tissues    O
.    O

1-Testosterone    B-Steroid115057744

1-Testosterone    B-Steroid115057744
(    O
dihydroboldenone    O
;    O
δ1-DHT    O
)    O

Mesabolone    B-Steroid115057744
–    O
17β-(1-methyloxycyclohexyl    O
)    O
ether    O
of    O
1-testosterone    B-Steroid115057744
(    O
dihydroboldenone    O
)    O

Androsterone    O
's    O
3β-isomer    O
is    O
epiandrosterone    O
,    O
and    O
its    O
5β-epimer    O
is    O
etiocholanolone    B-Steroid115057744
.    O

Androsterone    O
and    O
its    O
5β-isomer    O
,    O
etiocholanolone    B-Steroid115057744
,    O
are    O
produced    O
in    O
the    O
body    O
as    O
metabolites    O
of    O
testosterone    O
.    O

Etiocholanolone    B-Steroid115057744

He    O
later    O
released    O
a    O
statement    O
announcing    O
that    O
he    O
used    O
a    O
supplement    O
which    O
contains    O
7-Keto-DHEA    B-Steroid115057744
,    O
an    O
anabolic    O
agent    O
.    O

Metabolites    O
of    O
DHEA    O
include    O
DHEA    O
-    O
S    O
,    O
7α-hydroxy    O
-    O
DHEA    O
,    O
7β-hydroxy    O
-    O
DHEA    O
,    O
7-keto-DHEA    B-Steroid115057744
,    O
7α-hydroxyepiandrosterone    O
,    O
and    O
7β-hydroxyepiandrosterone    O
,    O
as    O
well    O
as    O
androstenediol    O
and    O
androstenedione    O
.    O

One    O
chemical    O
ingredient    O
in    O
the    O
extract    O
is    O
the    O
steroid    O
guggulsterone    B-Steroid115057744
,    O
which    O
acts    O
as    O
an    O
antagonist    O
of    O
the    O
farnesoid    O
X    O
receptor    O
,    O
once    O
believed    O
to    O
result    O
in    O
decreased    O
cholesterol    O
synthesis    O
in    O
the    O
liver    O
.    O

Zymosterol    B-Steroid115057744
is    O
a    O
cholesterol    O
intermediate    O
in    O
the    O
cholesterol    O
biosynthesis    O
.    O

Additionally    O
,    O
the    O
seeds    O
contain    O
phytosterol    B-Steroid115057744
which    O
may    O
contribute    O
toward    O
lower    O
levels    O
of    O
blood    B-Steroid115057744
cholesterol    I-Steroid115057744
.    O

Avocados    O
also    O
contain    O
phytosterols    B-Steroid115057744
and    O
carotenoids    O
,    O
such    O
as    O
lutein    O
and    O
zeaxanthin    O
.    O

Numerous    O
studies    O
have    O
revealed    O
the    O
presence    O
of    O
phenols    O
,    O
flavonoids    O
,    O
alkaloids    O
,    O
glycosides    O
,    O
phytosterol    B-Steroid115057744
,    O
carotenoids    O
,    O
tannins    O
,    O
fixed    O
oils    O
and    O
fats    O
form    O
different    O
parts    O
of    O
"    O
H.isora    O
"    O
,    O
in    O
varying    O
concentrations    O
.    O

α-Spinasterol    B-Steroid115057744
is    O
a    O
phytosterol    B-Steroid115057744
found    O
in    O
a    O
variety    O
of    O
plant    O
sources    O
such    O
as    O
spinach    O
,    O
from    O
which    O
it    O
gets    O
its    O
name    O
.    O

Daucosterol    B-Steroid115057744
(    O
eleutheroside    O
A    O
)    O
is    O
a    O
natural    O
phytosterol    B-Steroid115057744
-    O
like    O
compound    O
.    O

Campestanol    O
is    O
a    O
natural    O
phytosterol    B-Steroid115057744
.    O

Tatakin    O
(    O
4-methoxyisoscutellargin    O
)    O
,    O
takakin    O
8-O    O
-    O
glucoside    O
,    O
takakin    O
7-O    O
-    O
glucoside    O
,    O
sesamin    O
,    O
chrysophanol    O
,    O
emodin    O
,    O
parietin    O
,    O
bucegin    O
7-O    O
-    O
glucoside    O
,    O
isoscutellarein    O
,    O
isoscutellarein    O
7-O    O
-    O
glucoside    O
,    O
methoxsalen    O
,    O
aesculetin    O
,    O
estrone    O
,    O
scopoletin    O
,    O
phytosterols    B-Steroid115057744
(    O
a    O
mixture    O
of    O
β-sitosterol    B-Steroid115057744
,    O
stigmasterol    B-Steroid115057744
and    O
campesterol    O
)    O
and    O
α-amyrin    O
were    O
extracted    O
from    O
"    O
G.    O
bruguieri    O
"    O
.    O

Also    O
during    O
the    O
1970s    O
it    O
became    O
possible    O
to    O
produce    O
steroids    O
from    O
soy    O
phytosterols    B-Steroid115057744
,    O
including    O
progesterone    O
.    O

The    O
soup    O
offers    O
useful    O
quantities    O
of    O
Iron    O
,    O
magnesium    O
,    O
manganese    O
,    O
copper    O
,    O
calcium    O
,    O
vitamin    O
B1    O
,    O
vitamin    O
E    O
,    O
phytic    O
acid    O
,    O
phytosterols    B-Steroid115057744
and    O
sesamin    O
.    O

The    O
smallest    O
condensed    O
fraction    O
is    O
the    O
lowest    O
-    O
polarity    O
upper    O
phase    O
which    O
a    O
mix    O
of    O
phytosterols    B-Steroid115057744
and    O
other    O
oily    O
,    O
waxy    O
substances    O
.    O

Phytosterols    B-Steroid115057744
,    O
such    O
as    O
sitosterol    O
and    O
stigmasterol    O
,    O
and    O
hopanoids    B-Steroid115057744
serve    O
a    O
similar    O
function    O
in    O
plants    O
and    O
prokaryotes    O
.    O

Etynodiol    B-Steroid115057744

etynodiol    B-Steroid115057744
(    O
INN    O
)    O

These    O
varieties    O
contain    O
the    O
steroid    O
diosgenin    B-Steroid115057744
,    O
which    O
is    O
a    O
principal    O
material    O
used    O
in    O
the    O
manufacture    O
of    O
a    O
number    O
of    O
synthetic    O
steroidal    O
hormones    O
,    O
such    O
as    O
those    O
used    O
in    O
hormonal    O
contraception    O
.    O

The    O
Mexican    O
barbasco    O
trade    O
was    O
the    O
trade    O
of    O
the    O
diosgenin    B-Steroid115057744
-    O
rich    O
yam    O
species    O
"    O
Dioscorea    O
mexicana    O
"    O
,    O
"    O
Dioscorea    O
floribunda    O
"    O
and    O
"    O
Dioscorea    O
composita    O
"    O
which    O
emerged    O
in    O
Mexico    O
in    O
the    O
1950s    O
as    O
part    O
of    O
the    O
Mexican    O
steroid    O
industry    O
.    O

The    O
trade    O
started    O
when    O
Russell    O
Marker    O
,    O
a    O
chemist    O
looking    O
for    O
a    O
plant    O
source    O
from    O
which    O
to    O
extract    O
diosgenin    B-Steroid115057744
and    O
saponin    O
,    O
traveled    O
to    O
Veracruz    O
looking    O
for    O
the    O
yam    O
"    O
Dioscorea    O
mexicana    O
"    O
which    O
he    O
suspected    O
might    O
be    O
suitable    O
.    O

It    O
is    O
notable    O
for    O
its    O
production    O
of    O
diosgenin    B-Steroid115057744
,    O
which    O
is    O
a    O
precursor    O
for    O
the    O
synthesis    O
of    O
hormones    O
such    O
as    O
progesterone    O
.    O

Later    O
the    O
Mexican    O
barbasco    O
trade    O
focused    O
instead    O
on    O
"    O
Dioscorea    O
composita    O
"    O
instead    O
,    O
as    O
this    O
variety    O
has    O
a    O
higher    O
diosgenin    B-Steroid115057744
content    O
.    O

Extension    O
of    O
the    O
C17α    O
alkyl    O
chain    O
longer    O
than    O
an    O
ethyl    O
group    O
abolishes    O
androgenic    O
activity    O
and    O
converts    O
the    O
drug    O
into    O
an    O
antiandrogen    O
,    O
as    O
in    O
topterone    B-Steroid115057744
(    O
17α-propyltestosterone    O
)    O
and    O
allylestrenol    B-Steroid115057744
(    O
17α-allyl-3-deketo-19-nortestosterone    O
)    O
(    O
an    O
extended    O
-    O
chain    O
variant    O
of    O
ethylestrenol    O
)    O
.    O

Analogues    O
with    O
longer    O
C17α    O
chains    O
such    O
as    O
propyltestosterone    B-Steroid115057744
(    O
topterone    O
)    O
have    O
further    O
greatly    O
reduced    O
androgenic    O
activity    O
or    O
even    O
antiandrogenic    O
activity    O
.    O

The    O
molecule    O
on    O
the    O
left    O
is    O
β-sitosterol    B-Steroid115057744
.    O

Miscellaneous    O
others    O
(    O
e.g.    O
pectin    O
,    O
β-sitosterol    B-Steroid115057744
,    O
hexadecane    O
,    O
triacontane    O
,    O
kielcorin    O
,    O
norathyriol    O
)    O

"    O
U.    O
guianensis    O
"    O
contains    O
many    O
phytochemicals    O
(    O
(    O
-)-epicatechin    O
,    O
alkaloid    O
,    O
beta    O
-    O
Sitosterol    B-Steroid115057744
,    O
campesterol    O
,    O
campherol    O
,    O
catechol    O
,    O
catechutannic    O
acid    O
,    O
chlorogenic    O
acid    O
,    O
ellagic    O
acid    O
,    O
gallic    O
acid    O
,    O
hyperin    O
,    O
oleanolic    O
acid    O
,    O
rutin    O
,    O
stigmasterol    B-Steroid115057744
,    O
ursolic    O
acid    O
)    O
and    O
proanthocyanidin    O
B1    O
and    O
proanthocyanidin    O
B2    O
,    O
B    O
type    O
proanthocyanidins    O
,    O
in    O
the    O
root    O
.    O

It    O
is    O
the    O
glucoside    O
of    O
β-sitosterol    B-Steroid115057744
.    O

Analysis    O
of    O
the    O
methanolic    O
extract    O
of    O
the    O
aerial    O
parts    O
yields    O
sitosterol    B-Steroid115057744
,    O
stigmasterol    B-Steroid115057744
,    O
ursolic    O
acid    O
,    O
oleanolic    O
acid    O
and    O
brassicasterol    B-Steroid115057744
.    O

Major    O
chemical    O
constituents    O
are    O
hentriacontane    O
,    O
hentriacontanol    O
,    O
β-sitosterol    B-Steroid115057744
,    O
β-sitosterol    O
palmitate    O
,    O
β-sitosterol    O
-    O
D    O
-    O
glucoside    O
and    O
quercetin-3-rutinoside    O

In    O
addition    O
,    O
eight    O
unidentified    O
phospholipids    O
were    O
also    O
found    O
,    O
β-sitosterol    B-Steroid115057744
(    O
72.3%    O
of    O
the    O
total    O
sterols    O
)    O
,    O
campsterol    O
(    O
9.9%    O
)    O
,    O
and    O
stigmasterol    B-Steroid115057744
(    O
6.07%    O
)    O
being    O
prevalent    O
among    O
the    O
kenaf    O
genotypes    O
.    O

Tatakin    O
(    O
4-methoxyisoscutellargin    O
)    O
,    O
takakin    O
8-O    O
-    O
glucoside    O
,    O
takakin    O
7-O    O
-    O
glucoside    O
,    O
sesamin    O
,    O
chrysophanol    O
,    O
emodin    O
,    O
parietin    O
,    O
bucegin    O
7-O    O
-    O
glucoside    O
,    O
isoscutellarein    O
,    O
isoscutellarein    O
7-O    O
-    O
glucoside    O
,    O
methoxsalen    O
,    O
aesculetin    O
,    O
estrone    O
,    O
scopoletin    O
,    O
phytosterols    B-Steroid115057744
(    O
a    O
mixture    O
of    O
β-sitosterol    B-Steroid115057744
,    O
stigmasterol    B-Steroid115057744
and    O
campesterol    O
)    O
and    O
α-amyrin    O
were    O
extracted    O
from    O
"    O
G.    O
bruguieri    O
"    O
.    O

The    O
fruit    O
is    O
also    O
rich    O
in    O
plant    O
sterols    O
(    O
340–520    O
mg    O
/    O
kg    O
)    O
,    O
β-sitosterol    B-Steroid115057744
being    O
the    O
major    O
sterol    O
compound    O
as    O
it    O
constitutes    O
57–83%    O
of    O
total    O
sterols    O
.    O

Bergenin    O
,    O
catechin    O
,    O
gallic    O
acid    O
,    O
gallicin    O
,    O
catechin-7-O    O
-    O
glucoside    O
and    O
sitosterol    B-Steroid115057744
can    O
be    O
found    O
in    O
"    O
B.    O
ciliata    O
"    O
.    O

24-Ethyl    B-Steroid115057744
coprostanol    I-Steroid115057744
(    O
24-ethyl    O
5β-cholestan-3β-ol    O
)    O
is    O
a    O
29    O
carbon    O
stanol    B-Steroid115057744
formed    O
from    O
the    O
biohydrogenation    O
of    O
β-sitosterol    B-Steroid115057744
(    O
24-ethyl    O
cholest-5en-3β-ol    O
,    O
24-ethyl    O
cholesterol    O
)    O
in    O
the    O
gastrointestinal    O
tract    O
of    O
most    O
higher    O
animals    O
,    O
especially    O
herbivores    O
.    O

In    O
"    O
Drosophila    O
"    O
,    O
hormones    O
such    O
as    O
ecdysone    B-Steroid115057744
and    O
juvenile    O
hormone    O
can    O
promote    O
the    O
expression    O
of    O
certain    O
miRNAs    O
.    O

Very    O
detailed    O
studies    O
have    O
been    O
done    O
on    O
JH    O
,    O
JH    O
acid    O
,    O
ecdysone    B-Steroid115057744
,    O
and    O
JH    O
titers    O
have    O
been    O
done    O
in    O
precisely    O
timed    O
larvae    O
of    O
Manduca    O
sexta    O
as    O
a    O
function    O
of    O
development    O
during    O
the    O
fifth    O
larval    O
stadium    O
.    O

(    O
A    O
very    O
similar    O
timing    O
of    O
peaks    O
of    O
JH    O
esterase    O
and    O
ecdysone    B-Steroid115057744
has    O
been    O
observed    O
in    O
"    O
Galleria    O
mellonella    O
"    O
.    O

These    O
data    O
are    O
consistent    O
with    O
a    O
classical    O
model    O
for    O
lepidopterans    O
where    O
JH    O
is    O
high    O
at    O
each    O
larval    O
molt    O
,    O
but    O
must    O
rise    O
together    O
with    O
ecdysone    B-Steroid115057744
prior    O
to    O
pupation    O
to    O
initiate    O
the    O
pupal    O
molt    O
.    O

These    O
glands    O
secrete    O
an    O
ecdysteroid    B-Steroid115057744
called    O
ecdysone    B-Steroid115057744
,    O
or    O
the    O
moulting    O
hormone    O
,    O
which    O
initiates    O
the    O
epidermal    O
moulting    O
process    O
.    O

Cholane    B-Steroid115057744

Again    O
controlling    O
for    O
age    O
,    O
sex    O
,    O
and    O
BMI    O
,    O
DHEA    B-Steroid115057744
and    O
DHEA-S    B-Steroid115057744
have    O
been    O
found    O
to    O
be    O
predictive    O
of    O
larger    O
pituitary    O
gland    O
volume    O
,    O
which    O
was    O
also    O
associated    O
with    O
increased    O
ratings    O
of    O
social    O
anxiety    O
.    O

DHEA    B-Steroid115057744
sulfate    I-Steroid115057744

the    O
androgens    O
testosterone    O
and    O
dehydroepiandrosterone    B-Steroid115057744
sulfate    I-Steroid115057744

It    O
produces    O
androgens    O
,    O
mainly    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
,    O
DHEA    B-Steroid115057744
sulfate    I-Steroid115057744
(    O
DHEA    O
-    O
S    O
)    O
,    O
and    O
androstenedione    O
(    O
the    O
precursor    O
to    O
testosterone    O
)    O
in    O
humans    O
.    O

During    O
midgestation    O
,    O
the    O
fetal    O
zone    O
occupies    O
most    O
of    O
the    O
cortical    O
volume    O
and    O
produces    O
100–200    O
mg    O
/    O
day    O
of    O
DHEA-S    B-Steroid115057744
,    O
an    O
androgen    O
and    O
precursor    O
of    O
both    O
androgens    O
and    O
estrogens    O
(    O
female    O
sex    O
hormones    O
)    O
.    O

During    O
early    O
childhood    O
androgen    O
synthesis    O
and    O
secretion    O
remain    O
low    O
,    O
but    O
several    O
years    O
before    O
puberty    O
(    O
from    O
6–8    O
years    O
of    O
age    O
)    O
changes    O
occur    O
in    O
both    O
anatomical    O
and    O
functional    O
aspects    O
of    O
cortical    O
androgen    O
production    O
that    O
lead    O
to    O
increased    O
secretion    O
of    O
the    O
steroids    O
DHEA    B-Steroid115057744
and    O
DHEA-S    B-Steroid115057744
These    O
changes    O
are    O
part    O
of    O
a    O
process    O
called    O
adrenarche    O
,    O
which    O
has    O
only    O
been    O
described    O
in    O
humans    O
and    O
some    O
other    O
primates    O
.    O

The    O
endogenous    O
steroids    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
and    O
its    O
sulfate    O
ester    O
,    O
DHEA    B-Steroid115057744
sulfate    I-Steroid115057744
(    O
DHEA    O
-    O
S    O
)    O
,    O
have    O
been    O
identified    O
as    O
small    O
-    O
molecule    O
agonists    O
of    O
the    O
TrkA    O
and    O
p75NTR    O
with    O
high    O
affinity    O
(    O
around    O
5    O
nM    O
)    O
,    O
and    O
hence    O
as    O
so    O
-    O
called    O
"    O
microneurotrophins    O
"    O
.    O

Furazabol    B-Steroid115057744

Furazabol    B-Steroid115057744

5β-DHP    O
has    O
been    O
found    O
to    O
act    O
as    O
a    O
positive    O
allosteric    O
modulator    O
of    O
the    O
GABAA    O
receptor    O
(    O
albeit    O
with    O
an    O
affinity    O
for    O
this    O
receptor    O
regarded    O
as    O
relatively    O
low    O
(    O
in    O
comparison    O
to    O
3α-hydroxylated    O
progesterone    O
metabolites    O
such    O
as    O
pregnanolone    O
and    O
allopregnanolone    B-Steroid115057744
)    O
)    O
and    O
also    O
as    O
a    O
negative    O
allosteric    O
modulator    O
of    O
the    O
GABAA    O
-    O
rho    O
receptor    O
.    O

3α-DHP    O
has    O
been    O
found    O
to    O
act    O
as    O
a    O
positive    O
allosteric    O
modulator    O
of    O
the    O
GABAA    O
receptor    O
and    O
is    O
described    O
as    O
being    O
as    O
active    O
as    O
allopregnanolone    B-Steroid115057744
in    O
regard    O
to    O
this    O
action    O
.    O

Unlike    O
3α-dihydroprogesterone    O
,    O
3β-DHP    O
does    O
not    O
act    O
as    O
a    O
positive    O
allosteric    O
modulator    O
of    O
the    O
GABAA    O
,    O
which    O
is    O
in    O
accordance    O
with    O
the    O
fact    O
that    O
other    O
3β-hydroxylated    O
progesterone    O
metabolites    O
such    O
as    O
isopregnanolone    O
and    O
epipregnanolone    O
similarly    O
do    O
not    O
act    O
as    O
potentiators    O
of    O
this    O
receptor    O
and    O
instead    O
inhibit    O
it    O
as    O
well    O
as    O
reverse    O
the    O
effects    O
of    O
potentiators    O
like    O
allopregnanolone    B-Steroid115057744
.    O

Pharmacological    O
activation    O
of    O
TSPO    O
has    O
been    O
observed    O
to    O
be    O
a    O
potent    O
stimulator    O
of    O
steroid    O
biosynthesis    O
including    O
neuroactive    O
steroids    O
such    O
as    O
allopregnanolone    B-Steroid115057744
in    O
the    O
brain    O
,    O
which    O
exert    O
anxiolytic    O
properties    O
.    O

Allopregnanolone    B-Steroid115057744
has    O
been    O
identified    O
as    O
a    O
potential    O
drug    O
agent    O
.    O

Allopregnanolone    B-Steroid115057744

Neuroactive    O
steroids    O
,    O
e.g.    O
,    O
progesterone    O
and    O
its    O
active    O
metabolite    O
allopregnanolone    B-Steroid115057744
,    O
are    O
positive    O
modulators    O
of    O
the    O
GABAA    O
receptor    O
and    O
are    O
cross    O
tolerant    O
with    O
benzodiazepines    O
.    O

Allopregnanediol    O
,    O
or    O
5α-pregnane-3α,20α-diol    O
,    O
is    O
an    O
endogenous    O
metabolite    O
of    O
progesterone    O
and    O
allopregnanolone    B-Steroid115057744
and    O
an    O
isomer    O
of    O
pregnanediol    O
(    O
5β-pregnan-3α,20α-diol    O
)    O
.    O

3D    O
structure    O
model    O
of    O
an    O
anticalin    O
(    O
ribbon    O
)    O
in    O
complex    O
with    O
digitoxigenin    B-Steroid115057744
(    O
sticks    O
)    O
.    O

Certain    O
genera    O
including    O
the    O
sea    O
apples    O
in    O
the    O
genera    O
"    O
Paracucumaria    O
"    O
and    O
"    O
Pseudocolochirus    O
"    O
,    O
contain    O
toxic    O
holothurin    B-Steroid115057744
and    O
holotoxin    O
and    O
release    O
it    O
into    O
the    O
water    O
when    O
damaged    O
or    O
killed    O
.    O
Spawning    O

Cucurbitacin    B-Steroid115057744
D    I-Steroid115057744
is    O
a    O
plant    O
steroid    O
with    O
anticancer    O
activity    O
.    O

Halotestin    B-Steroid115057744

Fluoxymesterone    B-Steroid115057744

Fluoxymesterone    B-Steroid115057744

Bicalutamide    O
has    O
been    O
found    O
to    O
be    O
superior    O
to    O
the    O
spironolactone    O
(    O
which    O
has    O
also    O
been    O
used    O
,    O
in    O
combination    O
with    O
the    O
aromatase    O
inhibitor    O
testolactone    B-Steroid115057744
)    O
for    O
this    O
indication    O
;    O
it    O
has    O
shown    O
greater    O
effectiveness    O
and    O
possesses    O
fewer    O
side    O
effects    O
in    O
comparison    O
.    O

Aromatase    O
inhibitors    O
(    O
AIs    O
)    O
such    O
as    O
aminoglutethimide    O
,    O
anastrozole    O
,    O
exemestane    B-Steroid115057744
,    O
letrozole    O
,    O
and    O
testolactone    B-Steroid115057744
inhibit    O
the    O
production    O
of    O
estrogens    O
from    O
androgens    O
and    O
are    O
used    O
mainly    O
in    O
the    O
treatment    O
of    O
estrogen    O
receptor    O
-    O
positive    O
breast    O
cancer    O
.    O

Szatkowski    O
had    O
been    O
stopped    O
for    O
speeding    O
by    O
an    O
Ohio    O
State    O
Highway    O
Patrol    O
trooper    O
,    O
who    O
discovered    O
that    O
he    O
was    O
in    O
possession    O
of    O
18    O
grams    O
of    O
marijuana    O
and    O
five    O
Vicodin    O
pills    O
,    O
while    O
Brunk    O
was    O
in    O
possession    O
of    O
drug    O
paraphernalia    O
and    O
nine    O
tablets    O
of    O
Testolactone    B-Steroid115057744
.    O

Squalamine    B-Steroid115057744
is    O
an    O
aminosterol    O
compound    O
with    O
potent    O
broad    O
spectrum    O
antimicrobial    O
activity    O
discovered    O
in    O
the    O
tissues    O
of    O
the    O
dogfish    O
shark    O
(    O
"    O
Squalus    O
acanthias    O
"    O
)    O
by    O
a    O
team    O
led    O
by    O
Michael    O
Zasloff    O
.    O

Taurolithocholic    B-Steroid115057744
acid    I-Steroid115057744
is    O
a    O
bile    O
acid    O
.    O

17α-Hydroxylase/17,20-lyase    O
(    O
CYP17A1    O
)    O
inhibitors    O
such    O
as    O
abiraterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
etomidate    O
,    O
galeterone    O
,    O
ketoconazole    O
,    O
and    O
orteronel    O
inhibit    O
the    O
production    O
of    O
androgens    O
and    O
glucocorticoids    O
and    O
are    O
used    O
to    O
reduce    O
androgen    O
levels    O
in    O
the    O
treatment    O
of    O
prostate    O
cancer    O
.    O

Although    O
spironolactone    O
is    O
said    O
to    O
be    O
a    O
relatively    O
weak    O
inhibitor    O
of    O
17α-hydroxylase    O
and    O
17,20-lyase    O
,    O
at    O
least    O
compared    O
to    O
more    O
potent    O
steroidogenesis    O
inhibitors    O
like    O
ketoconazole    O
and    O
abiraterone    B-Steroid115057744
acetate    I-Steroid115057744
(    O
which    O
are    O
able    O
to    O
reduce    O
testosterone    O
concentrations    O
to    O
castrate    O
levels    O
)    O
,    O
this    O
action    O
is    O
considered    O
to    O
contribute    O
a    O
significant    O
portion    O
of    O
the    O
antiandrogen    O
effects    O
of    O
spironolactone    O
,    O
for    O
instance    O
lowering    O
testosterone    O
levels    O
in    O
women    O
with    O
hyperandrogenism    O
and    O
in    O
transgender    O
women    O
.    O

The    O
drug    O
abiraterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
which    O
is    O
used    O
to    O
treat    O
castration    O
-    O
resistant    O
prostate    O
cancer    O
,    O
blocks    O
the    O
biosynthesis    O
of    O
androgens    O
by    O
inhibiting    O
the    O
CYP17A1    O
enzyme    O
.    O

Other    O
risk    O
factors    O
include    O
alcoholism    O
,    O
low    B-Steroid115057744
cholesterol    I-Steroid115057744
,    O
blood    O
thinners    O
,    O
and    O
cocaine    O
use    O
.    O

Hypocholesterolemia    B-Steroid115057744
/    O
low    O
blood    O
cholesterol    O

Epiandrosterone    O
can    O
also    O
be    O
converted    O
from    O
the    O
natural    O
steroids    O
androstanediol    O
via    O
17β-hydroxysteroid    O
dehydrogenase    O
or    O
from    O
androstanedione    B-Steroid115057744
via    O
3β-hydroxysteroid    O
dehydrogenase    O
.    O

Androsterone    O
and    O
etiocholanolone    O
can    O
also    O
be    O
formed    O
from    O
androstenedione    O
via    O
the    O
action    O
of    O
5α-reductase    O
and    O
5β-reductase    O
forming    O
5α-androstanedione    B-Steroid115057744
and    O
5β-androstanedione    B-Steroid115057744
which    O
are    O
then    O
converted    O
to    O
androsterone    O
and    O
etiocholanolone    O
by    O
3α-hydroxysteroid    O
dehydrogenase    O
and    O
3β-hydroxysteroid    O
dehydrogenase    O
,    O
respectively    O
.    O

Dihydrotestosterone    O
↔    O
5α-Androstanedione    B-Steroid115057744
/    O
3α-Androstanediol    B-Steroid115057744
/    O
3β-Androstanediol    O

However    O
,    O
a    O
mouse    O
likely    O
undergoing    O
colonic    O
tumorigenesis    O
(    O
due    O
to    O
deoxycholate    B-Steroid115057744
added    O
to    O
its    O
diet    O
)    O
has    O
a    O
high    O
level    O
of    O
8-oxo    O
-    O
dG    O
in    O
its    O
colonic    O
epithelium    O
(    O
panel    O
B    O
)    O
.    O

Of    O
22    O
mice    O
fed    O
the    O
diet    O
supplemented    O
with    O
deoxycholate    B-Steroid115057744
,    O
20    O
(    O
91%    O
)    O
developed    O
colonic    O
tumors    O
after    O
10    O
months    O
on    O
the    O
diet    O
,    O
and    O
the    O
tumors    O
in    O
10    O
of    O
these    O
mice    O
(    O
45%    O
of    O
mice    O
)    O
included    O
an    O
adenocarcinoma    O
(    O
cancer    O
)    O
.    O

The    O
original    O
formulation    O
uses    O
sodium    O
deoxycholate    B-Steroid115057744
to    O
improve    O
solubility    O
.    O
Amphotericin    O
B    O
deoxycholate    O
(    O
ABD    O
)    O
is    O
administered    O
intravenously    O
,    O
though    O
with    O
frequent    O
adverse    O
effects    O
as    O
detailed    O
in    O
the    O
side    O
effects    O
section    O
.    O

Deoxycholic    B-Steroid115057744
acid    I-Steroid115057744

Although    O
recent    O
surveys    O
of    O
enterolith    O
composition    O
are    O
lacking    O
,    O
one    O
early    O
review    O
notes    O
struvite    O
(    O
as    O
in    O
equines    O
)    O
,    O
calcium    O
phosphate    O
,    O
and    O
calcium    O
carbonate    O
and    O
reports    O
choleic    O
acid    O
.    O
Deoxycholic    B-Steroid115057744
acid    I-Steroid115057744
and    O
cholic    O
acid    O
have    O
also    O
been    O
reported    O
.    O

Micronor    B-Steroid115057744

:    O
norethisterone    B-Steroid115057744
(    O
contraceptive    O
)    O

In    O
contrast    O
,    O
the    O
non    O
-    O
halogenated    O
19-nortestosterone    O
derivatives    O
norgestrel    O
,    O
norethisterone    B-Steroid115057744
,    O
noretynodrel    O
,    O
and    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
were    O
not    O
found    O
to    O
produce    O
such    O
nodules    O
.    O

It    O
is    O
a    O
chloroethynylated    O
derivative    O
of    O
norethisterone    B-Steroid115057744
.    O

In    O
contrast    O
,    O
the    O
non    O
-    O
halogenated    O
19-nortestosterone    O
derivatives    O
norgestrel    O
,    O
norethisterone    B-Steroid115057744
,    O
noretynodrel    O
,    O
and    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
which    O
are    O
much    O
less    O
potent    O
as    O
progestogens    O
,    O
did    O
not    O
produce    O
such    O
effects    O
at    O
the    O
dosages    O
tested    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Steroid115057744
)    O
,    O
desogestrel    B-Steroid115057744
,    O
ethylestrenol    O
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
ethinylestradiol    O
,    O
gestrinone    B-Steroid115057744
,    O
levonorgestrel    B-Steroid115057744
,    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    O
)    O
,    O
quinestrol    O
,    O
19-norprogesterone    B-Steroid115057744
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
.    O

Nandrolone    O
,    O
together    O
with    O
ethisterone    O
(    O
17α-ethynyltestosterone    O
)    O
,    O
is    O
also    O
the    O
parent    O
compound    O
of    O
a    O
large    O
group    O
of    O
progestins    O
,    O
the    O
norethisterone    B-Steroid115057744
(    O
17α-ethynyl-19-nortestosterone    O
)    O
derivatives    O
.    O

The    O
estranes    O
include    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
lynestrenol    B-Steroid115057744
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Steroid115057744
,    O
desogestrel    B-Steroid115057744
,    O
etonogestrel    B-Steroid115057744
,    O
gestodene    B-Steroid115057744
,    O
norgestimate    O
,    O
dienogest    B-Steroid115057744
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    O
.    O

In    O
1978    O
the    O
company    O
brought    O
to    O
market    O
the    O
first    O
once    O
-    O
a    O
-    O
week    O
oral    O
contraceptive    O
"    O
Deposiston    O
"    O
,    O
a    O
combination    O
of    O
ethinylestradiol    O
sulfonate    O
and    O
norethisterone    B-Steroid115057744
acetate    O
.    O

Treatment    O
with    O
a    O
progestin    O
,    O
norethisterone    B-Steroid115057744
,    O
reduced    O
her    O
estradiol    O
concentrations    O
to    O
normal    O
levels    O
and    O
decreased    O
the    O
size    O
of    O
her    O
ovaries    O
and    O
the    O
number    O
of    O
ovarian    O
cysts    O
,    O
alleviating    O
her    O
hypothalamic    O
-    O
pituitary    O
-    O
gonadal    O
axis    O
hyperactivity    O
and    O
ovarian    O
pathology    O
.    O

Examples    O
include    O
drugs    O
such    O
as    O
Norethisterone    B-Steroid115057744
,    O
Ethisterone    O
,    O
and    O
Lynestrenol    B-Steroid115057744
.    O

A    O
2001    O
comparative    O
study    O
of    O
the    O
IMS    O
LifeLink    O
Health    O
Plan    O
Claims    O
Database    O
interpreted    O
that    O
in    O
a    O
large    O
cohort    O
of    O
women    O
using    O
oral    O
contraceptives    O
,    O
there    O
was    O
found    O
a    O
small    O
,    O
statistically    O
significant    O
increase    O
in    O
the    O
risk    O
of    O
gallbladder    O
disease    O
associated    O
with    O
desogestrel    B-Steroid115057744
,    O
drospirenone    O
and    O
norethisterone    B-Steroid115057744
compared    O
with    O
levonorgestrel    B-Steroid115057744
.    O

Conversely    O
,    O
replacement    O
of    O
the    O
C17α    O
alkyl    O
group    O
with    O
an    O
ethynyl    O
group    O
greatly    O
reduces    O
but    O
does    O
not    O
abolish    O
androgenic    O
activity    O
,    O
as    O
in    O
ethisterone    O
(    O
17α-ethynyltestosterone    O
)    O
and    O
norethisterone    B-Steroid115057744
(    O
17α-ethynyl-19-nortestosterone    O
)    O
.    O

Camila    O
,    O
brand    O
name    O
of    O
a    O
progestogen    O
-    O
only    O
pill    O
containing    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O

Gestodene    B-Steroid115057744
is    O
a    O
19-nortestosterone    O
derivative    O
with    O
antimineralocorticoid    O
properties    O
.    O

gestodene    B-Steroid115057744
(    O
INN    O
)    O

The    O
estranes    O
include    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
lynestrenol    B-Steroid115057744
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Steroid115057744
,    O
desogestrel    B-Steroid115057744
,    O
etonogestrel    B-Steroid115057744
,    O
gestodene    B-Steroid115057744
,    O
norgestimate    O
,    O
dienogest    B-Steroid115057744
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    O
.    O

However    O
,    O
Park    O
Jong    O
-    O
sei    O
of    O
the    O
Olympic    O
Doping    O
Control    O
Center    O
found    O
that    O
Johnson    O
's    O
blood    O
and    O
urine    O
samples    O
contained    O
stanozolol    B-Steroid115057744
,    O
and    O
he    O
was    O
disqualified    O
three    O
days    O
later    O
.    O

In    O
July    O
2006    O
,    O
Zakari    O
was    O
reported    O
to    O
have    O
failed    O
a    O
drugs    O
test    O
for    O
the    O
banned    O
substance    O
stanozolol    B-Steroid115057744
.    O

Jenrry    O
Mejia    O
,    O
formerly    O
of    O
the    O
New    O
York    O
Mets    O
,    O
was    O
suspended    O
in    O
July    O
2015    O
when    O
he    O
tested    O
positive    O
for    O
boldenone    O
and    O
stanozolol    B-Steroid115057744
,    O
and    O
in    O
February    O
2016    O
he    O
again    O
tested    O
positive    O
for    O
boldenone    O
;    O
this    O
marked    O
Mejia    O
's    O
third    O
positive    O
test    O
for    O
a    O
performance    O
-    O
enhancing    O
drug    O
,    O
for    O
which    O
he    O
received    O
the    O
first    O
PED    O
-    O
related    O
lifetime    O
ban    O
in    O
MLB    O
history    O
.    O

Following    O
the    O
Strikeforce    O
card    O
on    O
June    O
22    O
,    O
2007    O
former    O
PRIDE    O
and    O
UFC    O
fighter    O
Phil    O
Baroni    O
tested    O
positive    O
for    O
boldenone    O
,    O
as    O
well    O
as    O
stanozolol    B-Steroid115057744
.    O

Liliya    O
Nurutdinova    O
(    O
Russia    O
)    O
was    O
disqualified    O
after    O
testing    O
positive    O
for    O
the    O
anabolic    O
steroid    O
stanozolol    B-Steroid115057744
.    O

The    O
original    O
bronze    O
medalist    O
Dmitriy    O
Polyunin    O
(    O
Uzbekistan    O
)    O
was    O
disqualifed    O
for    O
doping    O
after    O
his    O
sample    O
was    O
found    O
positive    O
for    O
the    O
anabolic    O
steroid    O
stanozolol    B-Steroid115057744
,    O
and    O
the    O
medal    O
was    O
instead    O
awarded    O
Mick    O
Hill    O
(    O
Great    O
Britain    O
)    O
.    O

Burkman    O
was    O
originally    O
chosen    O
to    O
be    O
on    O
the    O
inaugural    O
season    O
of    O
"    O
The    O
Ultimate    O
Fighter    O
"    O
,    O
but    O
he    O
failed    O
pre    O
-    O
show    O
drug    O
test    O
failure    O
and    O
admitted    O
to    O
taking    O
Winstrol    B-Steroid115057744
.    O

The    O
management    O
of    O
lipodermatosclerosis    O
may    O
include    O
treating    O
venous    O
insufficiency    O
with    O
leg    O
elevation    O
and    O
elastic    O
compression    O
stockings    O
;    O
in    O
some    O
difficult    O
cases    O
,    O
the    O
condition    O
may    O
be    O
improved    O
with    O
the    O
additional    O
use    O
of    O
the    O
fibrinolytic    O
agent    O
,    O
stanozol    B-Steroid115057744
.    O

Copeland    O
was    O
said    O
to    O
have    O
received    O
somatropin    O
,    O
genotropin    O
,    O
and    O
stanozolol    B-Steroid115057744
between    O
September    O
2004    O
and    O
February    O
2007    O
.    O

This    O
article    O
mentioned    O
several    O
current    O
and    O
former    O
WWE    O
wrestlers    O
,    O
including    O
Guerrero    O
,    O
who    O
was    O
alleged    O
to    O
have    O
obtained    O
hCG    O
and    O
the    O
steroid    O
stanozolol    B-Steroid115057744
in    O
early    O
2005    O
.    O

On    O
August    O
23    O
,    O
2004    O
,    O
Russian    O
shot    O
putter    O
Irina    O
Korzhanenko    O
was    O
stripped    O
of    O
her    O
gold    O
medal    O
and    O
thereby    O
received    O
a    O
lifetime    O
ban    O
by    O
the    O
International    O
Olympic    O
Committee    O
after    O
she    O
tested    O
positive    O
for    O
the    O
steroid    O
stanozolol    B-Steroid115057744
.    O

She    O
competed    O
at    O
the    O
2013    O
World    O
Championships    O
in    O
the    O
Women    O
's    O
+    O
75    O
kg    O
,    O
winning    O
the    O
Bronze    O
medal    O
but    O
later    O
lost    O
medal    O
and    O
was    O
banned    O
from    O
international    O
competition    O
by    O
the    O
International    O
Weightlifting    O
Federation    O
for    O
use    O
of    O
anabolic    O
steroid    O
Stanozolol    B-Steroid115057744
.    O

He    O
tested    O
positive    O
for    O
banned    O
substance    O
stanozolol    B-Steroid115057744
,    O
an    O
anabolic    O
steroid    O
.    O

One    O
positive    O
test    O
for    O
the    O
anabolic    O
steroid    O
stanozolol    B-Steroid115057744
at    O
the    O
GP    O
Carnevale    O
Europa    O
and    O
twice    O
for    O
the    O
hormone    O
testosterone    O
at    O
the    O
Giro    O
di    O
San    O
Marino    O
and    O
Sparkassen    O
Giro    O
Bochum    O
.    O

However    O
,    O
the    O
validity    O
of    O
her    O
record    O
and    O
title    O
was    O
called    O
into    O
question    O
by    O
a    O
positive    O
blood    O
test    O
result    O
for    O
the    O
banned    O
steroids    O
oxandrolone    B-Steroid115057744
and    O
stanozolol    B-Steroid115057744
,    O
and    O
she    O
was    O
"    O
provisionally    O
suspended    O
"    O
by    O
the    O
International    O
Weightlifting    O
Federation    O
.    O

In    O
June    O
2016    O
,    O
IWF    O
announced    O
that    O
retests    O
of    O
the    O
samples    O
taken    O
from    O
the    O
2012    O
Olympics    O
indicated    O
that    O
Zulfiya    O
Chinshanlo    O
had    O
tested    O
positive    O
for    O
prohibited    O
substances    O
,    O
namely    O
Oxandrolone    B-Steroid115057744
and    O
Stanazolol    B-Steroid115057744
.    O

Already    O
in    O
retirement    O
,    O
Antonova    O
was    O
suspended    O
from    O
competition    O
for    O
two    O
years    O
in    O
July    O
2013    O
,    O
after    O
a    O
re    O
-    O
tested    O
doping    O
sample    O
from    O
the    O
2009    O
world    O
championships    O
proved    O
positive    O
for    O
stanozolol    B-Steroid115057744
.    O

The    O
IAAF    O
reported    O
in    O
December    O
2015    O
that    O
Andrianova    O
would    O
be    O
retroactively    O
suspended    O
for    O
testing    O
positive    O
for    O
the    O
performance    O
-    O
enhancing    O
drug    O
stanozolol    B-Steroid115057744
.    O

On    O
April    O
3    O
,    O
MLB    O
announced    O
that    O
Santana    O
would    O
be    O
suspended    O
for    O
80    O
games    O
after    O
testing    O
positive    O
for    O
Stanozolol    B-Steroid115057744
,    O
a    O
performance    O
-    O
enhancing    O
drug    O
.    O

Stanozolol    B-Steroid115057744

He    O
was    O
due    O
to    O
compete    O
at    O
the    O
2012    O
Olympic    O
Games    O
but    O
was    O
withdrawn    O
after    O
his    O
A    O
-    O
sample    O
tested    O
positive    O
for    O
hydroxystanozolol    B-Steroid115057744
during    O
a    O
drug    O
test    O
.    O

He    O
was    O
due    O
to    O
compete    O
at    O
the    O
2012    O
Olympic    O
Games    O
but    O
was    O
withdrawn    O
after    O
his    O
A    O
-    O
sample    O
tested    O
positive    O
for    O
hydroxystanozolol    B-Steroid115057744
during    O
a    O
drug    O
test    O
.    O

He    O
was    O
due    O
to    O
compete    O
at    O
the    O
2012    O
Olympic    O
Games    O
but    O
was    O
withdrawn    O
after    O
his    O
A    O
-    O
sample    O
tested    O
positive    O
for    O
hydroxystanozolol    B-Steroid115057744
during    O
a    O
drug    O
test    O
.    O

Stanozolol    B-Steroid115057744
,    O
an    O
anabolic    O
steroid    O
.    O

After    O
the    O
fight    O
he    O
tested    O
positive    O
for    O
the    O
banned    O
substance    O
stanozolol    B-Steroid115057744
.    O

In    O
the    O
report    O
,    O
Kirk    O
Radomski    O
claimed    O
he    O
sold    O
Deca    O
-    O
Durabolin    O
and    O
Winstrol    B-Steroid115057744
to    O
Zaun    O
in    O
2001    O
,    O
after    O
a    O
referral    O
from    O
Jason    O
Grimsley    O
.    O

Stanozolol    B-Steroid115057744

In    O
September    O
2005    O
Baggaley    O
tested    O
positive    O
for    O
banned    O
steroids    O
(    O
stanozolol    B-Steroid115057744
and    O
methandienone    B-Steroid115057744
)    O
.    O

He    O
received    O
a    O
doping    O
ban    O
for    O
two    O
years    O
in    O
2001    O
,    O
after    O
testing    O
positive    O
for    O
stanozolol    B-Steroid115057744
at    O
the    O
Jamaican    O
Championships    O
.    O

He    O
finished    O
second    O
at    O
the    O
Jamaican    O
National    O
Championships    O
that    O
year    O
but    O
his    O
doping    O
test    O
from    O
the    O
competition    O
was    O
positive    O
for    O
the    O
banned    O
steroid    O
stanozolol    B-Steroid115057744
.    O

Delestrogen    B-Steroid115057744

estradiol    B-Steroid115057744
valerate    I-Steroid115057744
(    O
INN    O
)    O

Along    O
with    O
estradiol    B-Steroid115057744
valerate    I-Steroid115057744
,    O
estradiol    B-Steroid115057744
cypionate    I-Steroid115057744
,    O
and    O
estradiol    B-Steroid115057744
benzoate    I-Steroid115057744
,    O
estradiol    O
undecylate    O
is    O
or    O
has    O
been    O
used    O
as    O
an    O
intramuscular    O
estrogen    O
in    O
hormone    O
replacement    O
therapy    O
for    O
transgender    O
women    O
.    O

For    O
comparison    O
,    O
the    O
ester    O
chains    O
of    O
estradiol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
estradiol    B-Steroid115057744
valerate    I-Steroid115057744
,    O
and    O
estradiol    B-Steroid115057744
enanthate    I-Steroid115057744
have    O
2    O
,    O
5    O
,    O
and    O
7    O
carbon    O
atoms    O
,    O
respectively    O
.    O

Estradiol    O
undecylate    O
was    O
developed    O
,    O
along    O
with    O
estradiol    B-Steroid115057744
valerate    I-Steroid115057744
,    O
in    O
1954    O
.    O

Prior    O
to    O
the    O
development    O
and    O
introduction    O
of    O
estradiol    B-Steroid115057744
valerate    I-Steroid115057744
and    O
estradiol    B-Steroid115057744
cypionate    I-Steroid115057744
in    O
the    O
1950s    O
,    O
estradiol    O
dipropionate    O
and    O
estradiol    O
benzoate    O
were    O
the    O
most    O
widely    O
used    O
estradiol    O
esters    O
.    O

Estradiol    B-Steroid115057744
valerate    I-Steroid115057744

Algestone    B-Steroid115057744
acetophenide    I-Steroid115057744

Under    O
the    O
tentative    O
brand    O
name    O
Unimens    O
,    O
estradiol    O
butyrate    O
benzoate    O
was    O
studied    O
in    O
combination    O
with    O
the    O
progestogen    O
algestone    B-Steroid115057744
acetophenide    I-Steroid115057744
(    O
dihydroxyprogesterone    O
acetophenide    O
)    O
as    O
a    O
once    O
-    O
monthly    O
combined    O
injectable    O
contraceptive    O
(    O
at    O
doses    O
of    O
10    O
mg    O
and    O
150    O
mg    O
,    O
respectively    O
)    O
.    O

Nordinone    B-Steroid115057744
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
11α-hydroxy-17,17-dimethyl-18-norandrosta-4,13-dien-3-one    B-Steroid115057744
,    O
is    O
a    O
naturally    O
occurring    O
steroid    O
with    O
antiandrogen    O
properties    O
isolated    O
as    O
a    O
metabolite    O
from    O
the    O
fungus    O
"    O
Monocillium    O
nordinii    O
"    O
.    O

Oxymesterone    B-Steroid115057744

Oxymesterone    B-Steroid115057744

Medicinal    O
,    O
poisonous    O
,    O
and    O
spice    O
plants    O
-    O
more    O
than    O
300    O
plants    O
ordered    O
by    O
their    O
effective    O
substances    O
(    O
alkaloids    O
,    O
glycocholic    B-Steroid115057744
acid    I-Steroid115057744
,    O
tannins    O
,    O
ethereal    O
oils    O
,    O
vitamins    O
,    O
etc    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
choloyl    O
-    O
CoA    O
and    O
glycine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
glycocholate    B-Steroid115057744
.    O

Mixtures    O
with    O
3–5    O
°C    O
span    O
of    O
temperatures    O
and    O
ranges    O
from    O
about    O
17–23°C    O
to    O
about    O
37–40    O
°C    O
can    O
be    O
composed    O
from    O
varying    O
proportions    O
of    O
cholesteryl    B-Steroid115057744
oleyl    I-Steroid115057744
carbonate    I-Steroid115057744
,    O
cholesteryl    B-Steroid115057744
nonanoate    I-Steroid115057744
,    O
and    O
cholesteryl    B-Steroid115057744
benzoate    I-Steroid115057744
.    O

Adosterol    B-Steroid115057744
is    O
an    O
iodine    O
-    O
containing    O
sterol    O
.    O

CIMAP    O
is    O
also    O
involved    O
in    O
two    O
national    O
network    O
projects    O
as    O
nodal    O
laboratory    O
under    O
XII    O
Five    O
Year    O
Plan    O
that    O
include    O
i    O
)    O
pathway    O
engineering    O
and    O
system    O
biology    O
approach    O
towards    O
homologous    O
and    O
heterologous    O
expression    O
of    O
high    O
-    O
value    O
phytoceuticals    O
(    O
artemisinin    O
,    O
picrosides    O
,    O
morphine    O
,    O
withanolide    B-Steroid115057744
,    O
podophyllotoxin    O
)    O
and    O
ii    O
)    O
biological    O
and    O
chemical    O
transformations    O
of    O
plant    O
compounds    O
for    O
production    O
of    O
value    O
added    O
products    O
of    O
therapeutic    O
/    O
aroma    O
value    O
.    O

Like    O
plants    O
in    O
several    O
other    O
Solanaceae    O
genera    O
,    O
many    O
"    O
Jaborosa    O
"    O
species    O
contain    O
steroid    O
-    O
derived    O
compounds    O
called    O
withanolide    B-Steroid115057744
.    O

Daucosterol    B-Steroid115057744
(    O
eleutheroside    O
A    O
)    O
is    O
a    O
natural    O
phytosterol    B-Steroid115057744
-    O
like    O
compound    O
.    O

Sterols    O
isolated    O
from    O
the    O
mushroom    O
include    O
,    O
ganoderol    B-Steroid115057744
,    O
ganoderenic    B-Steroid115057744
acid    I-Steroid115057744
,    O
ganoderiol    B-Steroid115057744
,    O
ganodermanontriol    B-Steroid115057744
,    O
lucidadiol    B-Steroid115057744
,    O
and    O
ganodermadiol    B-Steroid115057744
.    O

The    O
berries    O
of    O
saw    O
palmetto    O
(    O
Serenoa    O
repens    O
)    O
,    O
a    O
small    O
palm    O
native    O
to    O
the    O
south    O
east    O
United    O
States    O
,    O
possess    O
a    O
dual    O
5a    O
-    O
reductase    O
inhibition    O
activity    O
,    O
due    O
to    O
their    O
high    O
content    O
of    O
phytosterols    O
:    O
β-sitosterol    B-Steroid115057744
,    O
stigmasterol    B-Steroid115057744
,    O
lupeol    O
,    O
lupenone    O
,    O
and    O
cycloartenol    B-Steroid115057744
.    O

Removing    O
a    O
hydrogen    O
from    O
carbons    O
22    O
and    O
23    O
yields    O
stigmasterol    B-Steroid115057744
(    O
stigmasta-5,22-dien-3β-ol    O
)    O
.    O

"    O
U.    O
guianensis    O
"    O
contains    O
many    O
phytochemicals    O
(    O
(    O
-)-epicatechin    O
,    O
alkaloid    O
,    O
beta    O
-    O
Sitosterol    B-Steroid115057744
,    O
campesterol    O
,    O
campherol    O
,    O
catechol    O
,    O
catechutannic    O
acid    O
,    O
chlorogenic    O
acid    O
,    O
ellagic    O
acid    O
,    O
gallic    O
acid    O
,    O
hyperin    O
,    O
oleanolic    O
acid    O
,    O
rutin    O
,    O
stigmasterol    B-Steroid115057744
,    O
ursolic    O
acid    O
)    O
and    O
proanthocyanidin    O
B1    O
and    O
proanthocyanidin    O
B2    O
,    O
B    O
type    O
proanthocyanidins    O
,    O
in    O
the    O
root    O
.    O

Analysis    O
of    O
the    O
methanolic    O
extract    O
of    O
the    O
aerial    O
parts    O
yields    O
sitosterol    B-Steroid115057744
,    O
stigmasterol    B-Steroid115057744
,    O
ursolic    O
acid    O
,    O
oleanolic    O
acid    O
and    O
brassicasterol    B-Steroid115057744
.    O

In    O
addition    O
,    O
eight    O
unidentified    O
phospholipids    O
were    O
also    O
found    O
,    O
β-sitosterol    B-Steroid115057744
(    O
72.3%    O
of    O
the    O
total    O
sterols    O
)    O
,    O
campsterol    O
(    O
9.9%    O
)    O
,    O
and    O
stigmasterol    B-Steroid115057744
(    O
6.07%    O
)    O
being    O
prevalent    O
among    O
the    O
kenaf    O
genotypes    O
.    O

Tatakin    O
(    O
4-methoxyisoscutellargin    O
)    O
,    O
takakin    O
8-O    O
-    O
glucoside    O
,    O
takakin    O
7-O    O
-    O
glucoside    O
,    O
sesamin    O
,    O
chrysophanol    O
,    O
emodin    O
,    O
parietin    O
,    O
bucegin    O
7-O    O
-    O
glucoside    O
,    O
isoscutellarein    O
,    O
isoscutellarein    O
7-O    O
-    O
glucoside    O
,    O
methoxsalen    O
,    O
aesculetin    O
,    O
estrone    O
,    O
scopoletin    O
,    O
phytosterols    B-Steroid115057744
(    O
a    O
mixture    O
of    O
β-sitosterol    B-Steroid115057744
,    O
stigmasterol    B-Steroid115057744
and    O
campesterol    O
)    O
and    O
α-amyrin    O
were    O
extracted    O
from    O
"    O
G.    O
bruguieri    O
"    O
.    O

Anti    O
-    O
aggregation    O
agents    O
such    O
as    O
apomorphine    O
,    O
or    O
carbenoxolone    B-Steroid115057744
.    O

Carbenoxolone    B-Steroid115057744
(    O
CBX    B-Steroid115057744
)    O
is    O
a    O
glycyrrhetinic    O
acid    O
derivative    O
with    O
a    O
steroid    O
-    O
like    O
structure    O
,    O
similar    O
to    O
substances    O
found    O
in    O
the    O
root    O
of    O
the    O
licorice    O
plant    O
.    O

Vecuronium    B-Steroid115057744

Vecuronium    B-Steroid115057744

The    O
"    O
mono"-    O
and    O
"    O
bis    O
"-    O
quaternary    O
azasteroid    O
series    O
of    O
compounds    O
to    O
which    O
candocuronium    O
belongs    O
are    O
based    O
on    O
the    O
same    O
principle    O
that    O
led    O
to    O
aminosteroids    O
such    O
as    O
pancuronium    B-Steroid115057744
,    O
vecuronium    B-Steroid115057744
and    O
rocuronium    B-Steroid115057744
:    O
use    O
of    O
the    O
steroid    O
skeleton    O
to    O
provide    O
a    O
somewhat    O
rigid    O
distance    O
between    O
the    O
two    O
quaternary    O
ammonium    O
centers    O
,    O
with    O
appendages    O
incorporating    O
fragments    O
of    O
choline    O
or    O
acetylcholine    O
.    O

In    O
2017    O
,    O
McKesson    O
was    O
involved    O
in    O
a    O
number    O
of    O
lawsuits    O
against    O
the    O
state    O
of    O
Arkansas    O
over    O
the    O
supply    O
of    O
vecuronium    B-Steroid115057744
bromide    I-Steroid115057744
.    O

Vecuronium    B-Steroid115057744

Metogest    B-Steroid115057744
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
name    O
SC-14207    B-Steroid115057744
)    O
,    O
also    O
known    O
as    O
16,16-dimethyl-19-nortestosterone    B-Steroid115057744
,    O
is    O
a    O
steroidal    O
antiandrogen    O
that    O
was    O
patented    O
in    O
1975    O
and    O
investigated    O
as    O
a    O
treatment    O
for    O
acne    O
but    O
was    O
never    O
marketed    O
.    O

Pancuronium    B-Steroid115057744
,    O
vecuronium    B-Steroid115057744
,    O
rocuronium    B-Steroid115057744
,    O
rapacuronium    O
,    O
dacuronium    O
,    O
malouètine    O
,    O
duador    O
,    O
dipyrandium    B-Steroid115057744
,    O
pipecuronium    O
,    O
chandonium    O
(    O
HS-310    O
)    O
,    O
HS-342    O
and    O
other    O
HS-    O
compounds    O
are    O
aminosteroidal    O
agents    O
.    O

Solanidine    B-Steroid115057744
is    O
a    O
poisonous    O
steroidal    O
alkaloid    O
chemical    O
compound    O
that    O
occurs    O
in    O
plants    O
of    O
the    O
Solanaceae    O
family    O
,    O
such    O
as    O
potato    O
and    O
"    O
Solanum    O
americanum    O
"    O
.    O

It    O
is    O
less    O
androgenic    O
than    O
the    O
related    O
compound    O
,    O
Δ4-androstenediol    B-Steroid115057744
,    O
and    O
has    O
been    O
found    O
to    O
stimulate    O
the    O
immune    O
system    O
.    O

4-Androstenediol    B-Steroid115057744
,    O
also    O
known    O
as    O
androst-4-ene-3β,17β-diol    B-Steroid115057744
,    O
is    O
an    O
androstenediol    O
that    O
is    O
converted    O
to    O
testosterone    O
.    O

The    O
genus    O
is    O
named    O
after    O
Cerberus    O
because    O
all    O
its    O
parts    O
are    O
poisonous    O
:    O
they    O
contain    O
cerberin    B-Steroid115057744
,    O
a    O
cardiac    O
glycoside    O
,    O
a    O
substance    O
that    O
blocks    O
electric    O
impulses    O
in    O
the    O
body    O
(    O
including    O
the    O
beating    O
of    O
the    O
heart    O
)    O
.    O

3β-HSD    O
is    O
potently    O
inhibited    O
by    O
azastene    B-Steroid115057744
,    O
cyanoketone    B-Steroid115057744
,    O
epostane    B-Steroid115057744
,    O
and    O
trilostane    B-Steroid115057744
.    O

They    O
are    O
used    O
in    O
food    O
products    O
such    O
as    O
Benecol    B-Steroid115057744
.    O

17α-Dihydroequilin    O
,    O
or    O
α-dihydroequilin    O
,    O
also    O
known    O
as    O
7-dehydro-17α-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),7-tetraen-3,17α-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
,    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    O
,    O
equilenin    O
,    O
and    O
17α-estradiol    B-Steroid115057744
.    O

17α-Dihydroequilenin    O
,    O
or    O
α-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17α-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17α-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    O
,    O
equilenin    O
,    O
and    O
17α-estradiol    B-Steroid115057744
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
1.2%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    O
)    O
.    O

16β,17α-Epiestriol    O
,    O
or    O
16,17-epiestriol    O
,    O
also    O
known    O
as    O
16β-hydroxy-17α-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10)-triene-3,16β,17α-triol    O
,    O
is    O
a    O
minor    O
and    O
weak    O
endogenous    O
steroidal    O
estrogen    O
that    O
is    O
related    O
to    O
17α-estradiol    B-Steroid115057744
and    O
estriol    O
.    O

This    O
evidence    O
convinced    O
most    O
physicians    O
who    O
specialize    O
in    O
diabetes    O
care    O
that    O
an    O
important    O
goal    O
of    O
treatment    O
is    O
to    O
make    O
the    O
biochemical    O
profile    O
of    O
the    O
diabetic    O
patient    O
(    O
blood    B-Steroid115057744
lipids    I-Steroid115057744
,    O
HbA1c    O
,    O
etc    O
.    O
)    O
as    O
close    O
to    O
the    O
values    O
of    O
non    O
-    O
diabetic    O
people    O
as    O
possible    O
.    O

Consumption    O
of    O
fibre    O
supplements    O
may    O
be    O
for    O
:    O
improving    O
dietary    O
intake    O
,    O
lowering    O
blood    B-Steroid115057744
cholesterol    I-Steroid115057744
,    O
alleviating    O
irritable    O
bowel    O
syndrome    O
,    O
reducing    O
the    O
risk    O
of    O
colon    O
cancer    O
,    O
and    O
increasing    O
feelings    O
of    O
satiety    O
.    O

Foods    O
that    O
are    O
high    O
in    O
viscous    O
fibres    O
have    O
been    O
found    O
to    O
lower    O
blood    B-Steroid115057744
cholesterol    I-Steroid115057744
by    O
binding    O
with    O
bile    O
acids    O
.    O

However    O
,    O
research    O
has    O
produced    O
mixed    O
results    O
with    O
respect    O
to    O
whether    O
fibre    O
supplements    O
are    O
as    O
effective    O
as    O
dietary    O
fibre    O
in    O
reducing    O
blood    B-Steroid115057744
cholesterol    I-Steroid115057744
.    O

Supplements    O
containing    O
extracted    O
insoluble    O
fibre    O
may    O
have    O
an    O
effect    O
on    O
blood    B-Steroid115057744
lipids    I-Steroid115057744
that    O
most    O
resembles    O
the    O
effects    O
of    O
dietary    O
fibre    O
.    O

In    O
a    O
more    O
recent    O
randomized    O
,    O
double    O
blind    O
clinical    O
study    O
of    O
58    O
hypercholesterolaemic    O
volunteers    O
,    O
an    O
extruded    O
carob    O
pulp    O
preparation    O
added    O
to    O
daily    O
diet    O
reduced    O
total    O
and    O
LDL    O
-    O
cholesterol    O
and    O
improved    O
the    O
ratio    O
of    O
HDL    O
:    O
LDL    O
cholesterol    O
in    O
all    O
participants    O
,    O
and    O
also    O
showed    O
a    O
marked    O
reduction    O
in    O
serum    B-Steroid115057744
cholesterol    I-Steroid115057744
in    O
the    O
women    O
of    O
the    O
study    O
.    O

The    O
NMR    O
(    O
Nuclear    O
Magnetic    O
Resonance    O
)    O
LipoProfile    O
test    O
is    O
a    O
specialized    O
laboratory    O
test    O
performed    O
on    O
a    O
blood    O
sample    O
that    O
provides    O
a    O
detailed    O
analysis    O
of    O
one    O
's    O
blood    B-Steroid115057744
lipids    I-Steroid115057744
including    O
the    O
number    O
of    O
Low    O
Density    O
Lipoproteins    O
(    O
LDL    O
)    O
,    O
the    O
most    O
atherogenic    O
of    O
the    O
lipoproteins    O
.    O

By    O
hydrogenating    O
the    O
double    O
bond    O
between    O
carbons    O
5    O
and    O
6    O
,    O
sitostanol    B-Steroid115057744
(    O
Stigmastanol    O
)    O
is    O
obtained    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Steroid115057744
)    O
,    O
desogestrel    B-Steroid115057744
,    O
ethylestrenol    O
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
ethinylestradiol    O
,    O
gestrinone    B-Steroid115057744
,    O
levonorgestrel    B-Steroid115057744
,    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    O
)    O
,    O
quinestrol    O
,    O
19-norprogesterone    B-Steroid115057744
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
.    O

The    O
estranes    O
include    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
,    O
norethisterone    B-Steroid115057744
enanthate    I-Steroid115057744
,    O
lynestrenol    B-Steroid115057744
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Steroid115057744
,    O
desogestrel    B-Steroid115057744
,    O
etonogestrel    B-Steroid115057744
,    O
gestodene    B-Steroid115057744
,    O
norgestimate    O
,    O
dienogest    B-Steroid115057744
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    O
.    O

No    O
statistically    O
significant    O
increase    O
in    O
risk    O
was    O
associated    O
with    O
the    O
other    O
formulations    O
of    O
oral    O
contraceptive    O
(    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
norgestrel    O
and    O
norgestimate    O
)    O
.    O

Methylprednisolone    B-Steroid115057744

However    O
,    O
most    O
vasculitis    O
in    O
general    O
are    O
treated    O
with    O
steroids    O
(    O
e.g.    O
methylprednisolone    B-Steroid115057744
)    O
because    O
the    O
underlying    O
cause    O
of    O
the    O
vasculitis    O
is    O
due    O
to    O
hyperactive    O
immunological    O
damage    O
.    O

Hydrocortisone    O
,    O
methylprednisolone    B-Steroid115057744
,    O
prednisolone    O
,    O
prednisone    O
,    O
and    O
triamcinolone    O
(    O
short-    O
to    O
medium    O
-    O
acting    O
glucocorticoids    O
)    O
.    O

The    O
preservative    O
-    O
free    O
methylprednisolone    B-Steroid115057744
acetate    O
(    O
MPA    O
)    O
injection    O
caused    O
limited    O
immunological    O
responsiveness    O
at    O
the    O
site    O
of    O
inoculation    O
,    O
allowed    O
the    O
fungus    O
to    O
be    O
vasculotropic    O
thus    O
resulting    O
in    O
a    O
necrotizing    O
fatal    O
disease    O
of    O
the    O
Central    O
nervous    O
system    O
(    O
CNS    O
)    O
.    O

In    O
adrenal    O
insufficiency    O
and    O
Addison    O
's    O
disease    O
,    O
dexamethasone    O
is    O
prescribed    O
when    O
the    O
patient    O
does    O
not    O
respond    O
well    O
to    O
prednisone    O
or    O
methylprednisolone    B-Steroid115057744
.    O

Methylprednisolone    B-Steroid115057744
therapy    O
shows    O
some    O
promise    O
in    O
short    O
-    O
term    O
prevention    O
of    O
attacks    O
,    O
even    O
though    O
its    O
mechanism    O
of    O
action    O
is    O
yet    O
to    O
be    O
discovered    O
.    O

The    O
patient    O
had    O
complete    O
resolution    O
of    O
symptoms    O
after    O
intravenous    O
therapy    O
with    O
methylprednisolone    B-Steroid115057744
.    O

High    O
dose    O
immunosuppression    O
is    O
required    O
(    O
intravenous    O
methylprednisolone    B-Steroid115057744
)    O
and    O
cyclophosphamide    O
,    O
plus    O
plasmapheresis    O
.    O

In    O
2007    O
Kyyrö    O
was    O
found    O
guilty    O
of    O
methylprednisolone    B-Steroid115057744
doping    O
.    O

Urgent    O
medical    O
attention    O
in    O
this    O
phase    O
consists    O
of    O
fluid    O
resuscitation    O
efforts    O
,    O
mainly    O
the    O
intravenous    O
administration    O
of    O
saline    O
solution    O
plus    O
hetastarch    O
or    O
albumin    O
and    O
colloids    O
(    O
to    O
increase    O
the    O
remaining    O
blood    O
flow    O
to    O
vital    O
organs    O
like    O
the    O
kidneys    O
)    O
,    O
as    O
well    O
as    O
glucocorticoids    O
(    O
steroids    O
like    O
methylprednisolone    B-Steroid115057744
,    O
to    O
reduce    O
or    O
stop    O
the    O
capillary    O
leak    O
)    O
.    O

Immunoassays    O
are    O
used    O
in    O
sports    O
anti    O
-    O
doping    O
laboratories    O
to    O
test    O
athletes    O
'    O
blood    O
samples    O
for    O
prohibited    O
recombinant    B-Steroid115057744
human    I-Steroid115057744
growth    I-Steroid115057744
hormone    I-Steroid115057744
(    O
rhGH    O
,    O
rGH    O
,    O
hGH    O
,    O
GH    O
)    O
.    O

5α-Androst-2-en-17-one    B-Steroid115057744
is    O
an    O
endogenous    O
,    O
naturally    O
occurring    O
,    O
orally    O
active    O
anabolic    O
-    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
dihydrotestosterone    O
(    O
DHT    O
)    O
.    O

Dihydrocortisone    B-Steroid115057744

Altrenogest    B-Steroid115057744

altrenogest    B-Steroid115057744
-    O
used    O
to    O
synchronize    O
estrus    O

Allylestrenol    B-Steroid115057744

Extension    O
of    O
the    O
C17α    O
alkyl    O
chain    O
longer    O
than    O
an    O
ethyl    O
group    O
abolishes    O
androgenic    O
activity    O
and    O
converts    O
the    O
drug    O
into    O
an    O
antiandrogen    O
,    O
as    O
in    O
topterone    B-Steroid115057744
(    O
17α-propyltestosterone    O
)    O
and    O
allylestrenol    B-Steroid115057744
(    O
17α-allyl-3-deketo-19-nortestosterone    O
)    O
(    O
an    O
extended    O
-    O
chain    O
variant    O
of    O
ethylestrenol    O
)    O
.    O

Future    O
attacks    O
of    O
hereditary    O
angioedema    O
can    O
be    O
prevented    O
by    O
the    O
use    O
of    O
androgens    O
such    O
as    O
danazol    B-Steroid115057744
,    O
oxandrolone    B-Steroid115057744
or    O
methyltestosterone    O
.    O

Danazol    B-Steroid115057744
may    O
also    O
be    O
prescribed    O
to    O
treat    O
this    O
condition    O
and    O
it    O
is    O
usually    O
considered    O
in    O
patients    O
on    O
whom    O
the    O
non    O
-    O
medical    O
treatment    O
fails    O
and    O
the    O
symptoms    O
are    O
intense    O
.    O

Steroid    O
sulfatase    O
(    O
STS    O
)    O
inhibitors    O
such    O
as    O
estradiol    O
sulfamate    O
,    O
estrone    O
sulfamate    O
,    O
irosustat    O
,    O
and    O
danazol    B-Steroid115057744
inhibit    O
the    O
conversion    O
of    O
steroid    O
sulfates    O
such    O
as    O
estrone    B-Steroid115057744
sulfate    I-Steroid115057744
and    O
DHEA    B-Steroid115057744
sulfate    I-Steroid115057744
into    O
their    O
hormonally    O
active    O
forms    O
.    O

Danazol    B-Steroid115057744
is    O
a    O
steroid    O
compound    O
that    O
has    O
been    O
labelled    O
as    O
an    O
"    O
Anterior    O
pituitary    O
suppressant    O
"    O
.    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
)    O
,    O
danazol    B-Steroid115057744
,    O
gestrinone    B-Steroid115057744
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    O
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

Treatment(s    O
)    O
with    O
mixed    O
success    O
:    O
omalizumab    O
(    O
anti    O
-    O
IgE    O
therapy    O
)    O
,    O
danazol    B-Steroid115057744
(    O
synthetic    O
androgen    O
)    O
,    O
propranolol    O
(    O
beta    O
blocker    O
)    O
,    O
zileuton    O
(    O
antileukotriene    O
)    O
.    O

Ergosterol    B-Steroid115057744
peroxide    I-Steroid115057744

The    O
triterpenes    O
3α-carboxyacetoxyquercinic    O
acid    O
,    O
3α-carboxyacetoxy-24-methylene-23-oxolanost-8-en-26-oic    O
acid    O
,    O
and    O
5α,8α-epidioxyergosta-6,22-dien-3β-ol    O
(    O
ergosterol    B-Steroid115057744
peroxide    I-Steroid115057744
)    O
have    O
been    O
isolated    O
from    O
"    O
D.    O
confragosa    O
"    O
.    O

Oral    O
Turinabol    O
,    O
combining    O
the    O
chemical    O
structures    O
of    O
clostebol    O
and    O
metandienone    B-Steroid115057744
,    O
was    O
widely    O
used    O
in    O
the    O
East    O
German    O
state    O
-    O
sponsored    O
doping    O
program    O
.    O

She    O
was    O
handed    O
an    O
eight    O
-    O
year    O
doping    O
ban    O
for    O
the    O
use    O
of    O
Methandienone    B-Steroid115057744
and    O
Dehydrochloromathyltestosterone    O
.    O

Boldenone    O
was    O
synthesized    O
in    O
an    O
attempt    O
to    O
create    O
a    O
long    O
-    O
acting    O
injectable    O
methandrostenolone    B-Steroid115057744
(    O
Dianabol    O
)    O
,    O
for    O
androgen    O
deficiency    O
disorders    O
.    O

Pulsabsakul    O
served    O
a    O
two    O
-    O
year    O
doping    O
ban    O
from    O
6    O
July    O
2011    O
to    O
6    O
July    O
2013    O
after    O
testing    O
positive    O
for    O
Methandienone    B-Steroid115057744
.    O

In    O
March    O
2007    O
,    O
he    O
received    O
a    O
two    O
-    O
year    O
ban    O
after    O
testing    O
positive    O
for    O
17-epimethandienone    B-Steroid115057744
.    O

Methandienone    B-Steroid115057744

Metandienone    B-Steroid115057744
(    O
INN    O
)    O
(    O
brand    O
names    O
Averbol    B-Steroid115057744
,    O
Dianabol    B-Steroid115057744
,    O
Danabol    B-Steroid115057744
,    O
Metanabol    B-Steroid115057744
,    O
Naposim    B-Steroid115057744
,    O
Vetanabol    B-Steroid115057744
)    O
,    O
or    O
methandienone    B-Steroid115057744
(    O
BAN    O
)    O
,    O
also    O
commonly    O
known    O
as    O
methandrostenolone    B-Steroid115057744
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic    O
-    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
and    O
a    O
17α-methylated    O
derivative    O
of    O
testosterone    O
which    O
was    O
formerly    O
used    O
medically    O
but    O
has    O
since    O
been    O
discontinued    O
in    O
most    O
countries    O
.    O

Metandienone    B-Steroid115057744
(methandrostenolone)    I-Steroid115057744

In    O
September    O
2005    O
Baggaley    O
tested    O
positive    O
for    O
banned    O
steroids    O
(    O
stanozolol    B-Steroid115057744
and    O
methandienone    B-Steroid115057744
)    O
.    O

Large    O
amounts    O
of    O
fertile    O
eggs    O
,    O
he    O
said    O
,    O
are    O
equal    O
to    O
the    O
anabolic    O
steroid    O
Dianabol    B-Steroid115057744
in    O
effectiveness    O
.    O

It    O
is    O
marketed    O
as    O
a    O
veterinary    O
combination    O
drug    O
with    O
methandriol    B-Steroid115057744
under    O
the    O
brand    O
name    O
Drive    O
.    O

Methandriol    B-Steroid115057744

Methandriol    B-Steroid115057744
(methylandrostenediol)    I-Steroid115057744

In    O
addition    O
,    O
it    O
is    O
also    O
the    O
distributor    O
of    O
"    O
Yingtaiqing    O
"-    O
branded    O
generic    O
diclofenac    O
sodium    O
sustained    O
-    O
release    O
capsules    O
,    O
the    O
"    O
Faneng    O
"-    O
branded    O
generic    O
alfacalcidol    B-Steroid115057744
soft    O
capsules    O
and    O
the    O
"    O
Yineng    O
"-    O
branded    O
generic    O
lentinan    O
injection    O
,    O
all    O
of    O
which    O
are    O
prescription    O
pharmaceuticals    O
manufactured    O
by    O
independent    O
third    O
parties    O
.    O

Fluprednisolone    B-Steroid115057744
=    O
6α-fluoro-11β,17α,21-trihydroxypregna-1,4-diene-3,20-dione    O

gestrinone    B-Steroid115057744
(    O
INN    O
)    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Steroid115057744
)    O
,    O
desogestrel    B-Steroid115057744
,    O
ethylestrenol    O
,    O
etynodiol    B-Steroid115057744
diacetate    I-Steroid115057744
,    O
ethinylestradiol    O
,    O
gestrinone    B-Steroid115057744
,    O
levonorgestrel    B-Steroid115057744
,    O
norethisterone    B-Steroid115057744
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    O
)    O
,    O
quinestrol    O
,    O
19-norprogesterone    B-Steroid115057744
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Steroid115057744
acetate    I-Steroid115057744
.    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-Steroid115057744
acetate    I-Steroid115057744
)    O
,    O
danazol    B-Steroid115057744
,    O
gestrinone    B-Steroid115057744
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    O
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

:    O
N02CB01    O
Flumedroxone    B-Steroid115057744

Saringosterol    B-Steroid115057744

Telapristone    B-Steroid115057744
(    O
INN    O
)    O
,    O
as    O
telapristone    B-Steroid115057744
acetate    I-Steroid115057744
(    O
proposed    O
brand    O
names    O
Proellex    B-Steroid115057744
,    O
Progenta    B-Steroid115057744
;    O
former    O
code    O
name    O
CDB-4124    B-Steroid115057744
)    O
,    O
is    O
a    O
synthetic    O
,    O
steroidal    O
selective    O
progesterone    O
receptor    O
modulator    O
(    O
SPRM    O
)    O
related    O
to    O
mifepristone    O
which    O
is    O
under    O
development    O
by    O
Repros    O
Therapeutics    O
for    O
the    O
treatment    O
of    O
breast    O
cancer    O
,    O
endometriosis    O
,    O
and    O
uterine    O
fibroids    O
.    O

telapristone    B-Steroid115057744
(    O
USAN    O
,    O
INN    O
)    O

Bevirimat    B-Steroid115057744
,    O
a    O
derivative    O
of    O
the    O
related    O
triterpenoid    O
betulinic    O
acid    O
,    O
is    O
under    O
development    O
as    O
an    O
anti    O
-    O
HIV    O
drug    O
;    O
however    O
,    O
moronic    O
acid    O
has    O
shown    O
better    O
antiviral    O
profiles    O
"    O
in    O
vitro    O
"    O
than    O
bevirimat    O
.    O

Notable    O
examples    O
include    O
the    O
non-17α-alkylated    O
trenbolone    B-Steroid115057744
and    O
the    O
17α-alkylated    O
ethylestrenol    O
(    O
ethylnandrol    O
)    O
and    O
metribolone    O
(    O
R-1881    O
)    O
,    O
as    O
well    O
as    O
the    O
17α-alkylated    O
designer    O
steroids    O
norboletone    B-Steroid115057744
and    O
tetrahydrogestrinone    B-Steroid115057744
(    O
THG    O
)    O
.    O

Tetrahydrogestrinone    B-Steroid115057744
(    O
THG    O
;    O
17α-ethyl-18-methyl-δ9,11    O
-    O
19-NT    O
)    O

The    O
IAAF    O
officially    O
annuls    O
all    O
of    O
Marion    O
Jones    O
'    O
competition    O
results    O
since    O
September    O
2000    O
,    O
including    O
her    O
medals    O
at    O
the    O
2001    O
World    O
Championships    O
,    O
in    O
the    O
wake    O
of    O
her    O
confession    O
to    O
having    O
used    O
steroids    B-Steroid115057744
in    O
2000    O
and    O
2001    O
.    O

Tetrahydrogestrinone    B-Steroid115057744
(THG)    I-Steroid115057744

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    O
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-Steroid115057744
,    O
ethyldienolone    B-Steroid115057744
,    O
tetrahydrogestrinone    B-Steroid115057744
,    O
bolenol    O
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    O
.    O

In    O
2003    O
,    O
it    O
was    O
reported    O
that    O
U.S.    O
authorities    O
found    O
e    O
-    O
mails    O
by    O
Victor    O
Conte    O
addressed    O
to    O
Tzekos    O
while    O
searching    O
BALCO    O
(    O
Bay    O
Area    O
Laboratory    O
Co    O
-    O
operative    O
)    O
,    O
the    O
California    O
company    O
secretly    O
dealing    O
Tetrahydrogestrinone    B-Steroid115057744
,    O
an    O
anabolic    O
steroid    O
specially    O
designed    O
so    O
as    O
to    O
make    O
it    O
undetectable    O
under    O
normal    O
drug    O
testing    O
.    O

In    O
addition    O
,    O
according    O
to    O
the    O
respected    O
French    O
paper    O
"    O
L'Equipe    O
,    O
"    O
Tzekos    O
was    O
directly    O
dealing    O
with    O
the    O
creator    O
of    O
norbolethone    B-Steroid115057744
and    O
THG    O
(    O
tetrahydrogestrinone    B-Steroid115057744
)    O
Patrick    O
Arnold    O
,    O
the    O
father    O
of    O
pro    O
-    O
hormone    O
craze    O
and    O
some    O
undetectable    O
designer    O
steroids    O
.    O

3β-HSD    O
is    O
potently    O
inhibited    O
by    O
azastene    B-Steroid115057744
,    O
cyanoketone    B-Steroid115057744
,    O
epostane    B-Steroid115057744
,    O
and    O
trilostane    B-Steroid115057744
.    O

Antcin    B-Steroid115057744
B    I-Steroid115057744
,    O
antrodioxolanone    O
,    O
antrocamphin    O
B    O
,    O
antroquinonol    O
,    O
antrocamphins    O
,    O
zhankuic    B-Steroid115057744
acid    I-Steroid115057744
,    O
and    O
other    O
antcins    O
have    O
been    O
reported    O
as    O
constituents    O
of    O
"    O
Taiwanofungus    O
camphoratus    O
"    O
.    O

Tibolone    B-Steroid115057744

Tibolone    B-Steroid115057744

Tibolone    B-Steroid115057744

"    O
Veratrum    O
"    O
species    O
contain    O
highly    O
toxic    O
steroidal    O
alkaloids    O
(    O
e.g.    O
veratridine    B-Steroid115057744
)    O
that    O
activate    O
sodium    O
ion    O
channels    O
and    O
cause    O
rapid    O
cardiac    O
failure    O
and    O
death    O
if    O
ingested    O
.    O

veratridine    B-Steroid115057744

The    O
drug    O
is    O
the    O
C17α    O
acetate    O
ester    O
of    O
osaterone    B-Steroid115057744
.    O

Desmosterol    B-Steroid115057744
is    O
a    O
molecule    O
similar    O
to    O
cholesterol    O
.    O

24-Dehydrocholesterol    O
reductase    O
(    O
24-DHCR    O
)    O
inhibitors    O
such    O
as    O
azacosterol    B-Steroid115057744
and    O
triparanol    O
inhibit    O
the    O
production    O
of    O
cholesterol    O
from    O
desmosterol    B-Steroid115057744
,    O
one    O
of    O
the    O
last    O
steps    O
in    O
cholesterol    O
biosynthesis    O
,    O
and    O
were    O
formerly    O
used    O
to    O
treat    O
hypercholesterolemia    O
,    O
but    O
were    O
withdrawn    O
from    O
the    O
market    O
due    O
to    O
toxicity    O
caused    O
by    O
accumulation    O
of    O
desmosterol    O
in    O
tissues    O
.    O

Estradiol    B-Steroid115057744
enanthate    I-Steroid115057744

For    O
comparison    O
,    O
the    O
ester    O
chains    O
of    O
estradiol    B-Steroid115057744
acetate    I-Steroid115057744
,    O
estradiol    B-Steroid115057744
valerate    I-Steroid115057744
,    O
and    O
estradiol    B-Steroid115057744
enanthate    I-Steroid115057744
have    O
2    O
,    O
5    O
,    O
and    O
7    O
carbon    O
atoms    O
,    O
respectively    O
.    O

dimethisterone    B-Steroid115057744
(    O
INN    O
)    O

Similarly    O
to    O
extension    O
of    O
the    O
C17α    O
alkyl    O
chain    O
,    O
extension    O
of    O
the    O
C17α    O
ethynyl    O
chain    O
abolishes    O
androgenic    O
activity    O
,    O
as    O
with    O
dimethisterone    B-Steroid115057744
(    O
6α,21-dimethylethisterone    O
)    O
.    O

SC-17599    B-Steroid115057744

Fungisterol    B-Steroid115057744
is    O
a    O
bio    O
-    O
active    O
sterol    O
made    O
by    O
certain    O
fungi    O
.    O

Cholesterol    O
(    O
(    O
3β)-cholest-5-en-3-ol    O
)    O
is    O
hydroxylated    O
by    O
cholesterol    O
side    O
-    O
chain    O
cleavage    O
enzyme    O
(    O
P450scc    O
)    O
to    O
form    O
22"R    O
"-    O
hydroxycholesterol    O
,    O
which    O
is    O
subsequently    O
hydroxlated    O
again    O
by    O
P450scc    O
to    O
form    O
20α,22"R"-dihydroxycholesterol    B-Steroid115057744
,    O
and    O
finally    O
the    O
bond    O
between    O
carbons    O
20    O
and    O
22    O
is    O
cleaved    O
by    O
P450scc    O
to    O
form    O
pregnenolone    B-Steroid115057744
(    O
(    O
3β)-3-hydroxypregn-5-en-20-one    O
)    O
,    O
the    O
precursor    O
to    O
the    O
steroid    O
hormones    O
.    O

Cholesterol    O
(    O
(    O
3β)-cholest-5-en-3-ol    O
)    O
is    O
hydroxylated    O
by    O
cholesterol    O
side    O
-    O
chain    O
cleavage    O
enzyme    O
(    O
P450scc    O
)    O
to    O
form    O
22"R"-hydroxycholesterol    B-Steroid115057744
,    O
which    O
is    O
subsequently    O
hydroxlated    O
again    O
by    O
P450scc    O
to    O
form    O
20α,22"R    O
"-    O
dihydroxycholesterol    O
,    O
and    O
finally    O
the    O
bond    O
between    O
carbons    O
20    O
and    O
22    O
is    O
cleaved    O
by    O
P450scc    O
to    O
form    O
pregnenolone    B-Steroid115057744
(    O
(    O
3β)-3-hydroxypregn-5-en-20-one    O
)    O
,    O
the    O
precursor    O
to    O
the    O
steroid    O
hormones    O
.    O

The    O
development    O
of    O
the    O
corpus    O
luteum    O
is    O
accompanied    O
by    O
an    O
increase    O
in    O
the    O
level    O
of    O
the    O
steroidogenic    O
enzyme    O
P450scc    O
that    O
converts    O
cholesterol    O
to    O
pregnenolone    B-Steroid115057744
in    O
the    O
mitochondria    O
.    O

It    O
has    O
also    O
been    O
found    O
to    O
act    O
as    O
an    O
agonist    O
of    O
the    O
human    O
pregnane    O
X    O
receptor    O
,    O
albeit    O
with    O
an    O
EC50    O
that    O
is    O
more    O
than    O
an    O
order    O
of    O
magnitude    O
lower    O
than    O
that    O
of    O
other    O
endogenous    O
pregnane    B-Steroid115057744
like    O
pregnenolone    B-Steroid115057744
,    O
pregnanediol    O
,    O
allopregnanedione    B-Steroid115057744
,    O
and    O
allopregnanolone    O
.    O

The    O
first    O
enzymatic    O
step    O
in    O
the    O
production    O
of    O
all    O
steroid    O
hormones    O
is    O
cleavage    O
of    O
the    O
cholesterol    O
side    O
chain    O
,    O
a    O
reaction    O
that    O
forms    O
pregnenolone    B-Steroid115057744
as    O
a    O
product    O
and    O
is    O
catalyzed    O
by    O
the    O
enzyme    O
P450scc    O
,    O
also    O
known    O
as    O
"    O
cholesterol    O
desmolase    O
"    O
.    O

3β-Hydroxysteroid    O
dehydrogenase/Δ5    O
-    O
4    O
isomerase    O
(    O
3β-HSD    O
)    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-Steroid115057744
,    O
17α-hydroxyprogesterone    O
from    O
17α-hydroxypregnenolone    O
,    O
and    O
androstenedione    O
from    O
dehydroepiandrosterone    B-Steroid115057744
(    O
DHEA    O
)    O
in    O
the    O
adrenal    O
gland    O
.    O

Pregnenolone    B-Steroid115057744
to    O
progesterone    O

P450scc    O
is    O
a    O
mitochondrial    O
enzyme    O
that    O
catalyzes    O
conversion    O
of    O
cholesterol    O
to    O
pregnenolone    B-Steroid115057744
.    O

File    O
:    O
Pregnenolone    B-Steroid115057744

Beclomethasone    B-Steroid115057744
dipropionate    I-Steroid115057744

One    O
commonly    O
used    O
therapy    O
is    O
beclometasone    B-Steroid115057744
dipropionate    I-Steroid115057744
.    O

It    O
is    O
also    O
used    O
in    O
some    O
pleochroic    O
dyes    O
and    O
together    O
with    O
e.g.    O
cholesteryl    B-Steroid115057744
oleyl    I-Steroid115057744
carbonate    I-Steroid115057744
and    O
cholesteryl    B-Steroid115057744
benzoate    I-Steroid115057744
in    O
some    O
thermochromic    O
applications    O
.    O

In    O
Reinitzer    O
's    O
reports    O
from    O
1888    O
on    O
the    O
melting    O
behaviour    O
of    O
cholesteryl    B-Steroid115057744
benzoate    I-Steroid115057744
,    O
there    O
is    O
a    O
note    O
that    O
the    O
substance    O
briefly    O
turned    O
blue    O
as    O
it    O
changed    O
from    O
clear    O
to    O
cloudy    O
upon    O
cooling    O
.    O

While    O
the    O
identity    O
of    O
natural    O
ligands    O
for    O
the    O
RORs    O
remains    O
controversial    O
,    O
similar    O
to    O
the    O
liver    O
X    O
receptors    O
(    O
LXRs    O
)    O
,    O
it    O
appears    O
that    O
the    O
RORs    O
are    O
activated    O
by    O
oxysterol    B-Steroid115057744
.    O

CYP27A1    O
converts    O
cholesterol    O
into    O
27-hydroxycholesterol    B-Steroid115057744
,    O
an    O
oxysterol    B-Steroid115057744
that    O
has    O
multiple    O
biological    O
functions    O
including    O
direct    O
,    O
tissue    O
-    O
specific    O
activation    O
of    O
the    O
estrogen    O
receptor    O
(    O
ER    O
)    O
(    O
it    O
has    O
been    O
characterized    O
as    O
a    O
selective    O
estrogen    O
receptor    O
modulator    O
)    O
and    O
the    O
liver    O
X    O
receptor    O
.    O

The    O
oxysterol    B-Steroid115057744
24(S),25-epoxylanosterol    O
,    O
which    O
is    O
preferentially    O
formed    O
over    O
lanosterol    B-Steroid115057744
during    O
partial    O
lanosterol    O
synthase    O
inhibition    O
,    O
is    O
believed    O
to    O
be    O
responsible    O
for    O
this    O
inhibition    O
of    O
HMG    O
-    O
CoA    O
reductase    O
activity    O
.    O

PKA    O
actively    O
phosphorylates    O
steroidogenic    B-Steroid115057744
acute    I-Steroid115057744
regulatory    I-Steroid115057744
protein    I-Steroid115057744
(    O
StAR    O
)    O
and    O
translocator    O
protein    O
to    O
transport    O
cholesterol    O
from    O
the    O
outer    O
mitochondrial    O
membrane    O
to    O
the    O
inner    O
mitochondrial    O
membrane    O
.    O

Transport    O
of    O
cholesterol    O
from    O
the    O
outer    O
to    O
the    O
inner    O
membrane    O
is    O
facilitated    O
by    O
steroidogenic    B-Steroid115057744
acute    I-Steroid115057744
regulatory    I-Steroid115057744
protein    I-Steroid115057744
and    O
is    O
the    O
rate    O
-    O
limiting    O
step    O
of    O
steroid    O
synthesis    O
.    O

This    O
step    O
is    O
mediated    O
primarily    O
by    O
the    O
steroidogenic    B-Steroid115057744
acute    I-Steroid115057744
regulatory    I-Steroid115057744
protein    I-Steroid115057744
(    O
StAR    O
or    O
STARD1    O
)    O
.    O

Hydroxystenozole    B-Steroid115057744

dehydrocholic    B-Steroid115057744
acid    I-Steroid115057744
(    O
INN    O
)    O

Glycochenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
is    O
a    O
bile    O
salt    O
formed    O
in    O
the    O
liver    O
from    O
chenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
and    O
glycine    O
,    O
usually    O
found    O
as    O
the    O
sodium    O
salt    O
.    O

Human    O
FGF19    O
transcripts    O
have    O
been    O
shown    O
to    O
be    O
stimulated    O
approximately    O
300-fold    O
by    O
physiological    O
concentrations    O
of    O
bile    O
acids    O
including    O
chenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
,    O
glycochenodeoxycholic    B-Steroid115057744
acid    I-Steroid115057744
and    O
obeticholic    O
acid    O
in    O
explants    O
of    O
ileal    O
mucosa    O
.    O

The    O
CYP    O
enzymes    O
metabolize    O
an    O
enormously    O
large    O
variety    O
of    O
small    O
and    O
large    O
molecules    O
including    O
foreign    O
chemical    O
substances    O
,    O
i.e.    O
xenobiotics    O
and    O
pharmaceuticals    O
,    O
as    O
well    O
as    O
a    O
diversity    O
of    O
endogenously    O
formed    O
substances    O
such    O
as    O
various    O
steroids    O
,    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
,    O
bilirubin    O
,    O
cholesterol    O
,    O
and    O
fatty    O
acids    O
.    O

Diseases    O
that    O
may    O
present    O
similar    O
to    O
an    O
anxiety    O
disorder    O
,    O
including    O
certain    O
endocrine    O
diseases    O
(    O
hypo-    O
and    O
hyperthyroidism    O
,    O
hyperprolactinemia    O
)    O
,    O
metabolic    O
disorders    O
(    O
diabetes    O
)    O
,    O
deficiency    O
states    O
(    O
low    O
levels    O
of    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
,    O
B2    O
,    O
B12    O
,    O
folic    O
acid    O
)    O
,    O
gastrointestinal    O
diseases    O
(    O
celiac    O
disease    O
,    O
non    O
-    O
celiac    O
gluten    O
sensitivity    O
,    O
inflammatory    O
bowel    O
disease    O
)    O
,    O
heart    O
diseases    O
,    O
blood    O
diseases    O
(    O
anemia    O
)    O
,    O
and    O
brain    O
degenerative    O
diseases    O
(    O
Parkinson    O
's    O
disease    O
,    O
dementia    O
,    O
multiple    O
sclerosis    O
,    O
Huntington    O
's    O
disease    O
)    O
.    O

Harry    O
Steenbock    O
,    O
biochemist    O
,    O
researcher    O
of    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744

Major    O
interests    O
include    O
the    O
role    O
of    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
,    O
omega-3s    O
,    O
and    O
folate    O
in    O
the    O
prevention    O
of    O
CVD    O
,    O
diabetes    O
,    O
and    O
cancer    O
,    O
and    O
assessment    O
of    O
endocrinologic    O
predictors    O
of    O
breast    O
cancer    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Robert    O
Turgot    O
Brinsmade    O
's    O
maternal    O
uncle    O
,    O
Harry    O
Steenbock    O
,    O
PhD    O
(    O
1886–1967    O
)    O
,    O
was    O
a    O
biochemistry    O
professor    O
at    O
the    O
University    O
of    O
Wisconsin    O
,    O
inventor    O
,    O
and    O
one    O
of    O
the    O
discoverers    O
of    O
vitamins    O
D    B-Steroid115057744
,    O
A    O
and    O
B.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

It    O
is    O
an    O
analog    O
of    O
vitamin    B-Steroid115057744
D    I-Steroid115057744

Vitamin    B-Steroid115057744
D    I-Steroid115057744
increases    O
absorption    O
of    O
calcium    O
and    O
phosphate    O
in    O
the    O
intestinal    O
tract    O
,    O
leading    O
to    O
elevated    O
levels    O
of    O
plasma    O
calcium    O
,    O
and    O
thus    O
lower    O
bone    O
resorption    O
.    O

High    O
lead    O
levels    O
cause    O
decreased    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
and    O
haemoglobin    O
synthesis    O
as    O
well    O
as    O
anemia    O
,    O
acute    O
central    O
nervous    O
system    O
disorders    O
,    O
and    O
possibly    O
death    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Other    O
hormones    O
appear    O
to    O
regulate    O
the    O
immune    O
system    O
as    O
well    O
,    O
most    O
notably    O
prolactin    O
,    O
growth    O
hormone    O
and    O
vitamin    B-Steroid115057744
D    I-Steroid115057744

This    O
is    O
essentially    O
a    O
signaling    O
device    O
that    O
allows    O
the    O
T    O
-    O
cell    O
to    O
bind    O
to    O
the    O
active    O
form    O
of    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
,    O
the    O
steroid    O
hormone    O
calcitriol    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

These    O
include    O
changes    O
in    O
cardiac    O
output    O
,    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
,    O
inflammation    O
,    O
sex    O
hormone    O
activity    O
,    O
lipoprotein    O
lipase    O
activity    O
,    O
and    O
GLUT4    O
activity    O
due    O
to    O
long    O
periods    O
of    O
muscular    O
unloading    O
,    O
among    O
others    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Ointment    O
and    O
creams    O
containing    O
coal    O
tar    O
,    O
dithranol    O
,    O
corticosteroids    O
(    O
i.e.    O
desoximetasone    O
)    O
,    O
fluocinonide    O
,    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
analogs    O
(    O
for    O
example    O
,    O
calcipotriol    O
)    O
,    O
and    O
retinoids    O
are    O
routinely    O
used    O
.    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Steroid115057744
(    O
a    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
)    O
-Standard    O
reference    O
range    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Steroid115057744
(    O
a    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
)    O

Calcium    O
and    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
supplementation    O
may    O
be    O
useful    O
in    O
some    O
.    O

Calcium    O
and    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
supplementation    O
may    O
be    O
useful    O
in    O
some    O
.    O

Calbindin    O
-    O
D28k    O
is    O
a    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
responsive    O
gene    O
in    O
many    O
tissues    O
,    O
in    O
particular    O
the    O
chick    O
intestine    O
,    O
where    O
it    O
has    O
a    O
clear    O
function    O
in    O
mediating    O
calcium    O
absorption    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Chapter    O
3    O
:    O
Sunlight    O
,    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
,    O
cholesterol    O
,    O
and    O
the    O
physiological    O
makeup    O
of    O
race    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Vitamin    B-Steroid115057744
D    I-Steroid115057744
blood    O
levels    O
:    O
0.23(0.147    O
)    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Vitamins    O
have    O
not    O
been    O
found    O
to    O
be    O
effective    O
at    O
preventing    O
cancer    O
,    O
although    O
low    O
blood    O
levels    O
of    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
are    O
correlated    O
with    O
increased    O
cancer    O
risk    O
.    O

This    O
encompasses    O
all    O
functions    O
of    O
the    O
kidney    O
,    O
including    O
maintenance    O
of    O
acid    O
-    O
base    O
balance    O
;    O
regulation    O
of    O
fluid    O
balance    O
;    O
regulation    O
of    O
sodium    O
,    O
potassium    O
,    O
and    O
other    O
electrolytes    O
;    O
clearance    O
of    O
toxins    O
;    O
absorption    O
of    O
glucose    O
,    O
amino    O
acids    O
,    O
and    O
other    O
small    O
molecules    O
;    O
regulation    O
of    O
blood    O
pressure    O
;    O
production    O
of    O
various    O
hormones    O
,    O
such    O
as    O
erythropoietin    O
;    O
and    O
activation    O
of    O
vitamin    B-Steroid115057744
D    I-Steroid115057744

Secretion    O
of    O
the    O
active    O
form    O
of    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
(    O
calcitriol    O
)    O
and    O
prostaglandins    O
.    O

They    O
are    O
also    O
a    O
good    O
source    O
of    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
,    O
calcium    O
,    O
and    O
protein    O
.    O

To    O
avoid    O
diseases    O
it    O
is    O
recommended    O
that    O
you    O
utilize    O
a    O
tank    O
with    O
heating    O
system    O
,    O
provide    O
the    O
turtles    O
with    O
daily    O
sun    O
light    O
or    O
special    O
UV    O
light    O
so    O
that    O
they    O
can    O
metabolise    O
the    O
vitamin    B-Steroid115057744
D    I-Steroid115057744

Topical    O
creams    O
and    O
lotions    O
are    O
currently    O
the    O
most    O
commonly    O
used    O
treatment    O
for    O
keratosis    O
pilaris    O
,    O
specifically    O
those    O
consisting    O
of    O
moisturizing    O
or    O
keratolytic    O
treatments    O
,    O
including    O
urea    O
,    O
lactic    O
acid    O
,    O
glycolic    O
acid    O
,    O
salicylic    O
acid    O
,    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
,    O
or    O
topical    O
retinoids    O
such    O
as    O
tretinoin    O
.    O

Cod    O
's    O
soft    O
liver    O
can    O
be    O
canned    O
or    O
fermented    O
into    O
cod    O
liver    O
oil    O
,    O
providing    O
an    O
excellent    O
source    O
of    O
vitamin    O
A    O
,    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
,    O
vitamin    O
E    O
and    O
omega-3    O
fatty    O
acids    O
(    O
EPA    O
and    O
DHA    O
)    O
.    O

The    O
role    O
of    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
on    O
atopic    O
dermatitis    O
is    O
not    O
clear    O
,    O
but    O
there    O
is    O
some    O
evidence    O
that    O
vitamin    O
D    O
supplementation    O
may    O
improve    O
its    O
symptoms    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Lumisterol    B-Steroid115057744
is    O
a    O
compound    O
that    O
is    O
part    O
of    O
the    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
family    O
of    O
steroid    O
compounds    O
.    O

One    O
of    O
his    O
earliest    O
contributions    O
while    O
at    O
the    O
Royal    O
Infirmary    O
,    O
in    O
1877    O
,    O
was    O
in    O
orthopaedics    O
,    O
by    O
means    O
of    O
the    O
development    O
of    O
the    O
first    O
bone    O
grafts    O
,    O
but    O
also    O
in    O
knee    O
surgery    O
using    O
a    O
special    O
instrument    O
(    O
Macewen    O
's    O
osteotome    O
)    O
both    O
techniques    O
becoming    O
key    O
treatments    O
for    O
the    O
highly    O
prevalent    O
disease    O
of    O
rickets    O
(    O
caused    O
by    O
a    O
lack    O
of    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
)    O
.    O

It    O
is    O
marketed    O
alone    O
as    O
well    O
as    O
in    O
combination    O
with    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
(    O
2,800    O
IU    O
and    O
5,600    O
IU    O
,    O
under    O
the    O
name    O
Fosamax+D    O
)    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Vitamin    O
D    O
and    O
Omega-3    O
Trial    O
(    O
VITAL    O
)    O
(    O
VITamin    O
D    O
and    O
OmegA-3    O
TriaL    O
)    O
is    O
a    O
7    O
year    O
trial    O
to    O
run    O
from    O
2010    O
to    O
determine    O
the    O
benefits    O
of    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
and    O
Omega-3    O
supplements    O
on    O
elderly    O
Americans    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
2014    O
,    O
President    O
Obama    O
ordered    O
a    O
prohibition    O
of    O
advertisements    O
for    O
unhealthy    O
foods    O
on    O
public    O
school    O
campuses    O
during    O
the    O
school    O
day    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
providing    O
the    O
lunch    O
.    O

The    O
cereal    O
marked    O
a    O
breakthrough    O
in    O
nutritional    O
science    O
:    O
it    O
helped    O
prevent    O
rickets    O
,    O
a    O
crippling    O
childhood    O
disease    O
,    O
by    O
ensuring    O
that    O
children    O
had    O
sufficient    O
vitamin    B-Steroid115057744
D    I-Steroid115057744
in    O
their    O
diet    O
.    O

Pablum    O
Mixed    O
Cereal    O
was    O
made    O
from    O
a    O
mixture    O
of    O
ground    O
and    O
precooked    O
wheat    O
(    O
farina    O
)    O
,    O
oatmeal    O
,    O
yellow    O
corn    O
meal    O
,    O
bone    O
meal    O
,    O
dried    O
brewer    O
's    O
yeast    O
,    O
and    O
powdered    O
alfalfa    O
leaf    O
,    O
fortified    O
with    O
reduced    O
iron    O
–    O
providing    O
an    O
assortment    O
of    O
minerals    O
and    O
vitamins    O
A    O
,    O
B1    O
,    O
B2    O
,    O
D    B-Steroid115057744
,    O
and    O
E.    O
Pablum    O
is    O
palatable    O
and    O
easily    O
digested    O
without    O
causing    O
side    O
effects    O
like    O
diarrhea    O
or    O
constipation    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744

All    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
,    O
all    O
US    O
public    O
school    O
districts    O
were    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

Additionally    O
,    O
all    O
snack    O
foods    O
sold    O
at    O
school    O
must    O
meet    O
competitive    O
nutrient    O
standards    O
,    O
meaning    O
they    O
must    O
have    O
fruits    O
,    O
vegetables    O
,    O
dairy    O
or    O
protein    O
in    O
them    O
or    O
contain    O
at    O
least    O
10    O
percent    O
of    O
the    O
daily    O
value    O
of    O
fiber    O
,    O
calcium    O
,    O
potassium    O
,    O
and    O
Vitamin    B-Steroid115057744
D    I-Steroid115057744
In    O
order    O
to    O
comply    O
with    O
the    O
Healthy    O
,    O
Hunger    O
-    O
Free    O
Kids    O
Act    O
of    O
2010    O
all    O
US    O
public    O
school    O
districts    O
are    O
required    O
to    O
raise    O
the    O
price    O
of    O
their    O
school    O
lunches    O
to    O
$    O
2.60    O
regardless    O
of    O
the    O
actual    O
cost    O
of    O
the    O
lunch    O
.    O

It    O
is    O
formed    O
from    O
episterol    B-Steroid115057744
through    O
action    O
of    O
the    O
enzyme    O
lathosterol    O
oxidase    O
,    O
and    O
is    O
then    O
converted    O
into    O
24-methylenecholesterol    O
by    O
7-dehydrocholesterol    O
reductase    O
.    O

Dexamethasone    B-Steroid115057744
isonicotinate    I-Steroid115057744
is    O
an    O
anti    O
-    O
inflammatory    O
,    O
anti    O
-    O
allergic    O
glucocorticoid    O
that    O
can    O
be    O
administered    O
orally    O
,    O
by    O
inhalation    O
,    O
locally    O
,    O
and    O
parenterally    O
.    O


